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Parkinson’s disease (PD) is characterised by motor symptoms caused by degeneration 
of dopaminergic neurons in the substantia nigra. The cause remains elusive and current 
treatments cannot halt or reverse progression. This thesis explores the effects of nicotinamide 
on cells associated with PD; exploring its roles in the development and protection of 
dopaminergic neurons, and its influence on microglia.  
Nicotinamide was tested on 46C mouse embryonic stem cells. Neural differentiation, 
indicated by Sox1-GFP expression, was identified by flow cytometry and 
immunocytochemistry. Neuroprotective effects of nicotinamide were assessed using a 6-
hydroxydopamine primary ventral mesencephalon (VM) cell model of PD, and tyrosine 
hydroxylase (TH) immunocytochemistry to identify dopaminergic neurons. Effects of 
nicotinamide on Iba1+ microglia were assessed in VM cultures and in isolated rat cortex 
microglial cultures.  
Nicotinamide limited proliferation of 46C cells over 7 days of differentiation. Sox1-GFP 
expression was lower in nicotinamide-treated cultures compared to control, but peak 
expression occurred earlier. β-III-tubulin+ neuron numbers remained unchanged at day 7. In 
VM cultures, TH+ neuron numbers were higher in nicotinamide-treated cultures at days 1, 4, 
and 7. However, nicotinamide did not protect TH+ neurons against 6-hydroxydopamine. 
Nicotinamide treatment showed reversible impairment of Iba1+ microglial proliferation in VM 
cultures. Lower numbers of Iba1+ microglia were observed in isolated microglial cultures with 
10 mM nicotinamide; however, nicotinamide did not prevent granulocyte-macrophage 
colony-stimulating factor-induced proliferation.  
Thus, nicotinamide could be utilised for novel PD treatments including promoting 
neuronal differentiation and restricting unwanted progenitor cell proliferation in stem cell 
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replacement therapy. Nicotinamide may also enhance dopaminergic differentiation or 
survival in primary VM cultures. Finally, nicotinamide’s ability to reduce microglial 
proliferation could be utilised as a novel therapy to slow progression at PD onset or may offer 
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1 General introduction 
1.1 Introduction to Parkinson’s disease 
1.1.1 Prevalence of Parkinson’s disease is expected to continue 
rising 
Neurodegenerative disorders describe a group of diseases associated with the 
progressive loss of neurons from the central nervous system (CNS) resulting in a wide range 
of symptoms from cognitive decline to movement impairment. Common neurodegenerative 
disorders include Alzheimer's disease (AD), Parkinson’s disease (PD), Huntington’s disease and 
multiple sclerosis and although all fall under this general term, they have vastly different 
presentations, aetiologies, and treatments. Much research is focused on understanding these 
diseases, their causes and developing new therapies and treatments.  
An estimated 10 million people are diagnosed with PD worldwide and this number is 
only expected to increase in future years (Fredericks et al., 2017) placing a heavy 
socioeconomic strain on societies. Between 1994-2013 in the UK, caring for PD patients was 
estimated to cost the NHS £5022 ± 4058 per year compared to age-matched controls £2001 ± 
2000, with costs including inpatient hospital stays, prescribed medication, and accident and 
emergency visits. However, these authors suggest that this estimate is conservative and that 
costs arising from nursing home, social services, lost productivity, and costs covered by 
patients/carers, or private healthcare, are not included (Weir et al., 2018). Therefore, PD 
places a heavy financial burden on government, and personal funds, and these costs are 
expected to rise.  
Due to the nature of PD, incidence rates (the number of diagnoses per 100,000 people) 
and prevalence (the number of people affected) are difficult to determine (Stern and 
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Siderowf, 2010). Some trends in PD diagnosis are consistently found across meta-analysis 
studies including age and gender which can contribute to predictive factors. The prevalence 
of PD is increased with age, with studies indicating highest prevalence between the ages of 
70-90 years. Significantly increased prevalence is also found in males compared to females 
(Horsfall et al., 2013; Pringsheim et al., 2014; Hirsch et al., 2016; Savica et al., 2016).  
Early onset PD (< 50 years of age) can often be misdiagnosed, as PD is typically 
considered an age-related condition, and so may not be considered as a diagnosis in younger 
people (Schrag, Ben-Shlomo and Quinn, 2002). High symptomatic variability (Postuma et al., 
2016) and the presence of a prodromal symptomatic phase (typically non-motor or subtle 
motor changes; Mahlknecht, Seppi and Poewe, 2015) preceding motor symptoms could also 
delay disease diagnosis (Berg et al., 2015); diagnosis is mostly dependent on the presence of 
bradykinesia, rigidity and resting tremor, although recent guidelines now suggest the inclusion 
of prodromal features (Postuma et al., 2016). In this regard, studies can fail to show a clear 
trend in incidence rates over time, with both increases and decreases predicted across 
different studies due to differences in the data collection and analysis, changes in definitions 
of PD, and geographical location. For instance a decrease in incidence rates of either 6% or 1% 
was observed in the UK in meta-analysis data dependent on the inclusion criteria (Horsfall et 
al., 2013); whilst another study found a significant increase in incidence rate in a single county 
in the U.S.A. (Savica et al., 2016). Overall, prevalence of PD is expected to rise over the coming 
years due to increases in population size (Dorsey et al., 2007; Rossi et al., 2018), the increasing 
average age of the population, and increases in life expectancy, with projections expecting a 
doubling in PD cases by 2050 (Bach et al., 2011). With no effective long-term treatments 





1.1.2 Parkinson’s disease can be difficult to diagnose 
PD is now one of the most common movement disorders (Oertel and Schulz, 2016) 
displaying a range of symptoms (Table 1.1). It is often characterised by the motor symptoms 
bradykinesia (a slowness in movement), resting tremor and rigidity, although non-motor 
symptoms including dementia, sleep disturbances, and autonomic dysfunction may also be 
present. Although PD is well characterised, the gold standard for diagnosis is expert opinion 
(Postuma et al., 2016), with diagnostic accuracy estimated to be at 82% (Rizzo et al., 2016), 
highlighting the need for an accurate and objective diagnostic test. Many diagnoses are based 
on the motor symptoms, requiring the presence of bradykinesia alongside either rigidity, 
resting tremor, or postural instability. Diagnosis is further strengthened by exclusion criteria 
(for instance exposure to a neurotoxin) and supportive criteria (such as unilateral onset and 
positive response to levodopa medication). Non-motor symptoms are not currently included 
as part of the diagnosis described by the Parkinson’s Disease Society Brain Bank which is 
followed by National Institute for Health and Care Excellence (NICE) guidance (Rogers et al., 
2017).  
Further subtype classification for PD has been suggested, with the presence of motor 
symptoms classed as clinical PD, the presence of prodromal motor and non-motor symptoms 
classed as prodromal PD, and the occurrence of neurodegeneration without symptoms 
classed as preclinical PD (Postuma et al., 2016). However, although prodromal features can 
provide a critical tool in the early diagnosis and treatment of PD, research into these 
symptoms is still relatively new. Their variability and coincidence with other diseases mean 
that they cannot currently be used as definitive diagnostic criteria (Berg et al., 2015). This 
emerging field could provide beneficial insights into disease progression and treatment.  
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Table 1.1 Table showing some the motor and non-motor symptoms that patients with PD may 
experience. Many of the non-motor symptoms manifest during the prodromal phase. *Denotes 
symptom associated with medication (Mahlknecht, Seppi and Poewe, 2015). 
 
The symptoms of PD, and treatment regimen, place a heavy burden on both people 
with PD and their carers. A decrease in mortality (PD mentioned on the death certificate) was 
observed between 1993-2006, possibly due to improvements in PD treatments and general 
medicine (Mylne et al., 2009); although, despite decades of research, the underlying 
mechanisms of PD, and an effective long-term treatment, remain elusive.  
 
1.1.3 Motor symptoms of Parkinson’s disease are caused by 
striatal dopaminergic denervation 
Originally described by James Parkinson in 1817 (Parkinson, 2002), the cause of the 
motor symptoms of PD was only discovered in 1960 when striatal dopamine deficiency was 
described by Ehringer and Hornykiewicz (Tolosa et al., 1998). The pathology has since been 
more accurately described. Braak et al. (2006) proposed 6 stages of Lewy body (LB) formation 







Tremor Cognitive impairment Insomnia Gastro-intestinal Pain 
Rigidity Depression Daytime sleepiness Genito-urinary Hyposmia 
Bradykinesia Psychosis REM sleep 
disturbance 
Circulatory Visual changes 
Postural instability Dementia     Hallucinations* 
Motor fluctuations Impulse control 
disorder* 
      
Dyskinesia* 
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synuclein which is involved in neurotransmitter release, synaptic plasticity, and possibly the 
regulation of dopamine storage and synaptic vesicle recycling (Johns, 2014). In the disease 
pathology suggested by Braak et al. (2006), stages 1 and 2 include the appearance of LBs in 
the medulla oblongata/pontine tegmentum and anterior olfactory structures. During stages 3 
and 4 initially subtle, but later severe, changes occur in the substantia nigra pars compacta 
(SNpc) and other areas of the basal midbrain and forebrain resulting in a reduction in 
dopamine neurons leading to the motor symptoms of PD. In the final stages, 5 and 6, lesions 
appear in the neocortex and can account for the non-motor symptoms. Although this staging 
can account for a number of the prodromal features, there is debate about the validity and 
accuracy of this proposed staging process across subtypes of PD (for instance early onset vs. 
late onset; Burke, Dauer and Vonsattel, 2008; Dickson et al., 2010; Jellinger, 2019).  
Despite the significance of non-motor symptoms in patient quality of life, research has 
typically focussed on the motor-symptoms of PD, the cause of which has long been established 
as the loss of dopaminergic neurons within the SNpc. Cheng, Ulane, & Burke (2010) reviewed 
estimates of the extent of SNpc neuron loss and whilst some studies observed losses of 50-
70% of dopaminergic neurons at motor symptom onset, more recent estimates support a 
more modest decrease in SNpc dopaminergic neurons of ~30%, compared to age-matched 
controls, at symptom onset. 
The substantia nigra (SN) is part of a collection of nuclei, termed the basal ganglia (BG), 
and is composed of 2 distinct regions, the pars reticulata (SNpr) and pars compacta. The SNpr 
is composed of gamma-aminobutyric acid (GABA) neurons projecting to the thalamus and is 
degenerated to a lesser extent by PD pathology, not contributing to the motor symptoms 
discussed here. The dopaminergic neurons of the SNpc project to the striatum (another 
structure of the BG) and are almost exclusively degenerated in PD. The BG, located in the 
midbrain (Figure 1.1), are a collection of nuclei involved in a number of circuits including eye 
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movement control, executive functions, emotional regulation, and the control of movement 
(Fazl and Fleisher, 2018), which will be the focus of this thesis. Some of the brain regions 
involved in motor control are shown in Figure 1.2. Signals from the cortex feed into the nuclei 
of the BG, and pons and cerebellum, motor loops which feed to the thalamus and back to the 
cortex. This simplified model of the BG (Figure 1.3 A) has both excitatory and inhibitory 
connections (yellow and red respectively) and is often used to illustrate this brain circuit. 
Despite some pitfalls and its simplicity, numerous animal models have confirmed the 
functionality of the BG in line with this model (Fazl and Fleisher, 2018), although more complex 
and detailed anatomy of the connections within the BG and dopaminergic signalling pathways 
are still being uncovered (Haber, 2014; Ogawa and Watabe-Uchida, 2018).  
 
Figure 1.1 Diagrams representing the nuclei of the basal ganglia and related structures (thalamus, 
ventral tegmental area) within the human brain. Although the size and positioning are not precise, 
these views give a general idea of the location and relational positioning of nuclei commented on in 
this PhD thesis. The sagittal brain diagram shows the approximate positioning of the basal ganglia 
within the brain, however, the thalamus and globus pallidus are positioned behind the putamen and 
cannot be accurately represented from this view. The coronal midbrain section (position indicated by 
the dashed line) has the substantia nigra super-imposed to show relative vertical positioning but is 
actually more caudal in relation to the other bodies of the basal ganglia. *Denotes loss of substantia 






Figure 1.2 Schematic illustrating some of the areas, connections and pathways involved in movement. 
Purple areas are in the cortex and are all interconnected with a particularly strong connection between 
the supplementary motor area and the primary motor cortex being highlighted here. They feed into 
loops within the basal ganglia and cerebellum, which both feed back through the thalamus. Green 
corresponds to the pathway that involves the cerebellum and pons which are involved in precision and 
timing of movement. Blue encompasses the basal ganglia inputs involved in control and initiation of 
movement with excitatory connections in yellow and inhibitory connections in red. Neurons in the 
striatum contain either the D1 or D2 dopamine receptor which correspond to the direct and indirect 
pathways respectively. 
 
Simply, dopaminergic neurons from the SNpc project to the striatum where dopamine 
can act as either an excitatory or inhibitory neurotransmitter dependent on the type of 
receptor that it binds to (D1 or D2 respectively). This gives rise to the direct (via the globus 
pallidus internal segment) and indirect (via the globus pallidus external segment) pathways 
(Figure 1.3 A). In PD, the loss of dopaminergic neurons in the SNpc, and subsequent depletion 
of dopamine in the striatum, disrupts the signalling pathway through the basal ganglia 
restricting the output from the thalamus to the cortex (Figure 1.3 B). Although analysis of 
dopamine levels in the striatum can be difficult to measure, extrapolate, and compare across 
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studies (either due to degradation post mortem, or the different in vivo techniques), it is 
estimated that dopamine levels in the striatum are ~50% lower, compared to healthy 
individuals, when PD motor-symptoms arise (Cheng, Ulane and Burke, 2010). Whilst the 
decrease in dopaminergic SN neurons is substantial, it is the more profound loss of striatal 
dopaminergic innervation which is responsible for the motor symptoms of PD. 
 
Figure 1.3 Diagram showing simplified circuitry of the basal ganglia and associated structures (cortex 
and thalamus).  
A) Normal brain circuity through the BG. Signalling for movement is sent from the cortex (purple), 
filtered through the nuclei of the BG and then sent back to the cortex via the thalamus (orange). Two 
pathways, the direct (D1) and indirect (D2), work through inhibitory (red) and excitatory (yellow) 
connections which culminate in disinhibition of the thalamus and therefore initiate movement. The 
direct pathway receives an excitatory signal from the SNpc which, when combined with the signal from 
the cortex, activates an inhibitory signal to the GPi, this reduces the inhibitory signal to the thalamus, 
thus initiating movement. The indirect pathway, however, receives an inhibitory signal from the SNpc. 
This overrides the excitatory signal received from the cortex and inhibits the inhibitory signal going to 
the GPe. This means that the GPe is able to inhibit the STN turning off the excitatory signal going to 
the GPi and also releasing the thalamus from inhibition.  
B) In PD, dopaminergic signalling from neurons in the SNpc is lost meaning that signalling through the 
BG is disrupted. Increased thickness of arrow indicates increased strength, decreased thickness 
represents diminished strength. The reduced signals from the SNpc mean that the D1 pathway does 
not have sufficient activation to inhibit the GPi and the D2 pathway is excited by the striatum without 
being inhibited by the SNpc culminating in over-inhibition of the thalamus. BG: basal ganglia, GPe: 
globus pallidus external, Gpi: globus pallidus internal, SNpc: substantia nigra pars compacta, STN: 
subthalamic nucleus 
 
The substantial decrease in striatal dopamine levels and dopaminergic neurons in the 
SNpc that is necessary before clinical symptoms are evident is thought to be due to 
compensatory mechanisms. There are a number of theories for compensatory mechanisms, 
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although this phenomenon has proven difficult to study due to the progressive, asymmetric, 
and prodromal/preclinical nature of PD; and a lack of animal models that accurately 
recapitulate these characteristics. Three stages of compensatory mechanisms have been 
proposed, from initial dopamine homeostatic mechanisms occurring in the striatum, to 
changes in BG activity adjusting for striatal dopamine loss, and finally compensatory 
mechanisms outside of the BG accommodating for BG signalling disruption (Bezard, Gross and 
Brotchie, 2003). These exact mechanisms are debated and there is also suggestion of 
contralateral mechanisms whereby the still functioning BG can compensate for abnormal 
thalamocortical signalling, with clinical manifestation apparent only after dopamine depletion 
on the secondarily affected side (Obeso et al., 2004). The presence of compensatory 
mechanisms explains the dissociation between the initial decrease in striatal dopamine levels 
and later appearance of motor symptoms arising from the significant loss of dopaminergic 
neurons from the SNpc. 
It is clear that striatal dopamine denervation and subsequent dopaminergic cell death 
are responsible for the motor symptoms of PD, however, the exact pathology of this cell death 
remains undefined. A number of factors are thought to be involved including α-synuclein 
aggregation/LB formation, mitochondrial dysfunction, and oxidative stress. 
 
1.1.4 Lewy body formation is a pathological hallmark of 
Parkinson’s disease 
One of the pathological hallmarks of PD is the presence of LBs which are caused by the 
progressive accumulation of α-synuclein (Lashuel et al. 2013). This protein is expressed in the 
brain and is involved in synaptic processes and neurotransmitter release, however, its precise 
function is unknown (Mehra, Sahay and Maji, 2019). Toxicity occurs from intracellular 
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accumulation of α-synuclein, thought to be caused by an imbalance between synthesis, 
aggregation, and removal. Unfolded α-synuclein monomers can interact, forming dimers 
which propagate to generate oligomers. Oligomers form fibrils by further addition of 
monomers, and the accumulation of fibrils leads to the formation of LBs (Lashuel et al., 2013). 
These intermediary stages, oligomers and fibrils, are suggested to be toxic through aberrant 
interactions with cytosolic proteins and organelles (Lashuel et al., 2013), and it is thought that 
LB formation is a protective mechanism to contain and limit damage from oligomers and 
fibrils. However, a recent LB formation in vitro model suggests that toxicity within neurons 
does not occur during fibrillization, but appears after LB formation (Mahul-Mellier et al., 
2020). 
It is suggested that α-synuclein fibrils, initially formed in the pre-synaptic terminals 
(Kramer and Schulz-Schaeffer, 2007), are transported to the perinuclear region over time 
where they form LB inclusions. The formation of LBs also involves the sequestration of other 
proteins, vesicles, lipids, microtubule complexes, and organelles including mitochondria and 
endoplasmic reticulum, all of which have been found within LB plaques (Mahul-Mellier et al., 
2020). This sequestration is thought to contribute to pathology through disruption of normal 
cellular function. 
Although the mechanisms behind aberrant α-synuclein appearance and subsequent 
toxicity in PD are not well understood, it is thought that α-synuclein filaments could impede 
axonal transport of essential proteins travelling from the soma to the dendrite (Galvin, Lee 
and Trojanowski, 2001). This results in a loss of structural and molecular integrity in the axon 
and dendrite which could cause axons to ‘die back’ and disconnect the SNpc from the striatum. 
The accumulation of α-synuclein could also lead to neurodegeneration through other 




1.1.5 Mitochondrial dysfunction and oxidative stress are 
involved in dopaminergic cell death 
Abnormal functioning of mitochondria can have a deleterious effect on a number of 
cellular pathways, culminating in cell death (Henchcliffe and Beal, 2008). Studies have found 
abnormal function and structure of mitochondria in the brains of some, but not all, PD patients 
(Moon and Paek, 2015). Post mortem analysis of the SNpc has found that although 
mitochondrial mass is unaffected in PD, activity of complex I (also known as NADH-ubiquinone 
reductase; Schapira et al., 1990) and complex II (succinate dehydrogenase; Grünewald et al., 
2016) is reduced in the SN of PD patients. 
The cause of the mitochondrial dysfunction observed in SN dopaminergic neurons of 
PD brains is unknown. However, α-synuclein aggregation and LB formation (Mahul-Mellier et 
al., 2020), genetic mutations (Zeng et al., 2018), and calcium dysregulation (Surmeier et al., 
2011) may contribute. The mitochondrial dysfunction and mitochondrial DNA defects 
observed in PD are linked to decreased mitochondrial membrane potential, reduced 
adenosine triphosphate (ATP) synthesis, and increased levels of reactive oxygen species (ROS) 
leading to oxidative stress (Moon and Paek, 2015; Chen, Turnbull and Reeve, 2019).  
Cellular oxidative stress refers to the over-production of ROS such as peroxides, 
hydroxyl radicals and superoxide, over cellular neutralisation mechanisms. ROS formation is 
part of normal cell functioning, however, uncontrolled ROS production results in oxidative 
stress and widespread cellular disruption through lipid peroxidation, mitochondrial 
dysfunction, and damage to nuclear DNA and cytosolic RNA (Montine et al., 2002; Guo et al., 
2013; Sanders and Greenamyren, 2013). Indicators of ROS are present in the brain areas 
affected by PD (Andersen, 2004), and serum from PD patients show higher levels of oxidative 
stress markers and lower levels of antioxidants (Medeiros et al., 2016).  
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Dopaminergic neurons of the SNpc are also more susceptible to oxidative damage than 
other neurons, which may explain their selective degeneration in PD. This is thought to be due 
to higher endogenous ROS production as a result of increased levels of iron, increased 
monoamine oxidase (MAO; an enzyme involved in the metabolism of dopamine) activity 
(Wang and Michaelis, 2010), and the reaction of dopamine with oxygen, producing superoxide 
radicals (Halliwell, 2006). The SNpc of PD patients also show reduced levels of the antioxidant 
glutathione (Pearce et al., 1997) suggesting a redox imbalance and increased oxidative stress. 
The presence of neuromelanin, the black pigment in dopaminergic neurons of the SNpc, has 
also been implicated as a contributor to the selective vulnerability of these neurons, however, 
its involvement in neurodegeneration/neuroprotection is debated (Vatassery, 1992; Zecca et 
al., 2001, 2008; Dias, Junn and Mouradian, 2013; Knörle, 2018). 
Other potential reasons for susceptibility of SNpc neurons is their relatively large size 
and protracted axonal transportation which increases neurofilament content, energy 
requirements, mitochondrial activity, and ATP production (Wang and Michaelis, 2010). It 
appears that throughout disease progression, it is the axons and their terminals in the 
striatum, rather than the cell soma in the SNpc, that is the initial site of degeneration (Cheng, 
Ulane and Burke, 2010). Although the cause of the motor symptoms of PD is very well 
described, the mechanisms behind the loss of these dopamine neurons are still being 
elucidated, and the initial cause for this pathology is still unknown for the majority of PD cases.  
 
1.1.6 The cause of Parkinson’s disease remains elusive 
Despite the well described pathology of PD, the cause of dopaminergic cell death is 
still mostly unknown. Having a family member with PD is one of the highest risk factors (Noyce 
et al., 2012), with first-degree relatives having a two- to three-fold increased likelihood of 
developing PD (Balestrino and Schapira, 2020). Gentic or ‘familial’ forms of PD have been 
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identified, and these are thought to account for approximately 10% of cases (Thomas and 
Beal, 2007), with several genes linked to the disease. These forms are often associated with 
early-onset cases (diagnosis before 50 years of age); with genetic forms accounting for 
approximately 50% of early-onset cases and only 2-3% of late-onset cases (Zeng et al., 2018). 
The first identified genetic link associated with PD was a mutation observed in the SNCA gene 
which encodes for α-synuclein (Polymeropoulos et al., 1997). A number of other genetic 
mutations are linked to the disease, typically associated with abnormal α-synuclein 
aggregation and mitochondrial dysfunction (Simón-Sánchez et al., 2009; Singleton, Farrer and 
Bonifati, 2013; Zeng et al., 2018), these are shown in Table 1.2 including identified mutations 





Table 1.2 Table displaying some of the genes (commonly used abbreviations and names) and mutations linked to PD. An associated role of each gene and some of 
the downstream effects linked to mutations are also described. Although this is not an exhaustive list of genetic mutations and their interactions, these are used to 
study genetic causes of PD and possible pathology. Adapted from: Polymeropoulos et al. (1997); Singleton, Farrer and Bonifati (2013); O’Regan et al. (2017); Zeng et 
al. (2018); Chen, Turnbull and Reeve (2019). 
Gene Mutation Role Downstream effects of mutation Onset association 
SNCA (synuclein 




G2019S, R1441C, I2020T, 





G411S, I368N, Q456X, 
A168P, H271Q, L347P, 
G309D 
Mitochondrial 
protein kinase  Mitochondrial dysfunction and calcium dysregulation, reduced Parkin recruitment Associated with early-onset, 1-8% of familial cases 
PARK2 (Parkin) R42P, R46P, K211N, 
C212Y, C253Y, C289G, 
C441R, R275W 
E3 ubiquitin ligase Inhibits mitochondrial Parkin recruitment and subsequent 
mitophagy Associated with early-onset and 10-25% of cases 
PARK7 (Protein 
deglycase DJ-1) L166P, M26I, L10P, P158Δ, D149A, DJ1-/-, L172Q 
Redox sensitive 
chaperone protein Attenuation of antioxidant response, mitochondrial dysfunction Associated with early-onset, 1-2% familial cases 
VPS35 (Vacuolar 







Mitochondrial dysfunction, decrease in complex I and II 







, N370S, L444P Lysosomal enzyme Reduced enzyme activity, accumulation of α-synuclein, 
mitochondrial dysfunction, macroautophagy dysfunction, 
endoplasmic reticulum stress 
5-25% of ‘idiopathic’ PD cases 




The remaining 90% of PD cases, classed as idiopathic, are thought to be due to 
environmental factors including age, toxins, and diet. These contributing factors may lead to 
cell death through accumulation of α-synuclein/LB formation, mitochondrial dysfunction, 
oxidative stress, and/or inflammatory activation. 
With just 1.2% of idiopathic cases classed as early-onset (Parkinson’s UK, 2019), age 
seems to be the main contributing risk factor for PD. Aging is associated with a number of 
brain changes including reduced brain weight (Elobeid et al., 2016), mitochondrial dysfunction 
(Chen, Turnbull and Reeve, 2019), decreased striatal dopamine and death of SNpc neurons 
(Carlsson, 1987; Huot, Lévesque and Parent, 2007), and presence of LBs (Elobeid et al., 2016), 
which are not associated with any symptoms of disease. Although these individuals may be 
classed as pre-clinical, very few aged brains completely lack any characteristics associated with 
neurodegenerative pathology (Wyss-Coray, 2016). Disruption of neurotrophic factors, such as 
brain derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor 
(GDNF), may also contribute to disease pathology with concentration changes observed in the 
ageing brain (Huot, Lévesque and Parent, 2007).  
Levels of BDNF, and the ratio of tyrosine hydroxylase (TH; an enzyme involved in the 
production of dopamine and present in SNpc dopaminergic neurons) to BDNF mRNA 
decreased more substantially with age in the SNpc compared to ventral tegmental area (VTA; 
dopaminergic nuclei situated laterally to the SN) of mice (Shaerzadeh et al., 2020). However, 
no significant difference in plasma BDNF was observed between PD and control groups (Costa 
et al., 2019). Levels of GDNF have been found to be decreased in the hippocampus of PD brains 
compared to control, however, levels of cerebral dopamine neurotrophic factor and basic 
fibroblast growth factor were increased (Virachit et al., 2019). This suggests that although 
increasing age is a risk factor for PD, other factors also influence the specific and increased 
degeneration observed in the SNpc PD brains compared to age-matched controls. 
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Results from meta-analysis studies should be interpreted with caution due to 
heterogeneity across studies and within study biases, however, this data can give clues to 
factors with potential causal links to PD surrounding environment and lifestyle. A number of 
positive and negative external factors have been identified as associated with PD. 
The development of severe parkinsonism in a group of young drug users after self-
administration of a synthetic heroin revealed 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine 
(MPTP) as a selective toxin of dopaminergic SN neurons (Langston et al., 1999). Parallels in 
cellular pathology between cell death in MPTP-poisoning and PD highlights the potential that 
PD could be caused by environmental toxins (Schapira et al., 1990). In humans, SN neurons 
are closely aligned to blood vessels suggesting that the SN may be more susceptible to blood-
borne agents (Webster, 2001). Farming, rural living, and well water drinking have been linked 
to a higher risk of PD and this is often thought to be associated with pesticide exposure, which 
also holds an increased risk of PD (Noyce et al., 2012). However, another study has shown 12% 
higher incidence rates in urban compared to rural areas (Horsfall et al., 2013). Differences in 
the collection of this data may account for the discrepancy observed here in incidence rates 
between rural and urban living. Rural and urban living may both lead to exposure to toxins but 
from different sources. These studies suggest that environmental toxins may contribute to an 
increased risk of PD, however, no specific toxin or route of exposure has been reliably 
associated with cases of PD. 
Certain lifestyle and diet choices may also contribute to the risk of developing PD. 
Smoking, alcohol intake, drinking coffee, and physical activity are reported to reduce the risk 
of PD (Noyce et al., 2012; Bellou et al., 2016). Data from meta-analysis studies can have both 
the benefit of encompassing many factors, and the downfall of being nonspecific. For instance, 
whilst increased dairy consumption is associated with an increased risk of developing PD, body 
mass index, fat, and cholesterol intake (which can also be associated with dairy products) do 
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not appear to influence the risk (Jiang et al., 2014; Bellou et al., 2016). Other dietary factors 
including vitamin intake/deficiency have also been implicated to varying degrees (Agim and 
Cannon, 2015; Bellou et al., 2016; Yang et al., 2017). A rise in PD in the UK between 1850 and 
1960 correlates with increases in meat intake and this trend is seen in populations across the 
world (Hill and Williams, 2017). It has also been suggested that a vegan diet reduces the risk 
of PD (McCarty, 2001). However, dietary factors and influences arising from these can be 
difficult to measure due to the range of nutrients found within foods and the requirement of 
participants to accurately record their dietary habits. 
Other correlating factors such as comorbidity with depression, anxiety, and 
constipation are associated with PD, however, it is not known whether these are preclinical 
symptoms, rather than causative risk factors (Bellou et al., 2016; Yang et al., 2017). As 
described above, mitochondrial dysfunction and oxidative stress are pathological features of 
PD, although it is unclear whether these represent a causal feature or are in response to 
damaging stimuli. Aside from chemical toxins that can cause the increased oxidative stress 
observed in PD, inflammation may also play a role in the cascade of events leading to neuronal 
cell death. 
Inflammation in the brain is part of a protective mechanism to maintain cellular health 
and homeostasis by removal of detrimental material. However, neuroinflammation is 
associated with the release of ROS (Wang et al., 2015) and an uncontrolled/unwarranted pro-
inflammatory response can cause cell and tissue damage, and has been linked to the loss of 
dopaminergic neurons in PD (Guo et al., 2018). Upregulation of the neuroinflammation 
signalling pathway has been observed in an α-synuclein in vitro LB mouse model (Mahul-
Mellier et al., 2020) suggesting a link between α-synuclein/LBs with an inflammatory 
response. However, it is not certain what may trigger an uncontrolled inflammatory response 
that could lead to specific SNpc cell death in humans.  
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The contributing factors to neurodegeneration in PD are well described, however, the 
initial factor in the cascade of events leading to specific SNpc cell death remains elusive. 
Despite the presence of this disease worldwide, significantly lower prevalence is reported in 
Asia compared to North America, Europe, and Australia, and authors suggest that genetic or 
environmental factors could explain these differences (Pringsheim et al., 2014). The wide 
array of risk factors associated with this disease also point to gene-environment interactions 
and it is probable that no single factor is responsible for PD (Horsfall et al., 2013). This range 
of potential contributing factors, the difficulty in studying the disease in vitro, and difficulty 
studying disease onset due to a preclinical phase mean that understanding features of 
dopaminergic SN neurons in health and disease may assist in understanding this specific 




1.2 Substantia nigra dopamine neurons are more 
susceptible to degeneration 
Dopamine (synthesis and breakdown shown in Figure 1.4) is a neurotransmitter used 
in six dopaminergic pathways in the human brain (mesolimbic, mesocortical, nigrostriatal, 
tuberoinfundibular, hypothalamospinal projection, and incertohypothalamic) and are 
associated with dopaminergic subtypes classified as A8-A16 (Table 1.3) numbered based on 
caudal to rostral location (Goridis and Rohrer, 2002). These different pathways also 
correspond to differing levels of dopamine in specific brain regions with lowest levels in the 
cortex (0.1 µg/g) and highest in the striatum (10 µg/g; Webster, 2001). Dopamine has 
widespread activity, being linked to movement, motivation, reward and pleasure, 




Figure 1.4 Schematic showing the synthesis and breakdown of dopamine. Molecules are shown in 
black, enzymes are shown in blue. Dopamine synthesis in neurons of the substantia nigra pars 
compacta starts with the conversion of L-tyrosine to L-Dihydroxyphenylalanine (L-DOPA) by the 
enzyme tyrosine hydroxylase (TH; a commonly used marker of dopaminergic neurons). L-DOPA is then 
converted into dopamine by L-amino acid decarboxylase. Dopamine is then stored in vesicles within 
the cell by vesicular monoamine transporter (VMAT). After release into the synaptic cleft, and 
subsequent post-synaptic stimulation, dopamine is either taken up by the pre-synaptic neuron via the 
dopamine transporter (DAT) or metabolised by monoamine oxidase (MAO) and catechol O-methyl 
transferase (COMT) resulting in the final production of homovanillic acid via the intermediate 




Table 1.3 Table showing the 9 subtypes of dopaminergic neurons, their associated pathways, location and some prominent efferent connections, associated 
behaviour/homeostatic activities, and diseases associate with disruption/loss of these neurons. *Associated hormones include gonadotrophin releasing hormone, 
thyroid stimulating hormone, and growth hormone. SNpc: substantia nigra pars compacta; VTA: ventral tegmental area; ADHD: attention deficit hyperactive 
disorder. Contributing papers: Björklund, Lindvall and Nobin (1975); Gasbarri et al. (1996); Le et al. (1999); Webster (2001); Blum et al. (2008); Haber (2014); 
Subramaniam and Roeper (2016); Cooper, Robison and Mazei-Robison (2017); Howes et al. (2017); Klein et al. (2019). 
Associated Pathway A# Location in Brain/Areas involved Associated activity Associated diseases 
 















VTA to prefrontal and perirhinal cortex Executive functions Schizophrenia, ADHD 
Hypothalamospinal projection A11 Dorsal posterior hypothalamus to neocortex, dorsal 
horn, intermediolateral nucleus 
Motor functions and muscular 
sensations 
Restless leg syndrome 
Tuberoinfundibular pathway A12 Arcuate nucleus to pituitary gland Prolactin release Hyperprolactinaemia 
Incertohypothalamic pathway A13 Zona incerta to hypothalamus Hormone release* 
 
 
A14  Periventricular nucleus 
  
 
A15 Rostral hypothalamic and periventricular nucleus 
  
 






Once dopamine has been synthesised, it is stored in vesicles by vesicular monoamine 
transporter (VMAT) 1 and 2 until it is released into the synaptic cleft (Lopes et al., 2017). 
Dopamine can elicit either inhibitory or excitatory responses dependent on the dopamine 
receptor it binds to. These receptors are often referred to as D1-D5, their binding effect and 
brain regions associated with highest expression are shown in Table 1.4. The D1 receptor, 
associated with an excitatory response, is the most abundantly expressed in the brain 
followed by the D2 receptor, associated with an inhibitory response, and the two are very 
rarely co-expressed in the same neuron (Klein et al., 2019). Differences in neuronal dopamine 
receptor expression appears to be a feature explored in the study of schizophrenia (Howes et 
al., 2017) but does not appear to be related to PD. To prevent continuous stimulation of the 
post-synaptic neuron, dopamine is removed from the synaptic cleft by either reuptake into 
the presynaptic neuron by the dopamine transporter (DAT), or it is deaminated by monoamine 
oxidase (MAO) or catechol O-methyl transferase (COMT), which are produced by both 
neurons and glia (Lopes et al., 2017).  
Table 1.4 Table showing the different dopamine receptors, their binding effect, and brain areas with 
abundant expression (Klein et al., 2019). 
 
Dopaminergic subtypes based on location, gene/protein expression, and 
electrophysiological patterns exist within the mammalian brain. The A9 dopaminergic neurons 
of the nigrostriatal pathway within the SNpc and A10 dopaminergic neurons of the mesolimbic 
and mesocortical projections from the VTA, are the most abundant and well-studied 
dopamine neurons in the brain (Webster, 2001). 
Receptor Binding effect Brain regions 
D1 Excitatory Caudate putamen, nucleus accumbens, substantia nigra pars reticular, 
olfactory bulb, amygdala, frontal cortex D5 Excitatory 
D2 Inhibitory 
Striatum, globus pallidus external, nucleus accumbens (core), ventral 
tegmental area, hypothalamus, amygdala, cortical areas, hippocampus, 




Dopaminergic neurons of the VTA receive inputs from the lateral orbital cortex, ventral 
striatum and pallidum, and lateral amygdala; whilst dopaminergic neurons of the SNpc receive 
inputs from sensory cortex, globus pallidus, entopeduncular nucleus, SNpr, subthalamic 
nucleus and zona incerta (Ogawa and Watabe-Uchida, 2018). Recent studies have further 
subtyped these based on location within these specific nuclei, and afferent and efferent 
connections (Subramaniam and Roeper, 2016; Poulin et al., 2018). 
Despite their regional proximity, dopaminergic neurons of the SNpc and VTA show 
distinct characteristics (Table 1.5), including efferent connections to the striatum (dorsal and 
ventral respectively), electrophysiology (Krashia et al., 2017), and expression of ion channels 
(review: Gantz et al., 2018). Marker expression differences have also been observed in mature 
dopaminergic neurons, with all SNpc neurons expressing GIRK2 (G protein-coupled inwardly-
rectifying potassium channel 2) but only ~55% of VTA neuron expressing GIRK2 (Reyes et al., 
2012). Marker expression, morphology and projections even vary within the ventral/dorsal 
subpopulations of SN and VTA, highlighting the complexity of these midbrain dopaminergic 
neurons (Björklund and Dunnett, 2007). 
Table 1.5 Table showing differences in marker expression across A8, A9 and A10 subtype dopaminergic 
neurons. Neurons of the A8 retrorubral field appear to be less studied, - indicates information for this 
marker was not commented on. 
 
Marker/ 
Characteristic A8 A9 A10 Reference 
Nurr1 Not essential Essential Essential Le et al. (1999) 
Calbindin Low Low High Liang, Sinton and German (1996) 






channels Khaliq and Bean (2010) 
Cytosolic 
dopamine - > A10 < A9 Mosharov et al. (2009) 
DAT - High Low Björklund and Dunnett (2007) 
Neuromelanin - High Low Kastner et al., (1992) 
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Midbrain dopamine neurons in retrorubral field (A8) and VTA (A10) also degenerate in 
PD but to a lesser extent than those in the SNpc (A9; German et al., 1992; Alberico, Cassell and 
Narayanan, 2015). Calcium binding protein (Calbindin) is differentially expressed across the 
dopaminergic nuclei of the midbrain and Calbindin+ neurons are selectively spared in both PD 
and MPTP-induced degeneration (German et al., 1992; Haber, 2014). Calbindin+ neurons also 
express lower levels of DAT (Björklund and Dunnett, 2007) which may contribute to their 
decreased vulnerability. 
Dopaminergic neurons of the SNpc are large with long, unmyelinated axons and high 
numbers of synapses (Bolam and Pissadaki, 2012). A dopaminergic neuron of the VTA is 
estimated to have approximately 12,000-30,000 synapses, whilst an SNpc dopaminergic 
neuron is estimated to give rise to approximately 102,000-245,000 synapses. These features 
of SNpc neurons result in a high energy demand and could make them more susceptible to 
perturbations in energy supply (Bolam and Pissadaki, 2012) leading to increased vulnerability.  
Neuromelanin is a dark, melanin pigment present in the SN and locus coeruleus of the 
human brain (and some other mammals including primates, horses, and sheep), appearing 
after 2-3 years of age in humans (Zecca et al., 2001) and progressively increasing with age 
(Knörle, 2018). Higher content of neuromelanin is observed in SNpc neurons compared to 
VTA, and the number of pigmented neurons is significantly lower in PD brains suggesting 
increased vulnerability of pigmented neurons to degeneration (Kastner et al., 1992). The 
involvement of neuromelanin in dopamine neuron degeneration in PD and its 
cytotoxic/cytoprotectant properties are debated. Neuromelanin has been found to be 
involved in cellular iron accumulation, oxidative stress, and calcium binding, although its role 




The differences highlighted here are observed between mature dopaminergic neurons 
of the SNpc and VTA and may contribute to the differing vulnerability of these neurons to 
degeneration in PD. However, specification of these subsets of neurons within the midbrain 





1.3 Midbrain development and homeostasis 
The development and maintenance of A9 dopaminergic neurons requires a complex 
combination of transcription factors and diffusible signals, shown in a simplified diagram in 
Figure 1.5 (Castelo-Branco et al., 2003; Arenas, Denham and Villaescusa, 2015). Whilst Nurr1, 
Pitx3, and Lmx1b expression are essential in the maintenance of A9 and A10 midbrain 
dopaminergic neurons, these post-mitotic transcription factors are not essential for other 
dopaminergic cell subtypes (Goridis and Rohrer, 2002; Bissonette and Roesch, 2016). 
Understanding the development of these A9 neurons can contribute to the development of 
treatments and also an understanding of potential causes of neurodegeneration. 
However, neurons only constitute a minority of the cellular composition in the human 
brain, with the majority broadly classed as glia (Jessen, 2004). Glia can be further subtyped 
into microglia (discussed in Chapter 1.4) and macroglia, which account for astrocytes, 
oligodendrocytes, and oligodendrocyte precursors (also termed NG2-glia) of the CNS. 
Diffusible factors termed netrins (extracellular proteins related to laminin), arising from the 
floor plate of the embryonic neural tube, are involved in directing both neuron and macroglia 
development. Neuroepithelial progenitor cells transform into radial glia which initially 
generate neurons before astrocyte and oligodendrocyte precursor generation through factors 




Figure 1.5 Diagram illustrating signalling patterns in the development of A9 dopaminergic neurons in 
vivo.  
A (coronal view of embryo):  
After the development of the three germ layers at around 3 weeks in human development (Pansky, 
1982) and around embryonic day 7 in mouse (Gray and Ross, 2011), signalling at the rostral end of the 
embryo leads to the formation of the neural tube.  
B (lateral view of neural tube):  
Coordinated expression and repression of Otx2 and Gbx2 (respectively) forms the midbrain-hindbrain 
boundary where the isthmic organiser (IsO) is generated. Sonic hedgehog (Shh), secreted by the 
notochord, induces Foxa2 which signals the formation of the floor plate (FP), from which, midbrain 
dopaminergic neurons are generated (Ono et al., 2007). Cells rostral to the IsO express Otx2 which 
regulates Wnt1, whilst cells caudal to the IsO, express Gbx2 which regulates Fgf8 (through Pax2). This 
gradient induces caudal/rostral patterning.  
C (coronal view of floor plate): 
During this time, the FP expresses Shh, creating a gradient regulating ventral/dorsal specification. 
Wnt1 is also expressed in two medial bands within the FP. High expression of Shh upregulates Foxa2 
which, alongside Foxa1 and Otx2, regulates expression of Lmx1a and Lmx1b. Lmx1b is required for the 
differentiation of dopamine progenitors; whilst Lmx1a is required for the specification of dopaminergic 
neurons in the FP, it also induces expression of Msx1 which supresses basal plate fate. An auto-
regulatory loop is formed with β-catenin which upregulates Lmx1a and Otx2. Lmx1a/b upregulate each 
other as well as Wnt1, Msx1, Nurr1 and Pitx3. The Shh-Foxa2 and Lmx1a/b-Wnt1-Otx2 networks 
regulate expression of Mash1 and Ngn2 in the ventral zone of the FP. Dopaminergic neurogenesis takes 
place in the ventral zone, as neuroblasts descend through the intermediate zone to the mantle zone, 
they differentiate into dopamine neurons and express transcriptions factors Nurr1, Pitx3, En1 and En2 
which are essential for maturation and maintenance. From here, A9 neurons migrate towards the SNpc 
with maturation typically occurring through weeks 6-11 in humans, and starting at E10.5 in mice 
(Arenas, Denham and Villaescusa, 2015). 
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The importance of glia is apparent in their roles in migration and axon guidance, 
neuron survival and regeneration, synapse maintenance, signal transduction, and immune 
response (Jessen, 2004; Losada-Perez, 2018). Astrocytes are the most abundant glial subtype 
in the CNS (Jessen, 2004) and are essential to neuron survival, with dysfunction related to a 
number of neurodegenerative disorders including PD (Phatnani and Maniatis, 2015). One of 
the important roles of glial cells is the breakdown of neurotransmitters. As described in Figure 
1.4, dopamine is degraded by MAO and COMT. MAO has two isoforms, A and B; both isoforms 
are expressed in astrocytes, whilst only MAO-A is expressed in dopaminergic neurons (Youdim 
and Bakhle, 2006). COMT is expressed by both astrocytes and microglia, with CNS expression 
highest in microglia, and it is not present in neurons of the SNpc (Meiser, Weindl and Hiller, 
2013). Although glia possess the ability to metabolise dopamine, their role in PD is often 
overlooked. However, their roles in dopamine transport are becoming an area of study 
(Meiser, Weindl and Hiller, 2013; Winner et al., 2017; Petrelli et al., 2020).  
Glia can be difficult to study in vitro, often displaying non-physiological phenotypes 
and expression profiles when isolated and expanded in culture (Ransohoff, 2016). However, 
their importance in development and homeostatic maintenance of the brain is clear and 
research into this field could help to find novel neurodegenerative/neuroprotective 





1.4.1 Microglia are the immune cells of the central nervous 
system 
Present in similar numbers to neurons, microglia represent 10-20% of the glial 
population (Soulet and Rivest, 2008). Unlike other CNS cell types which develop from the 
neural plate (Bear, Connors and Paradiso, 2007), microglia originate from yolk sac 
macrophages and migrate into the embryonic brain (Ginhoux et al., 2013) maintaining their 
capacity for self-renewal into adulthood (Bruttger et al., 2015). This migration is thought to 
take place very early in development, before formation of the blood brain barrier (BBB). 
Microglial cultures have been harvested from as early as embryonic day 10 (E10) rat brains 
(Ghosh and Ghosh, 2016). In vivo, their three-dimensional organisation is considered 
homogeneous and territorial with microglia keeping consistent cell to cell distances 
(Nimmerjahn, Kirchhoff and Helmchen, 2005).  
Whilst they are present throughout the CNS, their population density can change 
depending upon their location (Akiyama and McGeer, 1990). Microglia make up 5% of the 
cortex cell population increasing to 12% of the SN, with the basal ganglia being one of the 
most densely populated areas in mice (Lawson et al., 1990). Microglial density also varies 
across the BG of mice, with the VTA showing the lowest density and the SN showing the 
highest (De Biase et al., 2017). Alongside changes in population densities, microglia also 
exhibit morphological variation and unique expression profiles based on their location and 
organism age, this indicates how adaptive they are to their micro-environment (Lawson et al., 
1990; de Haas, Boddeke and Biber, 2008; Boche, Perry and Nicoll, 2013; Crain, Nikodemova 
and Watters, 2013; Ginhoux et al., 2013; Hayley et al., 2015; Ghosh and Ghosh, 2016; Tan, 
Yuan and Tian, 2020).  
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Microglia play important roles in brain development (Bilimoria and Stevens, 2015; 
Anderson and Vetter, 2018; Menassa and Gomez-Nicola, 2018) and homeostasis (Paolicelli et 
al., 2011; Schafer et al., 2012), with altered function associated with neurodegenerative 
conditions, including PD. Microglia are heavily involved in tissue remodelling, axon guidance, 
and synaptic pruning in brain development, with ongoing supportive and adverse interactions 
affecting adult neurogenesis in both the healthy and injured brain (Ekdahl, Kokaia and Lindvall, 
2009) highlighting their importance and influence throughout life. 
Although microglia share many features of circulating monocytes and tissue 
macrophages (Perry, Hume and Gordon, 1985; Akiyama and McGeer, 1990; Boche, Perry and 
Nicoll, 2013), not all that applies to circulating monocytes can be applied to microglia (Pepe et 
al., 2017; Haage et al., 2019). Just as in the peripheral immune system, microglia display pro-
inflammatory and anti-inflammatory states that have been classed to reflect those of the 
peripheral immune system, although the states of microglia are less well-defined and are still 
being uncovered.  
 
1.4.2 Microglia activation involves switching between 
phenotypes classed as M0, M1, and M2 
In healthy tissue, microglia have a highly ramified shape with active and dynamic 
processes (Soulet and Rivest, 2008). Typically, the soma shows few signs of migration, 
however, the processes are continuously forming and withdrawing, displaying highly motile 
filopodia-like projections (Nimmerjahn, Kirchhoff and Helmchen, 2005). This state is typically 
referred to as the ‘resting/surveillance’, or M0 state in which microglia are surveying the 
environment. However, microglia change their morphology, gene expression, function, 
motility and proliferation capacity in response to stimuli indicating immediate or potential 
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disruption of brain homeostasis (Nimmerjahn, Kirchhoff and Helmchen, 2005; Kettenmann et 
al., 2011). These changes result in microglia displaying M1 or M2 phenotypes, typically related 
with pro-inflammatory and anti-inflammatory functions respectively (Figure 1.6). These states 
are thought to be transitory, and, as individual cells can express both M1 and M2 features 
simultaneously, there is continuing debate about which markers are genuinely indicative of 
phenotype (Donat et al., 2017), with markers and morphology also varying across brain 
regions in healthy tissue (Lawson et al., 1990; De Biase et al., 2017).  
Microglia are constantly sensing their surroundings and are equipped with a range of 
receptors including toll-like receptors, nucleotide-binding oligomerisation domains, and 
scavenger receptors to recognise potentially harmful stimuli (Orihuela, Mcpherson and Harry, 
2016). In response to pro-inflammatory signals, microglia become “classically activated”, 
displaying an M1 phenotype with larger soma and shorter processes, typically described as 
amoeboid, or rod-like in shape (Davis, Foster and Thomas, 1994), and increased motility 
(Figure 1.6). This stage is often related to urgent responses and defence, attempting to limit 
damage and combat infection (Abd-El-Basset and Fedoroff, 1995; Nimmerjahn, Kirchhoff and 
Helmchen, 2005; Cho et al., 2006). During this stage microglia express a variety of cytokines 
including tumour necrosis factor-⍺ (TNF-⍺), interleukin (IL)-1β, IL-6, IL-12, and free radicals 
such as reactive oxygen and nitrogen species (ROS; RNS) meaning that this state is often 
related to neuronal damage induced by inflammation (Wang et al., 2015).  
“Alternatively activated” or M2 phenotypes include anti-inflammatory, repair-
promoting, and phagocytic behaviours (Smith et al., 2012). This polarisation has been further 
classified into M2a, M2b, and M2c subtypes with M2a associated with repair and 
regeneration, M2b associated with immune modulation (Chhor et al., 2013), and M2c 
associated with immune suppression (Gensel and Zhang, 2015). However, these subtypes 





Figure 1.6 Diagram illustrating some of the features of microglia. Morphology, expression profiles, and 
released factors change from M0 to either M1 (red) or M2 (green) with different activation stimuli 
shown in black. Red text indicates some of the characteristics associated with M1 activation, green 
text indicates characteristics of M2 activation, which can be further subtyped into a, b, and c associated 
factors.  
Arg: arginase; CCL2: monocyte chemoattractant protein; CD: cluster of differentiation molecule; CSF – 
colony stimulating factor; CXCL: chemokine ligand; Fcγ: fragment crystallisable gamma; Fizz1: Resistin-
like molecule alpha/found in inflammatory zone protein; G-CSF: granulocyte colony-stimulating factor; 
GM-CSF: Granulocyte-macrophage colony-stimulating factor; IFN-γ: interferon gamma; IL: interleukin; 
iNOS: nitric oxide synthase; LPS: lipopolysaccharide; MHC-II: major histocompatibility complex class II; 
NF-κB: nuclear factor-κB; PPARs: peroxisome proliferator-activated receptors; ROS: reactive oxygen 
species; TGF-β: transforming growth factor beta; TNF-α: tumour necrosis factor alpha; Ym1: eosinophil 
chemotactic factor-lymphocyte/chitinase 3-like 3. Zhang et al. (2005); Chhor et al. (2013); Tam and Ma 





1.4.3 Microglia have been implicated in neurodegeneration 
The activation state of microglia has been implicated in a number of brain diseases, 
including epilepsy and dementia (Devinsky et al., 2013; Clayton et al., 2017), with microglia 
observed at sites of neurodegeneration, both post-mortem and in vivo, in a variety of diseases 
including AD, PD (McGeer et al., 1988; Fan et al., 2015), multiple sclerosis, and amyotrophic 
lateral sclerosis (Liu and J.-S. Hong, 2003). Therefore, the inflammatory response of microglia 
has become a potential target for treatment for a number of neurodegenerative conditions 
(Liu and J.-S. Hong, 2003). 
Their exact role in neurodegeneration is unclear but microglia are thought to 
exacerbate the degeneration of neurons. Fan et al. (2015) found significant increases in 
microglial activation and decreases in glucose metabolism (which reflects neuronal synaptic 
function) in patients with AD, amnestic mild cognitive impairment (the transitional stage 
between healthy and AD), and PD dementia. Although this highlights a relationship between 
microglia activation and neuronal death, it does not necessarily show that microglia are the 
cause of neuronal death in AD and PD.  
Hypotheses for the microglial role in neurodegeneration include a sustained pro-
inflammatory state resulting in the generation of ROS and RNS causing neuronal damage; and 
an inability of microglia to clear aberrant or aggregated proteins leading to neurotoxicity and 
further stimulating a pro-inflammatory environment (Orihuela, Mcpherson and Harry, 2016). 
A potential cause for unwarranted microglial activation leading to degeneration is a process 
known as priming. It is possible that age or disease “primes” microglia, resulting in an 
exaggerated immune response (heightened or prolonged) to subsequent stimuli (whether 
infection, trauma, or something previously innocuous), potentially causing damage to 
otherwise healthy tissue (Perry and Teeling, 2013).  
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The strongest genetic risk factor for late onset AD is apolipoprotein E type 4 (APOE4) 
(Corder et al., 1993; Farrer, 1997; Liu et al., 2013; Belloy, Napolioni and Greicius, 2019). 
Expression has been found in some, but not all, astrocytes, <10% of microglia, and injured 
neurons (Uchihara et al., 1995; Grehan, Tse and Taylor, 2001; Xu et al., 2006). Although the 
mode of action is not clear, it is thought that isoforms of APOE4 are differentially involved in 
amyloid beta deposition and clearance (Kim, Basak and Holtzman, 2009; Liu et al., 2013). 
Furthermore, APOE has been linked to increased inflammatory microglial phenotype 
(Krasemann et al., 2017; Ulrich et al., 2018), however, microglial depletion in the P301S tau 
transgenic AD mouse model which is homozygous for human APOE4 prevented 
neurodegeneration (Shi et al., 2019) suggesting that it is the reaction of microglia to amyloid 
beta deposition driving neuronal degeneration.  
Proliferation is an indicator of microglial activation (Gensel and Zhang, 2015) and 
increased microglial numbers at sites of neurodegeneration have been associated with 
disease progression (Olmos-Alonso et al., 2016; Clayton et al., 2017; Mathys et al., 2017). 
Increasing microglia numbers and pro-inflammatory factors IL-1β and TNFα have been 
observed in a mouse model of frontotemporal dementia, corresponding with disease 
symptoms (Clayton et al., 2017). Whilst proliferative markers for microglia in this 
frontotemporal dementia model were low initially, Mathys et al. (2017) observed high 
proliferation early on in a mouse AD model. Inhibition of microglial proliferation (by the 
tyrosine kinase inhibitor GW2580) showed improvements in behaviour deficits and a shift 
from pro-inflammatory to anti-inflammatory phenotype, without affecting amyloid plaques 
(protein aggregates associated with AD pathology) in a mouse model of AD (Olmos-Alonso et 
al., 2016). However, depletion of microglia has been shown to suppress the propagation of 
abnormal tau protein aggregation through brain regions in another AD mouse model (Asai et 
al., 2015). Despite discrepancies in these studies, they indicate that microglia change with 
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disease progression, and that the route of pathogenesis differs across brain regions and 
disease models. 
A common risk factor in a number of neurodegenerative diseases, including PD, is 
ageing (Johnson, 2015; Collier, Kanaan and Kordower, 2017). Alongside a variety of other 
biological changes, microglial expression patterns change throughout life, suggesting a 
potential for different microglial responses to stimuli at different ages (Crain, Nikodemova and 
Watters, 2013). Ageing has been associated with changes in the neuroinflammatory 
environment, and microglia dysfunction could be a contributing factor to age associated 
neurodegeneration (Grabert et al., 2016). Contrary to over-active inflammation of microglia, 
it is also hypothesised that dystrophic, dysfunctional, or senescent microglia may result in 
reduced microglial neuroprotection (Streit and Xue, 2009; Askew et al., 2017). Ageing of 
microglia may be more problematic than for peripheral macrophages, as the latter are 
replenished from bone marrow stem cells, whereas microglia self-renew, perhaps with 
increased senescence. Although it is not clear how senescent microglia may contribute to 
neurodegeneration, aged microglia show compromised surveying activity in the M0 state, 
with fewer branches and slower process motility. Response to pro-inflammatory stimuli 
showed decreased migration and a pro-longed inflammatory response (Damani et al., 2011). 
A mouse model of tau-dependent degeneration also found a positive correlation between 
senescent cells and neuronal loss, with removal of these senescent glia preventing gliosis, tau 
deposition and neuronal degeneration (Bussian et al., 2018). 
Long term use of nonsteroidal anti-inflammatory drugs during mid-life has been shown 
to reduce the risk of AD, but not other forms of dementia (in ’T Veld et al., 2001). Therefore, 
further exploration of the roles of microglia in neurodegeneration, and perhaps a more 
targeted approach to microglia, are required to fully assess potential benefits and 
development of improved treatments. 
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1.4.4 Roles of microglia in Parkinson’s disease 
As previously discussed, there are a number of ways that microglia could be implicated 
in neurodegenerative disease including PD, and a number of studies have shown the 
possibility of microglia involvement specific to PD, including increased inflammatory markers 
present in the serum of PD patients (Medeiros et al., 2016).  
A number of studies have shown that activated microglia can destroy otherwise 
healthy neurons. Injection of lipopolysaccharide (LPS; molecules found on many bacterial 
species which elicit an inflammatory response) into the nigrostriatal pathway of rats resulted 
in microglia activation and subsequent destruction of dopaminergic neurons, despite a lack of 
toxic effect of LPS to dopamine neurons alone (Bronstein et al., 1995; Herrera et al., 2000). 
Microglia have also been shown to destroy dopaminergic neurons after transection of the 
medial forebrain bundle (Cho et al., 2006), suggesting that microglia may destroy damaged 
neurons. 
Injection of neuromelanin into the SN of rats resulted in strong microglia activation 
and significant dopamine neuron loss (Zecca et al., 2008) suggesting that the presence of 
neuromelanin may be a contributing factor in the selective vulnerability of SNpc dopaminergic 
neurons. Neuromelanin is phagocytosed and degraded by microglia, however it also elicits a 
pro-inflammatory response through release of detrimental factors including ROS (W. Zhang et 
al., 2011). Although neuromelanin is also present in healthy individuals, it is possible that cell 
death triggered by external factors could release neuromelanin which in turn exacerbates 
dopaminergic neuronal degeneration of the SNpc, with a feed forward cycle of neuronal 
damage and uncontrolled inflammation amplifying and potentiating neurotoxicity (Gao and 
Hong, 2008). This idea is supported by Langston et al. (1999) with the observation of continued 
degeneration in individuals with MPTP-induced parkinsonism displaying ongoing 
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degeneration of dopaminergic neurons years after the initial insult with microglial clusters 
around neurons and extracellular neuromelanin in the SNpc.  
Dopaminergic neurons of the SNpc may also be inherently more vulnerable to 
degeneration exacerbated by microglia due to their higher iron content. Iron was able to 
potentiate pro-inflammatory microglial activation and neurotoxicity in rat neuron-astrocyte-
microglia cultures leading to selective and progressive dopamine neuron degeneration (Zhang 
et al., 2014). Both of these mechanisms, an adverse response to iron or neuromelanin, are 
based on neurons dying and releasing their contents, heightening the microglial inflammatory 
response, rather than instigating the inflammation. It remains unclear whether inflammation 
may be associated with the onset of PD pathology, or whether it simply exacerbates the 
process. 
Microglia are closely involved in synapse maintenance and constantly receive signals 
from neurons. Dopamine receptors 1-4 are expressed on human microglia (Mastroeni et al., 
2009) and dopamine has been found to be involved in inflammatory regulation. It is suggested 
that decreased dopamine signalling induces a pro-inflammatory response through a change 
in dopamine receptor stimulation from low-affinity receptors (in response to high 
homeostatic conditions) to high-affinity receptors (in response to reduced dopamine levels; 
Broome et al., 2020). Further suggesting a role for microglia in the propagation of 
dopaminergic neuron death. 
Microglia may also be involved in the spread and toxicity of α-synuclein. PD derived 
exosomes containing α-synuclein were phagocytosed by microglia, inducing an inflammatory 
response with the release of pro-inflammatory cytokines, nitric oxide production, and 
increased proliferation. Microglia were also shown to transmit this α-synuclein from human 
exosomes to mouse striatal neurons. Exosomes also suppressed autophagy, increasing the 
accumulation of α-synuclein (Xia et al., 2019). Microglia senescence with age, observed by a 
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decrease in branching complexity, soma size increases and ‘surveillance area’ decreases, in 
SNpc and VTA of aged mice (1, 6, 9, 18, 24 months; Shaerzadeh et al., 2020), may also be a 
factor in α-synuclein pathology in PD. 
Microglia show a clear role in the pathogenesis of PD, although the exact relationship, 
and series of degenerative events, is difficult to assess. Pro-inflammatory microglia likely 
contribute to disease progression, therefore, the switching of microglia to an anti-
inflammatory M2 state could be critical to ending inflammation and supporting 
repair/regeneration. There is reason to believe that neuro-immunomodulatory treatments 
targeting microglia could be therapeutically beneficial in PD (Liu and J.-S. Hong, 2003; Choi, 
Koppula and Suk, 2011). However, progression in this area of research relies on the use of 
models of PD.  
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1.5 Models of Parkinson’s disease 
The inaccessible nature of the brain in general, and specifically the SNpc, alongside a 
dissociation between PD pathology and motor-symptom onset, means that studying the 
molecular changes occurring in PD is often not possible until post-mortem. Whilst this 
captures the end stages of the disease, early pathology is not able to be elucidated. Not only 
does this limit our understanding of possible causes, but also disease onset, the ideal point in 
time when most interventions would be applied. Therefore, PD models that reproduce key 
features of the disease and its progression are often used to study both potential factors that 
could cause the disease as well as possible treatments. 
The variety of pathologies, including progressive degeneration, α-synuclein 
aggregation, mitochondrial dysfunction, and inflammation; coupled with a natural 
susceptibility that is restricted to humans; make it difficult to study complete PD pathology in 
one model. 
 
1.5.1 In vivo models of Parkinson’s disease 
Animals are not naturally susceptible to PD, the symptoms must be induced and so 
models do not capture the full spectrum of PD, how it begins in idiopathic cases, and how it 
progresses. Full characteristics of SNpc dopamine neurons are also not present in rodent 
models, for example, the presence of neuromelanin is restricted to humans, primates, and 
some other mammals (Webster, 2001). However, models do allow for study of some of the 
motor and behavioural deficits experienced by people with PD. A number of animal models of 
PD have been developed, typically dependent on the administration of a toxin that targets 
dopaminergic neurons. The use of 6-hydroxydopamine (6-OHDA) and MPTP are perhaps the 
most popular models, although the use of rotenone and lactacystin also produce parkinsonian 
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symptoms and pathological hallmarks of PD. Some of the animal models of PD are described 
below, although this list is not exhaustive.  
Since 6-OHDA cannot cross the BBB (Simola, Morelli and Carta, 2007) administration 
of 6-OHDA is applied by direct injection, typically unilaterally, into the SN or medial forebrain 
bundle, inducing the loss of the nigrostriatal dopaminergic pathway. Injection of desipramine 
(a noradrenaline transporter inhibitor) 30-60 mins prior to 6-OHDA improves specificity of 
dopaminergic toxicity. This method is commonly chosen for the rat model of PD, with 
administration of amphetamine used to study the unilateral motor deficits induced by 
destruction of the nigrostriatal pathway through rotation tests (Duty and Jenner, 2011). 
Toxicity occurs through accumulation of 6-OHDA into dopaminergic neurons which 
subsequently results in neuronal dysfunction through oxidative stress (via auto-oxidation of 
6-OHDA) and direct inhibition of mitochondrial activity (Simola, Morelli and Carta, 2007). 
Microglial activation (Cicchetti et al., 2002) and the pro-inflammatory marker TNF-α (Mogi et 
al., 2000) are also increased in the 6-OHDA rat model which corresponds to the 
neuroinflammation response observed in PD brains.  
The toxin MPTP was later discovered as a selective toxin for SN dopaminergic neurons 
with the effects also observed in the primate brain, generating a primate model of PD (Duty 
and Jenner, 2011). MPTP is able to cross the BBB, after which it is taken up and metabolised 
by astrocytes through MAO activity producing the toxin 1-methyl-4-phenylpyridinium (MPP+) 
which is then selectively taken up by dopaminergic neurons where it inhibits mitochondrial 
activity (Dias, Junn and Mouradian, 2013; Chen, Turnbull and Reeve, 2019). However, rodents 
are less sensitive than primates to MPTP toxicity due to a more rapid clearance of MPTP and 
its metabolites (Johannessen et al., 1985), although some specific mouse breeds are more 
susceptible (Duty and Jenner, 2011). One of the proposed mechanisms for MPTP-induced 
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toxicity is through poly(ADP-ribose) polymerase (PARP) activation, with PARP-/- mice showing 
resistance to MPTP mediated toxicity (Mandir et al., 1999).  
The organic pesticide rotenone is also used to generate animal models of PD. This toxin 
is able to easily cross the BBB and diffuse into neurons where it accumulates within 
mitochondria inhibiting complex I (Duty and Jenner, 2011). Degeneration starts in the axon 
terminals retrogradely progressing towards to the soma, and also involves the aggregation of 
α-synuclein and appearance of LBs (Greenamyre, Betarbet and Sherer, 2003). Other hallmarks 
of PD degeneration are also observed including oxidative stress, and microglial inflammation, 
however, toxicity is not limited to the CNS and it can produce mortality through cardiovascular 
toxicity (Duty and Jenner, 2011).  
Another method for the in vivo modelling of PD is through proteasome inhibition. 
Proteasome dysfunction is a possible pathogenic mechanism for the degeneration of 
dopamine neurons in PD. A proteasome inhibitor commonly used is lactacystin, which is 
typically, and most reliably, used to produce in vivo models generating PD-like symptoms from 
injection into the SN or medial forebrain bundle of rodents. The mechanisms for toxicity are 
suggested to include the production of ROS, mitochondrial dysfunction, and accumulation of 
iron and α-synuclein (Bentea, Verbruggen and Massie, 2017).  
Genetic based models have also been developed, typically using mutations linked to 
the hereditary forms of PD such as LRRK2, PINK1, GBA, and DJ-1 (Dawson, Ko and Dawson, 
2010). These models can provide insights into pathogenesis and molecular mechanisms of the 
disease as well as providing a testbed for potential new treatments, although their application 
may be restricted to genetic, rather than idiopathic, PD.  
These in vivo models all provide methods to study the mechanisms behind, and 
potential treatments for, PD. Each have advantages and disadvantages with reviews in the 
literature both across and within these model systems (Greenamyre, Betarbet and Sherer, 
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2003; Dawson, Ko and Dawson, 2010; Duty and Jenner, 2011; Bentea, Verbruggen and Massie, 
2017). The most commonly used and well-characterised toxin for in vivo models appears to 
be MPTP, although 6-OHDA is also widely used.  
 
1.5.2 In vitro models of Parkinson’s disease 
In vitro models provide a more controlled environment to study the cellular and 
molecular pathophysiological mechanisms that may take place in PD degeneration, with 
advantages and disadvantages to their simplicity. A variety of cell lines and primary derived 
cultures, alongside the use of genetic manipulations and the toxins described above, are 
typically used to generate in vitro PD models. To accurately recapitulate the dopaminergic 
neuron degeneration that occurs in PD, ideally, cell models should have the same features as 
SNpc dopaminergic neurons (described in Table 1.5). Some of the available cell lines and 
culture techniques used to model PD are described below, however, these examples are not 
exhaustive. 
The PC12 cell line is derived from rat pheochromocytoma (Zou et al., 2016) and has 
the ability to synthesise, store, release, and uptake catecholamines, including dopamine, as 
well differentiate into neuron-like cells in response to nerve growth factor. Advantages of the 
use of these cells as an in vitro model include that they are well-studied and characterised, 
can be genetically modified, and have characteristics of dopaminergic neurons (review: 
Malagelada and Greene, 2008). However, this cell line is derived from cancerous rat adrenal 
tissue, severely limiting its application to human dopaminergic neurons. Nevertheless, 
research can be extrapolated to other PD models and this cell line can provide a method for 
the quick processing of theories surrounding PD.  
The RCSN-3 cell line is derived from adult rat SN. In their proliferative state, RCSN-3 
cells express enzymes involved in catecholaminergic synthesis, including TH, synthesise and 
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release dopamine, and express dopamine, noradrenaline, and serotonin transporter (review: 
Paris et al., 2008). Whilst these cells hold the advantage of derivation from the SN, they are 
not truly representative of dopamine neurons.  
One of the most commonly used cell lines described as an in vitro PD model is the 
human neuroblastoma cell line SH-SY5Y (Kermer et al., 2015; Anis et al., 2018; Elyasi et al., 
2018; Morroni et al., 2018; Rafiepour et al., 2018; Wang et al., 2018). These cells are easy to 
maintain and proliferate in culture and upon application/withdrawal of specific factors can 
differentiate into catecholaminergic-like neurons expressing markers involved in the synthesis 
of dopamine and noradrenaline. This cell line also holds the advantage of being human. 
However, whilst this cell line has proven valuable in the understanding of PD pathology, its 
derivation from a neuroblastoma means that it cannot accurately recapitulate A9 
dopaminergic neurons (review: Xicoy, Wieringa and Martens, 2017), and do not display their 
specific characteristics as outlined in Chapter 1.2.  
Human embryonic stem cell (hESC) lines are typically used to study the development 
of dopaminergic neurons with the aim of reliably generating large numbers of dopaminergic 
neurons (this is discussed in more detail in Chapter 1.7). However, much of this research is 
focussed on the generation of neurons as a therapeutic tool (discussed in Chapter 1.6.3) rather 
than modelling disease; this may be due to the difficulty in generating large numbers of 
specific A9 dopaminergic neurons (Arenas, Denham and Villaescusa, 2015) to then model 
degeneration. Neural stem cell (NSC) lines such the v-myc immortalised hVM1 cell line derived 
from human ventral mesencephalon provide a source of cells that more readily differentiate 
into midbrain dopaminergic neurons. NSCs allow for the study of factors involved in later 
specification of midbrain dopamine neurons and can also provide models for screening of 
pharmacological therapies for PD (Villa et al., 2009). The use of stem cells for modelling PD 
can be difficult due to large variation in dopamine neuron yield across cell lines and 
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differentiation protocols. However, these cell lines can provide a valuable tool in studying 
development and vulnerabilities of dopaminergic neurons through genetic manipulation of 
these cells (Simmnacher et al., 2020). 
Induced pluripotent stem cells (iPSCs) can also provide a valuable tool for 
understanding the pathology of PD. A number of iPSC cell lines derived from PD patients have 
been developed and differentiated towards dopaminergic phenotypes allowing for the study 
of the molecular mechanisms involved in hereditary forms of PD. These cells have been critical 
in the study of PD, especially surrounding genetic risk factors, although there can be great 
variability across cell lines dependent on reprogramming methods and differentiation 
protocols. Whilst improvements are still needed, iPSCs provide great potential for PD 
modelling in vitro and further exploration of disease pathogenesis and treatment options 
(review: Hu et al., 2020). 
Primary cultures derived from the developing ventral mesencephalon (VM) have been 
considered the gold standard for in vitro modelling of PD (Pruszak et al., 2009). This method 
allows for generation of genuine SNpc dopamine neurons, typically from rat, and as well as 
providing a testbed for protection from toxic insult in mature cultures, it can also be used to 
assess developing midbrain dopaminergic neurons. These cultures hold the advantage of 
containing other cell types present in the SN, providing an in vitro environment that more 
closely mimics the brain and allowing for the study of cell-cell interactions (Pruszak et al., 
2009). Also related to this technique is the use of VM organotypic slice cultures, typically 
derived from postnatal rat. These hold the advantage of maintaining cellular interactions and 
3-dimensional structure, as well as identification of the A8, A9, and A10 midbrain 
dopaminergic regions. However, they are more labour intensive, sensitive, and vulnerable to 
degradation than embryonic VM cultures and can present variation within, and across 
experimental repeats (Stahl, Skare and Torp, 2009).  
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These cell cultures represent the initial set-up, however, to truly model PD, 
dopaminergic cell death needs to be induced. As described in Chapter 1.5.1, toxins are 
typically used to target dopaminergic neurons. Due to the need for conversion of MPTP to 
MPP+ by astrocytes, it is not often used in in vitro models and 6-OHDA tends to be the most 
popular toxin to induce cell death in these cultures. MPTP also holds a higher risk of toxicity 
to humans than 6-OHDA, making it a more dangerous toxin for researchers to handle. 
Typically, the choice of toxin is dependent on the cell death pathway that is under 
investigation.  
Despite decades of research and the development of a myriad of in vivo and in vitro 
PD models, the pathogenesis of idiopathic PD is not yet fully understood, and effective long-





1.6 Treatments for the motor symptoms of Parkinson’s 
disease 
1.6.1 Current and future therapies for Parkinson’s disease 
There are a variety of methods currently used to treat PD throughout disease 
progression, with focus relating to the motor (Fox et al., 2011) and non-motor symptoms 
(Seppi et al., 2011) of the disease, with short-term effectiveness of pharmacological and 
surgical treatments (Goetz et al., 2005). The main treatment for the symptoms of PD is 
pharmacological, aiming to restore dopamine levels, with neurosurgery (deep brain 
stimulation; DBS) to restore the disrupted signalling through the BG, typically reserved for 
more advanced disease stages. Other therapies such as physiotherapy and speech therapy are 
also used alongside these (Oertel and Schulz, 2016). Although current treatments can alleviate 
symptoms, no long-term, or restorative therapies are available.  
Some of the current treatments, and their mode of action, for the motor symptoms of 
PD are displayed in Figure 1.7. Levodopa was the first and remains the most effective drug for 
treating the motor symptoms of PD (Thanvi, Lo and Robinson, 2007) by crossing the BBB and 
replenishing dopamine levels. However, long term use leads to further complications such as 
dyskinesias and on-off fluctuations of dystonia which are hard to counteract (Fabbrini et al., 
2007). 
Dopamine agonists mimic dopamine and act directly on D1 and D2 receptors (Brooks, 
2000). However, they are typically ineffective without levodopa supplementation (Pilleri and 
Antonini, 2015), can induce hallucinations (Poewe, 2008), and decrease in effectiveness over 





Figure 1.7 Schematic showing how current treatments ease the motor symptoms of PD. Building on 
Figure 1.3 B, loss of SNpc dopaminergic neurons disrupts signalling through the nuclei of the BG (red 
inhibitory, yellow excitatory; increased/decreased thickness represents increased/decreased strength 
of signal respectively). Pharmacological intervention through administration of Levodopa (the 
precursor to dopamine which can cross the BBB), COMT inhibitors (reduce the breakdown of 
dopamine), MOA-B inhibitors (limit the breakdown of dopamine), and dopamine agonists (compounds 
which activate D1 and D2 receptors) increase the level of available dopamine and dopamine signalling 
in the striatum. CRT also aims to increase levels of dopamine by placement of dopaminergic neurons 
into the striatum. These interventions work by restoring the lost dopaminergic signalling in the 
striatum which in turn restores the direct (D1) and indirect (D2) signalling pathways through the nuclei 
of the BG (green arrows) releasing the thalamus from inhibition.  
Deep brain stimulation is a neurosurgical approach to counter the motor symptoms of PD. Electrodes 
are typically placed within the STN or GPi, although different targets can produce different effects 
meaning that DBS can be tailored to each individual patient (Pizzolato & Mandat 2012). Continuous, 
high frequency stimulation is used to inactivate the target area and ease signalling disruption (brown 
arrows) to the thalamus, restoring signalling to the cortex. BBB: blood brain barrier, BG: basal ganglia, 
COMT: catechol-O-methyltransferase, CRT: cell replacement therapy, GPe: globus pallidus external, 
GPi: globus pallidus internal, MOA-B: monoamine oxidase B, SNpc: substantia nigra pars compacta, 
STN: subthalamic nucleus. 
 
COMT inhibitors can be used alongside levodopa, prolonging its pharmacological effect 
by blocking degradation (Kiss and Soares-Da-Silva, 2014). They can provide a neuroprotective 
effect from levodopa-induced neuropathy (Cossu et al., 2016), however, they can also be toxic 
to the liver (Kaakkola, 2010). Similarly to COMT, the administration of MAO-B inhibitors 
prevent the breakdown of dopamine (Schapira, 2011). However, these can also cause 
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hallucinations and headaches, and can result in the production of neurotoxic metabolites 
(Park et al., 2013). 
These pharmacological treatments increase levels of dopamine to restore BG 
signalling, however, this increase is not restricted to the striatum and can affect other 
dopamine signalling pathways. Intelligent dosing of medications significantly improves the 
lives of PD patients, however, combinations and timings can become complex and need 
tailoring to each individual. They also do not represent a long-term treatment solution as they 
only restore dopamine levels temporarily (i.e. immediately after administration), lose 
effectiveness over time due to non-physiological activation of dopamine receptors and 
continued neurodegeneration (Cenci and Konradi, 2010), and can produce debilitating side 
effects that outweigh initial benefits (Foster and Hoffer, 2004). 
DBS is a surgical technique that places electrodes into specific sites within the brain 
(Figure 1.7) utilising continuous high frequency stimulation to inactivate the target area, 
thereby blocking the signals that cause the motor symptoms of PD, notably the resting tremor. 
DBS has shown significant improvements on test scores (UPDRS-III and PDQ-39; Deuschl, 
2006) lasting at least 5 years (Krack et al., 2003), and has also been found to partially alleviate 
some non-motor symptoms of PD (Wolz et al., 2012).  
Although the symptoms of PD can be fairly well managed at the start of the disease, 
there is nothing to slow, halt or reverse disease progression, and current treatments lose 
effectiveness over time and can produce debilitating side effects (Oertel & Schulz 2016). 
Therefore, there is a major unmet need for therapies that offer neuroprotection for dopamine 




1.6.2 Future therapies may serve to protect dopamine neurons 
from degeneration 
As discussed in Chapter 1.1.6, the cause of dopaminergic degeneration in idiopathic 
PD remains unknown despite an in-depth understanding of the pathological features involved 
in their demise (Chapters 1.1.3, 1.1.4, 1.1.5). The dissociation between commencement of 
striatal dopamine loss and appearance of clinical features reaching the threshold for a 
diagnosis make it difficult to detect the disease at onset, although serum markers and risk 
factors may assist in overcoming this difficulty (Chapter 1.1.6). With this potential 
development it may be possible to protect dopamine neurons from the pathological process 
before substantial cell death and induction of symptoms by providing the optimum 
environment for their survival. 
Preventing the pathological process may be possible through administration of 
neuroprotective compounds. Administration of the growth factors neurturin and GDNF 
directly into the brain of PD patients found improvements in motor symptoms in some studies, 
however, placebo-controlled trials failed to show growth factor-induced improvements over 
placebo administration. There are a number of possible reasons for the outcomes of these 
trials, with one being suboptimal patient selection where degeneration of the nigrostriatal 
pathway was too advanced (Kirkeby and Barker, 2019). Application of this type of 
neuroprotective treatment may only be beneficial to less clinically advanced patients by 
slowing disease progression rather than restoring dopamine signalling. 
Inflammation and microglia have also been implicated in PD (Chapter 1.4.4), therefore, 
prevention of disease progression may also be possible through modulation of the brain’s 
immune system. The influence of anti-inflammatory medication on the risk of developing PD 
is not clear. Exposure to some non-steroidal anti-inflammatory drugs, such as ibuprofen, but 
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not aspirin, can reduce the risk of developing PD (Rees et al., 2011). Two specific 
immunosuppressants, corticosteroids and inosine monophosphate dehydrogenase inhibitors, 
have also been strongly associated with a lower risk of PD (Racette et al., 2018). This suggests 
that perhaps a more targeted approach to immune modulation is required for PD.  
Microglia may also be involved in a potential future therapy for PD, (in association with 
cell replacement therapy [CRT, described below]). Thus, through microglial interaction with 
grafted cells and/or their roles in embryonic brain development, microglia may one day be 
utilised to support the restoration of the nigrostriatal pathway. 
 
1.6.3 Cell transplantation is a promising therapy to restore 
dopamine signalling 
The aim of CRT is to restore the lost motor functions in PD by grafting dopaminergic 
neurons into the striatum to restore dopamine signalling. Ideally graft placement would be 
into the SN, to allow the rebuilding of complex topographical efferent and afferent 
connections (Haber, 2014), however, restoration of efferent connections from SN to striatum 
is not currently possible, due to inhibitory signals located within the nigrostriatal pathway in 
the adult brain. However, some progress has been made which shows potential for the 
reformation of full circuitry (Toledo-Aral et al., 2003; Shen, Hoffer and Wang, 2009; Thompson 
et al., 2009; Ghosh et al., 2019). 
CRT for PD has been tested in a number of clinical trials, with tissue from aborted 
human foetuses, containing SN progenitors, transplanted into the striatum of patients. A 
number of studies have shown reductions in motor symptoms, with some patients able to 
discontinue medication, and effects reaching 18 years post-transplant (Lindvall et al., 1990; 
Freed et al., 1992; Kefalopoulou et al., 2014), considerably higher than other treatments. 
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However, results have been varied and some patients received little to no benefit from the 
procedure, or developed graft induced dyskinesia (GID; Freed et al., 2001; Olanow et al., 2003; 
Barker et al., 2013).  
The development of GID as a side effect of CRT is poorly understood yet it is a potential 
barrier to the development of CRT as a therapy for PD. The replication of GID in animal models 
has proven difficult, however, Kordower et al. (2016) found that a higher dopamine deficit 
prior to grafting increased vulnerability to GID in parkinsonian monkeys. Although no 
relationship was found between the magnitude of dopamine reinnervation (measured by 
positron emission tomography) and the development of GID in grafted patients (Hagell et al., 
2002), Ma et al. (2002) suggest that their development could be due to unbalanced and 
uneven increases of dopamine within the graft. Another suggestion is that GIDs arise from the 
presence of serotonergic neurons within grafts (Politis et al., 2010; Shin et al., 2012) 
highlighting the need for well-characterised and defined graft sources. 
The discrepancies between early CRT trials are often accredited to the large variations 
regarding tissue source and preparation, aftercare, disease progression prior to 
transplantation, and assessment methods. A recent, ongoing clinical trial, TRANSEURO, is 
attempting to address the inconsistencies prevalent in CRT research for PD. Collaborators 
have drawn from raw data to develop a standardised technique designed to provide the best 
clinical outcome, with robust assessment measures for data collection pre- and post-
transplantation. Conclusions drawn from this trial will help to determine the future of CRT for 
PD (Barker et al., 2019). 
Grafts have been shown to survive and integrate, with surviving transplanted 
dopamine neurons observed post mortem (Hagell and Brundin, 2001) and fluorodopa 
positron-emission tomography showing an increase in the synthesis and storage of dopamine 
in the striatum post-transplantation (Lindvall et al., 1990; Freed et al., 1992).  
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Currently, the gold standard graft for CRT is considered to be human foetal VM tissue, 
although it is recognised that this is an unsustainable source (Barker et al., 2019; Parmar, 
Grealish and Henchcliffe, 2020). Therefore, protocols to generate suitable supplies of 
dopaminergic neurons from other sources are still required for CRT to be a sustainable, 
standardised therapy for PD. Hagell and Brundin (2001) suggest that, in order to achieve 
clinical benefit, the grafted cells must express phenotypic and genetic markers of A9 
dopaminergic neurons, be excitable and release dopamine, contain no proliferating cells, and 
survive transplantation in numbers of at least 100,000.  
One of the consistent problems with CRT is the poor survival rate of dopamine 
neurons, with numbers depleted to 1-20% of the total originally grafted. This cell death occurs 
through both necrosis and apoptosis arising from factors including sample preparation and a 
non-supportive host environment (inducing oxidative stress or lacking in suitable growth 
factors; review: Castilho, Hansson, & Brundin, 2000). The use of immunosuppression in CRT is 
varied and the effects are not well understood, although the consensus seems to be that 
immune suppression is beneficial to graft survival (Moriarty, Parish and Dowd, 2018). The 
recruitment of microglia to the graft site may be beneficial, or at least not detrimental, to 
grafted dopamine neurons (Duan et al., 1998; Zietlow, Dunnett and Fawcett, 1999). However, 
the activation state of recruited microglia (M1/M2) and their subsequent roles in graft 
integration and survival, are not well described. Furthermore, the duration of the immune 
response to the transplantation process is unknown. These factors contribute to the ambiguity 
of the role of microglia in CRT, and consequently the need for immunosuppression (review: 
Tomov, 2020).  
Biomaterials which allow for provision of a supportive, cell adhesion environment, or 
localised and sustained release of growth factors, or protection from host immune cells may 
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assist in developing CRT as a treatment for PD (Moriarty, Parish and Dowd, 2018) by helping 
the survival of transplants and also reducing the volume of tissue required. 
Stem cells, defined by their ability to both self-renew and to differentiate and produce 
mature progeny, are a potential source of dopaminergic neurons for CRT. They can be 
classified by their potential for differentiation as totipotent (able to give rise to all cell types 
including embryonic and extra-embryonic), pluripotent (able to give rise to all embryonic cell 
types), multipotent (able to give rise to a more restricted cell lineage such as mesodermal, 
ectodermal or endodermal), and oligopotent (able to give rise to more restricted cells such as 
those within an organ; Wagers & Weissman 2004). Their importance in clinical research 
includes their use as tools for the study of development, disease modelling, drug screening, 
and gene identification (both as genetic risk factors or as therapeutic targets); and their 
potential for use in cell therapies (Reubinoff et al., 2001; Shakhova and Sommer, 2010).  
Human stem cells can be derived from a number of sources (Figure 1.8), with both 
human ESCs and iPSCs thought to be the most suitable and sustainable source of dopaminergic 
neurons for CRT (Parmar, Grealish and Henchcliffe, 2020). Grafts derived from these sources 
reportedly contain fewer astrocytes and serotonergic neurons (which contribute to graft 
induced dyskinesia) than VM tissue grafts; and may also promote vascularisation through 
inclusion of vascular leptomeningeal cells. ESCs or iPSCs from stem cell banks would provide 
a defined and consistent supply of dopaminergic progenitors, easily assessed for quality 
control purposes. However, ESC and some iPSC grafts (derived from iPSC banks) do have the 
limitation of being allogenic, presenting the risk of immune rejection or need for long-term 
immune suppression. The use of allogenic ESCs without immune suppression showed poor 
survival and no functional recovery in a monkey MPTP CRT model (Hallett et al., 2014). 
However, researchers have proposed that the use of homozygous human leukocyte antigen 
typed iPSCs could match over 90% of a country’s population (Nakatsuji, Nakajima and 
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Tokunaga, 2008; Taylor et al., 2012) reducing the need for immune suppression and risk of 
rejection. 
The use of autologous iPSCs can eliminate the risk of immune rejection and has shown 
functional motor recovery and survival for up to 2 years in a monkey MPTP PD model (Hallett 
et al., 2014). This study also showed no recovery with the use of an alternative differentiation 
protocol, and others have shown differences in the numbers of surviving TH+ neurons 
between different iPSC lines (Kikuchi et al., 2017), highlighting the importance of the 
differentiation protocol and donor cells in the survival of grafted cells. The variability arising 
from iPSCs raises concerns of reproducibility, lack of quality control checks, and an increased 
time period for the generation of suitable cells for transplantation. Retaining genetic risk 
factors of PD also poses another detriment to the use of autologous iPSCs (Fan, Winanto and 
Ng, 2020), although only 10% of PD cases have a known genetic risk factor. No differences 
were found between iPSC grafts derived from healthy and PD individuals in an MPTP monkey 
model (Kikuchi et al., 2017), suggesting that autologous iPSCs may not pose an increased risk. 
However, this model was only followed up for 24 months, and as the specific cause of PD 
remains unknown it is suspected that gene-environment interactions play a role (Horsfall et 
al., 2013). Also, the age-related nature of PD suggests the potential for degeneration in iPSCs 
may be delayed, although the long-term in vivo viability of dopaminergic neurons from PD 




Figure 1.8 Diagram illustrating some of the sources of human stem cells that may be applicable to cell 
replacement therapies. (Wagers and Weissman, 2004; Revazova et al., 2007; Chen, He and Zhang, 
2009; Trounson and McDonald, 2015) 
 
The promising results from the use of stem cell grafts in animal models of PD 
encourages the potential use of stem cells in CRT for PD. However, in vitro differentiation of 
stem cells into dopaminergic neurons is a complex process requiring a number of factors. 





1.7 Dopaminergic neuron development in vitro 
As discussed in Figure 1.5, the in vivo development and maintenance of midbrain 
dopaminergic neurons requires a complex signalling pattern throughout embryogenesis. 
Replication of this signalling pathway may assist in the development of dopaminergic neurons 
suitable for CRT for PD. It is also important to be able to identify this subset of neurons prior 
to terminal differentiation as mature neurons show lower viability after transplantation 
(Barker et al., 1995; Fricker et al., 1996; Brederlau et al., 2006) and therefore neural 
progenitors or immature neurons may provide a more useful cell population for 
transplantation. 
In vitro generation of midbrain dopaminergic neurons has vastly improved. Early 
protocols were able to differentiate large numbers of TH+ neurons, but not with the A9 
specificity required for use in CRT (Arenas, Denham and Villaescusa, 2015). Protocols can now 
generate high percentages of dopaminergic neurons between 60-97% TH+ from human ESCs 
and iPSCs. However these protocols utilise co-culture and feeder cell techniques that are not 
clinically transferable due to the risk of contamination with undesirable cell types or the risks 
associated with xenogeneic products which are commonly used as feeder cells (Kriks et al., 
2011; Gonzalez et al., 2013; Llames et al., 2015). A selection of studies that have shown 
differentiation and transplantation of TH+ neurons into PD models are listed in Table 1.6 with 
survival of TH+ neurons composing up to 54% of grafted cells (Kirkeby et al., 2012). Arenas, 
Denham and Villaescusa (2015) provide an in-depth review on current generation of A9 
specific neurons from pluripotent stem cell sources. They highlight a number of future 
challenges and criteria for the generation of neurons suitable for CRT for PD including the 
need for short and scalable protocols using defined components in line with good 
manufacturing practice (GMP) guidelines (Bedford et al., 2018) . One class of molecules that 
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are well defined and essential to life are vitamins, which may hold potential for use in the 




Table 1.6 Table showing some studies that have successfully transplanted dopaminergic neurons, derived from human stem cells, in PD models.  
Dopamine 
Neuron Yield 




Other cell types present Reference 
TH/FOXA2+: 
~2.6% of 
grafted cells in 
mouse; 







Dual SMAD inhibition, floor plate 
induction. Shh, purmorphamine, FGF8, 
CHIR99021, AA, BDNF, GDNF, transforming 
growth factor type β3 (TGFβ3), dibutyryl 
cyclic AMP (db-cAMP) 
Yes, 18-20 
weeks 6-
OHDA rat and 
mouse; 














Few GABA+, 5-HT+ 
neurons 








Dual SMAD inhibition and embryoid body 
formation, activation of Wnt signalling 
(using CHIR99021), Shh 
Maintained on mouse embryonic 
fibroblasts 
Yes, 18 weeks 
in 6-OHDA rat 
Improved EN1, NURR1, 
LMX1A, FOXA2, 
TH, AADC, GIRK2 






iPSCs 836B3 Dual SMAD inhibition and floor plate 
induction, activation of wnt signalling 
(CHIR99021) 
Isolation of CORIN+ cells 
Yes, 16 weeks 
in 6-OHDA rat 
Improved MAP2, LMX1A, 






1.2% 5-HT+ neurons 
Doi et al. 
(2014) 
TH+: ~3-4% of 
grafted cells 
ESCs H9 Dual SMAD inhibition, Shh, 
purmorphamine, CHIR99021, AA, BDNF, 



















Cells grown on Lam-111, 16 day protocol, 
basal medium Neurobasal + DMEM/F12 
with N2. Additional SB431542, Noggin, 
Shh-C24II, CHIR99021, FGF8b, B27, BDNF, 
AA; GMP grade protocol 
Yes, 
6-OHDA rat 
Improved FOXA2, OTX2, 
LMX1A, LMX1B, 
TH, GIRK2 
Few CALB+ neurons Kirkeby et 
al. (2017) 




8 iPSC lines, 
healthy and 
PD donors 
Dual SMAD inhibition and floor plate 
induction, isolation of CORIN
+
 cells, db-
cAMP, DAPT  
Yes, MPTP 
monkey 
Improved FOXA2, TUJ1, 
NURR1, TH, 
GIRK2, DAT 
No or few OCT4+, SOX1+, 
PAX6+, Ki67+ 
proliferating markers  
5-HT+, GABA+, GFAP+, 






1.8 Vitamins in the central nervous system 
Between the early 19th century and mid-20th century, the structure and major 
functions of each of the 13 key vitamins was elucidated (Table 1.7; Semba, 2012) and it is now 
common knowledge that vitamins, in small amounts, are essential for maintaining health 
throughout the body, including the brain.  
Table 1.7 Table displaying the 13 key vitamins, other names by which they can be known, and some 
examples of their physiological functions. RDI: recommended daily intake is given in mg per day for 
adults (women/men if values differ), data obtained from Public health England. * denotes no 
recommended intake given, doses below are not considered detrimental. Adapted from Fricker et al. 
(2018). 
Vitamin Other Names Examples of physiological functions RDI (mg) 
A Retinol, Retinoic Acid, Retinal, 
Carotenoid 
Growth, maintenance of skin, bone development, maintenance of 
myelin, maintenance of colour and peripheral vision, steroid 
hormone synthesis, resistance to infection 0.6/0.7 
B1 Thiamine Growth, appetite, digestion, nerve activity, energy production, coenzyme in pyruvate metabolism 0.8/1 
B2 Riboflavin 
Growth and development of foetus, constituent of flavoproteins, 
redox systems and respiratory enzymes, maintenance of mucosal, 





Maintenance of NAD and NADP, coenzyme in lipid catabolism, 
oxidative deamination 13.2/16.5 





Protein, carbohydrate, and lipid metabolism, coenzyme in amino 
acid metabolism, growth 1.2/1.4 
B7 Biotin, protective factor X 
Growth, maintenance of skin, hair, bone marrow and sex glands, 
coenzyme for carboxylation reactions, biosynthesis of aspartate 
and unsaturated fatty acids *< 0.9 
B9 Folic acid, Folacin, Folinic acid 
Synthesis of nucleic acid, differentiation of embryonic nervous 
system, metabolism of tyrosine and histidine, synthesis of choline, 
one-carbon transfer mechanisms 0.2 
B12 Cobalamin Coenzyme in nucleic acid, protein and lipid synthesis, maintenance of epithelial cells and nervous system 0.15 





Normal growth, Ca and P absorption, increases citrate blood 
levels, maintains and activates alkaline phosphatase in bone, 
maintains serum calcium and phosphorus levels 0.1 
E Tocopherol, Tokopharm, 
Tocotrienols 
Antioxidant, normal growth maintenance, aids absorption of 
unsaturated fatty acids, maintains normal muscular metabolism 
and integrity of vascular system and central nervous system 3/4 
K Prothrombin factor, 
Menaquinones 
Blood clotting mechanisms, electron transport mechanisms, 




Studies have shown the importance of vitamins in the differentiation and survival of 
neuronal cells (Kasuya, 1975; Bain et al., 1995; Christie et al., 2008; Erceg et al., 2008; 
Ulatowski and Manor, 2015). They have an antioxidant role in the central and peripheral 
nervous system (Vatassery, Smith and Quach, 1989; Vatassery, 1992), with imbalance during 
pregnancy shown to adversely affect antioxidant defence mechanisms (Roy et al., 2014), and 
to alter adult gene expression of neurotrophins and signalling molecules such as BDNF, nerve 
growth factor, tropomyosin receptor kinase B (TrkB) and cyclic adenosine monophosphate 
(cAMP) response element binding protein (CREB; Sable et al., 2014). This highlights their 
importance in the developing nervous system. Vitamins are commonly used in a number of 
different in vitro differentiation protocols (Griffin et al., 2017) and nicotinamide has been 
shown to enhance the differentiation potential of calcitriol and retinoic acid in human 
myeloblastic leukaemia cells (Shen and Yen, 2009). The potential interactions of vitamins A 
(retinoic acid), B3 (nicotinamide), C (ascorbic acid; AA), and D3 (calcitriol) in the development 





Figure 1.9 Schematic showing genes and proteins involved in dopaminergic differentiation and how vitamins A, B3, C, and D3 may interact with these. Orange boxes 
indicate stem cell expression, black boxes represent expression at the neural precursor stage, green shows expression in dopamine precursors and purple shows 
expression in mature dopamine neurons. En1/2 are essential for dopaminergic development and maintenance. Arrow-headed lines show upregulation and bar-
headed lines downregulation. Vitamin B3 (nicotinamide) may promote differentiation through inhibition of Sirt1 which is required by Oct4 to maintain self-renewal 
and inhibit differentiation (Williams et al., 2016). Vitamin A (retinoic acid) increases levels of En1 (Cooper et al., 2010), mediates Nurr1 signalling (Wallen-Mackenzie 
et al., 2003), and can counteract Pitx3 deficiency (Jacobs et al., 2007). Vitamin C (ascorbic acid) promotes Nurr1 recruitment (He et al., 2015). Vitamin D3 (calcitriol) 
upregulates GDNF (Orme, Bhangal and Fricker, 2013) which induces Pitx3 expression (Peng et al., 2011) and maternal deficiency of calcitriol reduces Nurr1 




1.9 Calcitriol and Parkinson’s disease 
Calcitriol is an active metabolite of vitamin D3. Although commonly known for its 
importance in bone growth, the vitamin D receptor is found in over 36 cell types (Norman, 
2008). In developing rats, the vitamin D receptor is found in the superior colliculus which later 
becomes the dopaminergic midbrain (Veenstra et al., 1998) and its onset at E15 coincides with 
the establishment of dopaminergic neurons suggesting a link between calcitriol and dopamine 
neuron development and maintenance (Gates et al., 2006). This timing also corresponds with 
an increase in neural apoptosis and decrease in mitosis (Burkert, McGrath and Eyles, 2003) 
and deficiency of vitamin D3 during development results in reduced levels of Nurr1 (Cui et al., 
2010) suggesting a role in dopaminergic maturation.  
Vitamin D3 has also been found to have neuroprotective properties (Wang et al., 2000, 
2001; Soilu-Hänninen et al., 2012) and deficiency could be a contributing factor to PD 
(Newmark and Newmark, 2007). However, a study of genetically reduced vitamin D3 levels 
showed no clear causal risk of developing PD (Larsson et al., 2017).  
Calcitriol increased levels of dopamine in the striatum and SN of 6-OHDA treated rats, 
however, this effect was not seen in ‘aged’ (22 month old) rats suggesting that 
neuroprotection via calcitriol could be reduced with age (Cass and Peters, 2017). Orme, 
Bhangal and Fricker (2013) found neuroprotective properties of calcitriol through 
upregulation of GDNF in cultures derived from E12 rat VM. With peak neurogenesis of TH+ 
neurons occurring at E12 in the rat embryo, and almost 80% of dopamine neurons generated 
between E12 and E14 (Gates et al., 2006), calcitriol may exert therefore neuroprotective 
effects on dopaminergic neurons at an early time point. Together, this suggests that calcitriol 
may play an important role in the development, maturation, and maintenance of dopamine 
neurons, however, calcitriol alone may not be sufficient.  
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1.10 Nicotinamide may also have roles in Parkinson’s 
disease 
Nicotinamide is suggested to have roles in both health and disease (Williams and 
Ramsden, 2005a), although due to a wide range of derivatives and biological affects, the exact 
role and mechanisms of nicotinamide’s activity is unclear. This PhD has focussed on 
uncovering the potential effects that nicotinamide has on neural cell types and how this may 
be utilised in research specific to PD. 
 
1.10.1 Vitamin B3 metabolism 
Vitamin B3 is the collective term used to describe the water soluble molecules nicotinic 
acid (NA; a.k.a. niacin) and nicotinamide (a.k.a. niacinamide) which are obtained through diet 
from foods including meat, fish, eggs, mushrooms and fortified cereals (Bogan and Brenner, 
2008). This is the body’s chief source of nicotinamide adenine dinucleotide (NAD+), although 
the essential amino acid tryptophan can also provide a source of NAD+ via metabolism in the 
liver and kidneys (Fukuwatari and Shibata, 2013). More recently, nicotinamide riboside (NR), 
found in cow’s milk, has also been discovered as a precursor to NAD+ (Bieganowski and 
Brenner, 2004). The processes involved in the generation of NAD+ from tryptophan, NA, 
nicotinamide, and NR, as well as a number of metabolites and pathways surrounding 
nicotinamide, are shown in Figure 1.10.  
Although tryptophan, NA, nicotinamide, and NR produce NAD+, each precursor has a 
different route and therefore different molecular intermediates, enzyme requirements, 
effects, advantages, and disadvantages. Tryptophan requires the kynurenine pathway, NA the 
Preiss-Handler pathway and nicotinamide and NR the Salvage pathway (Figure 1.10). 
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Tryptophan metabolism occurs via the kynurenine pathway (Figure 1.10) which has 
two branches active in different tissues and cell types. These produce a range of biologically 
and neurologically active intermediates (for review see: Castro-Portuguez & Sutphin, 2020). 
However, with the 8-step process producing just 1 mg of nicotinamide from 67 mg of 
tryptophan (Fukuwatari and Shibata, 2013) and low activity of kynurenine pathway enzymes 
in brain compared to peripheral organs (Schwarcz et al., 2012) it may not be the most 
productive method for increasing NAD+ levels in the brain.  
NA requires a 3-step process known as the Preiss-Handler pathway for conversion to 
NAD+ (Figure 1.10). However, high doses of NA given as a drug results in the adverse effect of 
flushing and therefore, NA supplementation is not considered a tolerable route for increasing 
NAD+ levels in humans. 
Nicotinamide is converted to NAD+ via the 2-step salvage pathway (Figure 1.10) with 
nicotinamide phosphoribosyl-transferase (NAMPT) producing the intermediate component 
nicotinamide mononucleotide (NMN), which is converted to NAD+ by the enzyme 
nicotinamide mononucleotide adenylyltransferase (NMNAT) of which there are three 
isoforms (NMNAT1, NMNAT2, NMNAT3). NR enters the salvage pathway producing the NMN 
intermediate through nicotinamide riboside kinase activity and synthesising NAD+ in a 2-step 
process. The use of NR can increase levels of NAD+ (T. Yang et al., 2007) without increasing 
levels of nicotinamide. Nicotinamide can be considered as a feedback/signalling molecule as 
it is produced by and inhibits sirtuin and PARP activity, and, through this mechanism, may be 
involved in the maintenance of NAD+ levels (Feldman et al., 2015). NR may be beneficial in 





Figure 1.10 Schematic showing the pathways in the production of NAD+ and compounds associated 
with nicotinamide. The Kynurenine pathway (highlighted by brown arrows), generating NAD+ from 
tryptophan (tryptophan to quinolinic acid not shown in detail), is an 8-step process, producing a range 
of biologically and neurologically active intermediates. The Preiss-Handler pathway (highlighted by 
green arrows) utilises a 3-step process to generate NAD+ from nicotinic acid (NA). The salvage pathway 
(shown in pink) is a 2-step process converting nicotinamide to NAD+ which is then recycled back to 
nicotinamide through NAD+ ‘consumption’ (red) by CD38 (cyclic ADP ribose hydrolase), PARPs 
(poly(ADP-ribose) polymerases), and sirtuins. Nicotinamide riboside also enters the salvage pathway 
through conversion to nicotinamide mononucleotide. Nicotinamidase, or Pnc1 (grey), bi-directionally 
converts nicotinamide to NA, although this enzyme is only present in invertebrates which do not 
possess NAMPT and instead convert nicotinamide to NA for NAD+ generation via the Preiss-Handler 
pathway, suggesting that the salvage pathway is more evolutionarily advanced (Vrablik et al., 2009; 
Imai and Guarente, 2016). Each molecule/compound is written in black, whilst enzymes are written in 
blue. Purple shows the processes that convert NAD+ to NADH, and the reverse. Adapted from Fricker 
et al. (2018). 
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Aside from the salvage pathway, nicotinamide can also be converted to N-
methylnicotinamide or 1-methylnicotinamide, metabolites commonly found in urine, and low 
levels can be considered a marker of niacin deficiency (Bender, Earl and Lees, 1979). This takes 
place through nicotinamide N-methyltransferase (NNMT) activity, an enzyme that is 
expressed in the CNS with varying levels across brain regions and is present in dopaminergic 
neurons, but not glia, of the SN (Parsons et al., 2002).  
The plasma concentrations of NA and nicotinamide vary across studies. NA has been 
suggested at 4-122 nM (Ashourian and Mousdicas, 2006) with concentrations of up to 57,000 
nM in children (Adams and Audhya, 2011). Whilst observed serum levels of nicotinamide have 
included 840 nM (Ito et al., 2020) and approximately 4000 nM (Odum and Wakwe, 2012). The 
differences observed across these studies could arise from dietary differences across subjects. 
Oral administration of nicotinamide dose-dependently increases plasma concentrations 
(between 30 mins to 4 hours correlating with increased dose, with more variation between 
individual patients at higher doses) with final plasma concentrations of approximately 1.2 mM 
(156 ± 34 µg/mL) and 1.4 mM (177 ± 23 µg/mL) for 6 g and 10 g doses respectively. Doses of 
up to 6 g were well tolerated, however, half of patients ingesting 10 g had severe nausea and 
vomiting (Dragovic et al., 1995). Direct application of 10 mM nicotinamide to human 
pluripotent stem cells has increased intracellular concentrations from 0.01 mM to 1.5 mM 
after 1 hour of incubation (Meng et al., 2018). This suggests that in vitro studies can be 
extrapolated to the in vivo environment as administration of exogenous nicotinamide can 
increase concentrations within both in vitro and in vivo systems. 
Nicotinamide and its derivatives have been reported to be at a higher concentration 
in cerebrospinal fluid (~15 µM) than in serum, with approximately 0.5 mM/kg in the brain. 
After intravenous injection into rabbit, nicotinamide was more readily taken up into the 
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cerebrospinal fluid than NA (Spector, 1979); whilst NA was shown to be a better precursor to 
NAD+ than nicotinamide in the liver, intestine, and kidney (Bogan and Brenner, 2008). 
The potential for nicotinamide to treat a variety of diseases including neurological 
disorders, skin disorders, and cancer has been discussed across the literature. Hwang and Song 
(2020) provide a review of nicotinamide, potential uses, and the positive and negative effects 
experienced with high doses. The effects of nicotinamide on the body may be through direct 
effects of nicotinamide, through conversion to nicotinamide derivatives, or through enzymes 
that utilise NAD+ such as sirtuins, poly(ADP-ribose) polymerases (PARPs), and CD38 (Banasik, 
Stedeford and Strosznajder, 2012).  
 
1.10.2 Nicotinamide and NAD+ in the brain 
Nicotinamide crosses the BBB (Spector and Johanson, 2007) and can be converted into 
NAD+ by neural cells, leading to increased levels of NAD+, NADH, NADP+, and NADPH, 
collectively termed the pyridine nucleotides (Banasik, Stedeford and Strosznajder, 2012), and 
has been shown to be transported into mouse astrocytes through extracellular pH-sensitive 
mechanisms (Suzuki et al., 2010). Administration of nicotinamide to mice increased levels of 
NAD+, NADH, NADP+, and NADPH in the brain. Although increases varied across different brain 
regions, significant increases were seen in striatum and midbrain regions (Klaidman, 
Mukherjee and Adams, 2001). 
Generation of NAD+ through the salvage pathway is initiated by the conversion of 
nicotinamide to NMN by the enzyme NAMPT. Expression of NAMPT has been observed in the 
rat and human brain (Kitani, Okuno and Fujisawa, 2003), and specifically in neurons (Stein et 
al., 2014), with higher expression in neurons than astrocytes (Zhang et al., 2010; Wang et al., 
2011). Overexpression of NAMPT, in vivo and in vitro, has shown neuroprotective effects 
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(Wang et al., 2011), and knockout, in mouse forebrain excitatory neurons, has led to cortical 
atrophy and abnormal dendrite morphology (Stein et al., 2014). 
NMN is then converted to NAD+ by NMNAT, whose expression has been observed in 
brain tissue (Orsomando et al., 2012). The activity of NMNAT has also been implicated in 
neuroprotection and is suggested to be specifically involved in axon protection (Sasaki, Araki 
and Milbrandt, 2006; Coleman and Freeman, 2010; Ljungberg et al., 2012; Lavado-Roldán and 
Fernández-Chacón, 2016). 
Nicotinamide is implicated as an important modulator of CNS health and disease, with 
involvement in neuronal injury, stroke, Huntington’s disease, AD, and PD (Fricker et al., 2018). 
Overexpression of Pcn1 (also known as nicotinamidase; which bi-directionally converts 
nicotinamide to NA) extends drosophila lifespan (Balan et al., 2008). Overexpression of 
NAMPT is protective in in vivo and in vitro stroke models, whilst blocking NAMPT (using FK866) 
aggravates neuronal injury in these models, an effect that was prevented by addition of NMN 
(Wang et al., 2011).Treatment of an AD mouse model with NMN restored respiratory function 
(Long et al., 2015); and application of nicotinic acid mononucleotide (NaMN), NMN, and NR 
can delay axonal degeneration after axotomy (Sasaki, Araki and Milbrandt, 2006). If 
mitochondrial dysfunction and axonal degeneration are features of PD (as discussed in 
Chapters 1.1.5 and 1.1.6), increasing levels of NMN and NR, which are involved in NAD+ 
synthesis, may be beneficial for neuroprotection.  
NAD is present in two forms, oxidised (NAD+) and reduced (NADH), which are vital 
cofactors in glycolysis, beta-oxidation, Krebs cycle, and the electron transport chain. These 
redox reactions cycle the reversible conversion of NAD+ to NADH (Figure 1.10), never depleting 
the pool of NAD+. A portion of NAD+ can be converted into NADP+, with the addition of a 
phosphate group by NAD kinase, which can also cycle between oxidised (NADP+) and reduced 
(NADPH) forms, or be converted back to NAD+ through NAD phosphatase. Anabolic redox 
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reactions use NADP+/NADPH, whereas NAD+/NADH is used for catabolic reactions (Bogan and 
Brenner, 2008; Spaans et al., 2015). Collectively, the pyridine nucleotides are crucial in around 
200 enzymatic reactions with functionality in a number of cytoprotectant roles (Williams and 
Ramsden, 2005b). 
Reduced serum levels of NAD+ and NADH are found in patients with multiple sclerosis 
(Braidy et al., 2013) and NAD homeostasis is altered with age (Massudi et al., 2012; Braidy et 
al., 2014; Zhu et al., 2015) suggesting a role in age-related diseases. Overexpression of NAMPT 
increases NAD+ levels and protects cells through protection of mitochondrial NAD+ levels (H. 
Yang et al., 2007). 
NAD+ is utilised by the mitochondrial respiratory electron transport chain in the 
synthesis of ATP, a molecule that provides energy in many cellular processes. Depletion of 
NAD+ can also lead to depletion of ATP and decreased cell viability (Berger et al., 1987; 
Stubberfield and Cohen, 1988), suggesting that nicotinamide could provide protection 
through maintenance of NAD+ and subsequently ATP levels. Nicotinamide has also been found 
to maintain mitochondrial membrane potential and prevent membrane depolarisation 
resulting in the release of cytochrome c (involved in apoptotic signalling), an effect observed 
in models of oxidative stress (Li, Chong and Maiese, 2006). 
There are many cellular pathways and functions affected by NAD+, and NAD+ levels, 
meaning that NAD+ can be considered a signalling molecule, with increased levels inducing cell 
survival mechanisms (Schultz and Sinclair, 2016). NAD+ is used by processes which ‘consume’ 
it, leading to the production of nicotinamide which is recycled into the salvage pathway to 
generate more NAD+. ‘Consumers’ of NAD+ include sirtuins, PARPs and CD38 and may be a 





1.10.3 Nicotinamide and sirtuins 
Sirtuins are a family of histone deacetylases involved in the regulation of many 
essential biological processes throughout the body and have been linked to aging and 
longevity (Imai and Guarente, 2016). There are 7 isoforms, named Sirt1-Sirt7, which mostly 
function in the deacetylation of proteins resulting in changes to protein surface charge, 
conformation, and interactions. In this process, the acetylated group is transferred from the 
protein to ADP-ribose, using NAD+, and releasing nicotinamide (Wang et al., 2019). The actions 
of sirtuins are complex and are still being uncovered, although their activity in 
neurodegenerative disease, including PD, has long been established (Jęśko et al., 2017; Tang, 
2017).  
Sirtuin mRNA expression is highest in the brain compared to other organs and is often 
linked to cellular replicative lifespan (Michishita et al., 2005). Sirt1 expression can be 
considered both neuroprotective and neurotoxic dependent on cell type, stress, and 
conditions, for example showing neuroprotection in models of axonal degeneration and AD 
(Sansone et al., 2013). 
Nicotinamide is a non-competitive inhibitor of sirtuins and inhibits Sirt1, Sirt2, Sirt3 
and Sirt6 to different extents (Bitterman et al., 2002; Avalos, Bever and Wolberger, 2005), and 
it is proposed that NAD+ levels regulate sirtuin activity (Feldman et al., 2015).  
 
1.10.4 Nicotinamide and poly(ADP-ribose) polymerases 
PARPs are a family of 17 proteins that utilise NAD+ as a substrate for generating ADP-
ribose modification on target proteins and are involved in a number of cellular functions 
including cell survival, DNA repair, and genomic stability (Herceg and Wang, 2001; Amé, 
Spenlehauer and De Murcia, 2004; Cseh et al., 2017). PARP-1 is the most abundantly 
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expressed and best characterised isoform (Cseh et al., 2017). It is activated by DNA strand 
breaks and involved in DNA repair, with inhibition of PARP-1 increasing the sensitivity of cells 
to DNA damaging agents (Herceg & Wang, 2001). However, PARP-1 also plays a role in cell 
death through both apoptosis and necrosis (review: Virág & Szabó, 2002) with severe stress 
leading to over-activation (Cimadamore et al., 2009); and PARP-1 activation leading to NAD+ 
and ATP depletion (Alano et al., 2010), and involvement in the release and translocation of 
apoptosis-inducing factor (Herceg and Wang, 2001; Amé, Spenlehauer and De Murcia, 2004). 
PARP-1 has also been implicated in neurite outgrowth (Stoica et al., 2014), proliferation (Hong 
et al., 2019) and inflammation (Kauppinen and Swanson, 2005). It can be described as a 
double-edged sword due to involvement in both cell survival and cell death.  
Nicotinamide is an inhibitor of PARP-1; although Ki and IC50 values vary across the 
literature ranging from 5.6 – 52 µM and 31 – 210 µM respectively  (Banasik, Stedeford and 
Strosznajder, 2012), this suggests that serum levels, especially with supplemented 
nicotinamide, may be adequate to inhibit PARP-1 activity. Nicotinamide can rescue primary 
mouse astrocytes from cell death induced by a DNA alkylating agent (N-methyl-N′-nitro- N-
nitrosoguanidine) which activates PARP-1 expression (Suzuki et al., 2010). Since PARP-1 
activity cleaves NAD+ into ADP-ribose and nicotinamide, the release of nicotinamide could be 
considered as feedback inhibition. PARP inhibition has also shown cytoprotective effects from 
hydrogen peroxide (Zhang et al., 2000), and genetic disruption of PARP provides 
neuroprotection in cerebrovascular disease models (Eliasson et al., 1997).  
 
1.10.5 Nicotinamide and cyclic ADP ribose hydrolase 
Cyclic ADP ribose hydrolase, also known as CD38, is a transmembrane glycoprotein 
which converts NAD+ into nicotinamide, adenosine diphosphate-ribose (ADPR), and cyclic 
ADPR (Hamblin, 2003). It is expressed in neurons (Mizuguchi et al., 1995), astrocytes (Verderio 
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et al., 2001), and microglia (Mayo et al., 2008). CD38 has a number of functions including a 
role in calcium signalling, through the production of cyclic ADPR (Verderio et al., 2001), and 
roles in neurodegeneration and neuroinflammation, proposed to be through CD38 regulation 
of NAD+ levels (for review see: Guerreiro et al., 2020). 
In primary cultured mouse microglia, cyclic ADPR promoted pro-inflammatory 
microglia activation, associated with increased expression and activity of CD38, and increased 
intracellular calcium concentration, following exposure to the pro-inflammatory stimuli LPS 
and IFNɣ (Mayo et al., 2008). 
Overexpression of CD38 (in the human embryonic kidney 293T cell line) led to a 35% 
decrease in intracellular NAD+ levels (Hu et al., 2013). With CD38 expression and activity 
increasing with age it is thought to be involved in the age-related decline of NAD+. CD38 is also 
involved in the degradation of NMN, indicating a further possibility for modulating CD38 in 
therapies aiming to restore NAD+ levels (Camacho-Pereira et al., 2016). 
 
1.10.6 Nicotinamide and Parkinson’s Disease 
Nicotinamide may have a role in PD, however, the exact implication is unknown 
(Williams and Ramsden, 2005a; Hill and Williams, 2017). Significant reductions in the level of 
NAD+, nicotinamide ribonucleotide (an NAD+ salvage metabolite), and NR were found in PINK1 
mutant drosophila. Dietary supplementation of nicotinamide improved mitochondrial 
function and prevented the loss of dopaminergic neurons (Lehmann, Loh and Martins, 2017). 
Similarly, NR supplementation protected dopamine neurons and climbing ability in the 
drosophila GBA-PD model (Schöndorf et al., 2018). 
GBA-PD iPSCs show a reduced NAD+/NADH redox state suggesting a reduction in NAD+. 
Treatment with nicotinamide, NMN and NR showed increases in NAD+ levels (nicotinamide 
showed the least increase and NR the most). NR also restored mitochondrial cristae 
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morphology and reduced mitochondrial ROS production in GBA-PD neurons. Therefore 
increasing NAD+ levels may rescue mitochondrial dysfunction The effect of NR was abolished 
by a Sirt1 inhibitor, suggesting a potential mechanism for this effect. (Schöndorf et al., 2018). 
Nicotinamide has also shown protection in an MPTP mouse model (Anderson, Bradbury and 
Schneider, 2008), further suggesting the potential for nicotinamide as a neuroprotectant.  
Significantly upregulated levels of NAMPT mRNA have been observed in blood samples 
from PD patients (Santiago, Littlefield and Potashkin, 2016). Inhibition of NAMPT in a PC12 6-
OHDA model increased the vulnerability of these cells to toxicity, whilst application of NMN 
(the product of NAMPT activity) protected cells (Zou et al., 2016). This suggests a role of 
NAMPT, and/or the substrates involved, in PD, although the exact relationship is unclear.  
NA has been shown to reduce inflammation in RAW264.7 cells (a mouse cell line with 
macrophage/monocyte morphology; Giri et al., 2019) and can skew peripheral macrophages 
from M1 polarisation to M2 polarisation in PD patients (Wakade et al., 2018). This is proposed 
to be mediated through GPR109A, an anti-inflammatory receptor with a high affinity for NA, 
which is upregulated in the blood and SN of PD patients (Wakade et al., 2014). However, 
nicotinamide has virtually no GPR109A activity (Pike, 2005) but may still exert effects on 
immune cells directly, through increased NAD+ levels (Haag et al., 2007), or through 
nicotinamide’s interactions with sirtuins and PARPs. 
However, it is also possible that high levels of nicotinamide may induce detrimental 
effects. Levels of nicotinamide are high in meat, particularly beef, and a correlation of 
increased meat in diets and PD incidence is observed across international populations (Hill 
and Williams, 2017). Argentina, with high beef consumption has one of the highest incidence 
rates, whilst poor, rural China and Nigeria, with mostly vegetarian diets, have the lowest 
incidence rates (Williams and Ramsden, 2005b). Furthermore, a vegan diet is suggested to 
reduce the risk of PD (McCarty, 2001).  
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A method for which high levels of nicotinamide may increase the risk of PD is through 
NNMT activity which converts nicotinamide to N-methylnicotinamide (Figure 1.10) a substrate 
that is toxic to dopamine neurons (Fukushima et al., 2002), likened to MPP+ (Parsons et al., 
2002), and has been linked to PD pathology (Fukushima, 2005). Higher levels of NNMT activity 
have been found in brains from PD patients compared to controls (Parsons et al., 2002) and 
this activity is also reflected in substantially higher levels of N-methylnicotinamide in urine of 
PD patients (Green et al., 1991).  
As discussed in Chapter 1.1.6, intake of alcohol, caffeine and nicotine (through 
smoking) are associated with a lower risk of developing PD. These compounds may interfere 
with NNMT activity decreasing the production of N-methylnicotinamide (Williams and 
Ramsden, 2005b).  
It is unclear the exact role that nicotinamide may play in PD, whether it is neurotoxic, 
neuroprotective, or how this interaction may be conveyed through the variety of mechanisms 
and derivatives that nicotinamide possesses. Further research into the effects of nicotinamide 
on neural cells implicated in PD may assist in the development of future therapies or provide 




1.11 Aims and Objectives 
Despite decades of research and an in-depth knowledge of the structural organisation 
of the nuclei involved in PD neurodegeneration, and the variety of pathological features 
displayed, a true understanding of the pathological mechanisms remains largely unknown and 
a curative therapy elusive. However, ongoing research in this field can help to highlight, 
develop, and improve potential treatments for PD including understanding the roles of non-
neuronal cells. Similarly, although vitamins are known to exert a myriad of effects on the CNS, 
and nicotinamide has been suggested as a possible neuroprotectant, further investigation is 
required before their full potential can be harnessed.  
Therefore, the aims of this PhD thesis are: 
I. To assess the potential of nicotinamide in the differentiation of dopaminergic 
neurons from stem cells to aid the development of CRT for the treatment of 
the motor symptoms of PD. 
II. To assess the potential protective actions of nicotinamide on dopaminergic 
neurons, which may assist in the development of future therapies for PD. 
III. To explore the potential effects of nicotinamide on microglia and whether this 
could be utilised to understand the mechanisms of immune modulation; both 




2 Materials and Methods 
2.1 Reagents, antibodies, and equipment 
General reagents used in this PhD project are shown in tables. 
• Reagents, their manufacturing company and relevant storage conditions are 
described in Table 2.1. 
• Primary antibodies and their dilutions are supplied in Table 2.2. 
• Secondary antibodies and their dilutions are shown in Table 2.3. 
• Equipment and software used in this PhD thesis are displayed in Table 2.4. 
 
2.2 Overall experimental design 
This PhD project used 2 key analytical techniques, microscopy and flow cytometry, to 
analyse cell cultures. The experimental design for microscopy analysis is shown in Figure 2.1. 
Typically, each experiment consisted of at least 3 experimental repeats or ‘n’ numbers. This 
term is used to describe each experiment where cells were derived from separate biological 
sources including different litters, split litters (2 tandem experiments from one litter split from 
dissection stage), or split cell cultures. Using multiple experimental repeats ensures results are 
observed across separate biological repeats are not confined to a singular biological anomaly. 
It also contributes to producing more robust data with smaller error margins. It is generally 
accepted that scientific experiments should be repeated at least in triplicate to confirm 
observed results. 
Each experimental repeat contained control and treatment conditions. Each treatment 
condition had 3-4 coverslips termed ‘technical replicates’. Each technical replicate consisted 
of 3-4 micrographs/images; this allowed for observation of an area and quantitative cell 
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numbers that were deemed representative of the cell population. Cell numbers counted from 
these images were depictive of treatment conditions and were sufficient to show the 
observed differences through statistical tests.  
For flow cytometry, each condition had 1 or 2 samples, termed ‘technical replicates’, 
run through the flow cytometer and 4 experimental repeats (n number). The use of technical 
replicates ensures reliability and consistency within each experimental repeat and considers 






Table 2.1 Table of reagents used in this PhD thesis. 
Product Name Manufacturer Code Solvent Storage of solution 
6-Hydroxydopamine hydrobromide Sigma 162957 85 mM ascorbic acid 100 mM, 10 µL aliquots, -80°C, no freeze thaw 
B27 Gibco 17504044   
Borate buffer – Sodium tetraborate Sigma 221732 Water 25 mM, adjust to pH 8, stored at 4°C, sterile filtered 
Calcitriol R&D Systems 2551 DMSO  
CHIR-99021 Sigma  SML1046   
Dnase Fisher Scientific 10649890   
Dulbecco's Modified Eagle Medium (DMEM) 4.5 
g/L w/o L-glutamine w/o sodium pyruvate Lonza 12-733f 
  
Dulbecco's Modified Eagle Medium (DMEM)-F12 
with Ultraglutamine Lonza BE04-687F/U1 
  
EC23 StemCell Technologies 73102   
Foetal bovine serum Corning 35-079-CV   
Gelatin 0.1% Embryomax, porcine, type A Sigma ES-0006-B   
Glasgow's Minimum Essential Medium (GMEM) 
high glucose Gibco 21710025 
  
Glucose Sigma G7021 Water 30% solution (15 g into 50 mL), sterile filtered, stored at 4°C 
GM-CSF PeproTech 400-23 Water 25 µg/mL in 0.1% bovine serum albumin (PBS), -80°C 
HEPES HyClone SH30237.01   
Laminin, mouse Merck CC095 PBS -20°C 
L-Ascorbic acid Sigma A4544 Water Powder kept in dark at -20°C, solution used immediately 
MycoAlert Plus Mycoplasma detection kit Lonza LT07-701   
N2 Gibco 17502048   
Neurobasal Gibco 21103049   




Normal Donkey Serum Jackson ImmunoResearch 017-000-121 Water -20°C 
Normal Goat Serum Jackson ImmunoResearch 005-000-121-JIR Water -20°C 
Paraformaldehyde Fisher Scientific 11473704 PBS 4% stored at -20°C 
PD0325901 Sigma PZ0162   
PenStrep: Penicillin Streptomycin Lonza/SLS LZDE17-602E   
Poly-D-Lysine Corning/SLS 354210 PBS -20°C 
Polyethylenimine Aldrich 408727 25 mM borate buffer 10% stored at 4°C, sterile filtered 
Propidium Iodide Invitrogen P3566   
Sodium Pyruvate Lonza LZBE13-115E   
Triton X-100 Sigma X100 PBS  
Trypan Blue 0.4% Fisher Scientific 15250061   
TrypLE Fisher Scientific 10573283   
Ultraglutamine Lonza BE17-605E/U1   
Vectashield mounting medium with DAPI Vectorlabs H-1200   






Table 2.2 Table of primary antibodies used in this PhD thesis. 
Target Host Species Manufacturer Code Dilution Ratio 
GFAP Rabbit DAKO Z0335 1:1000 
GFAP Mouse Biologend 644701 1:500 
GFP Rabbit Novus Biologicals NB600-308 1:1000 
Iba1 Goat Abcam ab5076 1:500 
Nestin Mouse BD Biosciences 611658 1:200 
Serotonin Goat Abcam ab66047 1:500 
Tyrosine hydroxylase Rabbit Merck AB152 1:1000 
β-III-tubulin Mouse Biolegend 801201 1:1000 
β-III-tubulin Rabbit Biolegend 802001 1:1000 
 
Table 2.3 Table of secondary antibodies used in this PhD thesis. 
Fluorophore Target Species Host Species Manufacturer Code Dilution Ratio 
488 Mouse Goat Invitrogen A28175 1:500 
488 Mouse Donkey Jackson Immuno 715-545-150 1:500 
488 Mouse Donkey Invitrogen A21202 1:500 
594 Goat Donkey Jackson Immuno 705-585-003 1:500 
594 Rabbit Goat Invitrogen A-11012 1:500 
647 Rabbit Donkey Abcam ab150067 1:500 
 
Table 2.4 Table of equipment used in this PhD thesis. 
Equipment/Software Brand Model 
Dissecting microscope Leica S6D 
Flow Cytometer Guava EasyCyte 6-2L 
InCyte Guava 3.1 
FlowJo BD Biosciences X.0.7 
Microscope Nikon Eclipse 80i 
Microscope Nikon Eclipse Ti 
Microscope camera Hammamatsu C4742-95 
NiS Elements Nikon 2.32 
Image J National Institutes of Health 1.51j8 
Plate reader Promega Glomax Multi Detection System 






Figure 2.1 Schematic demonstrating the experimental design and equations used to normalise data. 
Each experiment consisted of at least 3 experimental repeats or ‘n’ numbers (orange). Experimental 
repeats contained control and treatment condition. Each treatment condition had 3-4 coverslips 
termed ‘technical replicates’, with 3-4 micrographs/images taken of each technical replicate. 
Equations explain the calculation used to normalise data. The average quantified value/measurement 
from each technical replicate was divided by the average number of the control condition of that 




2.3 General cell culture:  
2.3.1 Maintenance, incubation, and media 
Each cell culture system was maintained in a humidified incubator at 37 °C with 5% 
CO2. All cell culture was carried out using aseptic techniques with the use of a class II laminar 
flow hood. Non-sterile reagents such as phosphate buffered saline (PBS) and distilled water 
dH2O were autoclaved at 121 °C and 20 psi (20 mins) prior to use. Any reagents that were not 
able to be autoclaved, such as media components, were sterile filtered through 0.2 µm syringe 
filters.  
Different culture media, outlined in Table 2.5, were used for each culture system. The 
mouse embryonic stem cell line 46C was maintained in 2i and N2B27 media for proliferation 
and differentiation respectively. Primary rat embryonic day 14 (E14) cultures were dissected 
using dissection medium and maintained in neural cell medium (NCM). Pure microglial 
cultures were maintained in D10 media. All media were stored at 4 °C and kept for no longer 
than 2 weeks. 
When handling cells, all reagents and media were either warm (pre-warmed to 37 °C 
in a water bath), or cold (kept on ice or at 4 °C) as stated in the text. 
 
2.3.2 Preparation of cell adhesion surfaces 
Cell culture flasks, wells and coverslips were coated to promote adherent, monolayer 
growth. Each culture system required different substrates, the procedure for each is outlined 




For 0.1% gelatin coating, the bases of flasks/wells were fully covered with 0.1% gelatin 
and left for a minimum of 30 mins at room temperature. The gelatin was then aspirated and 
plasticware was washed with warm PBS, which was removed just prior to cell seeding. 
Table 2.5 Table showing the media used for each culture system in this PhD thesis. 
Culture System Media Reagent Concentration 
46C N2B27 
DMEM-F12 with Ultraglutamine 1:1 Neurobasal 
Neurobasal 1:1 DMEM-F12 
Ultraglutamine 1 mM 
B27 1 X 
N2 0.5 X 
PenStrep  100 U/mL 
β-mercaptoethanol 0.1 mM 
46C 2i 
N2B27  
CHIR99021 3 µM 
PD03259010 1 µM 
Primary rat E14 VM 
and WGE Dissection media 
DMEM-F12  
HEPES 50 mM 
Glucose 0.6 % 
Primary rat E14 VM 
and WGE 




PenStrep 100 U/mL 
Foetal bovine serum 1 % 
B27 1 X 
Ultraglutamine 1 mM 
Pure Microglial 




DMEM (4.5 g/mL glucose)  
Foetal bovine serum 10% 
Ultraglutamine 2 mM 
Sodium Pyruvate 1 mM 
PenStrep 100 U/mL 
 
Prior to coating, coverslips were dipped in 70% ethanol and dried under ultraviolet 
(UV) light for sterilisation. Coverslips were then coated with either poly-D-lysine (PDL) alone, 
PDL and laminin, or polyethylenimine (PEI) and PDL, dependent on each culture system. 
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For PDL coating, coverslips were submerged in PDL (10 µg/mL) for a minimum of 30 
mins at room temperature. Coverslips were then washed 3 times with dH2O and left in the 
final wash until aspiration just prior to cell seeding. 
For PDL and laminin coating, coverslips were submerged in PDL (10 µg/mL) for a 
minimum of 1 hour at room temperature. PDL was then aspirated and coverslips were washed 
3 times with dH2O. Laminin (2 µg/mL) was then applied, ensuring complete coverage of 
coverslips, which were placed in the incubator at 37 °C overnight. Laminin was removed and 
coverslips were washed 3 times with dH2O, aspirating the final wash just prior to cell seeding. 
To coat coverslips with PEI and PDL, coverslips were immersed in PEI (0.05%) for a 
minimum of 1 hour at room temperature. PEI was then removed and coverslips were washed 
4 times with dH2O, then left in PDL (10 µg/mL) overnight in the incubator. Coverslips were 
washed 3 times with dH2O with the final wash aspirated just prior to cell seeding. 
 
2.3.3 Cell counting and seeding 
To seed cell cultures at the appropriate density, cell counts were undertaken using a 
Neubauer chamber. After centrifugation and aspiration of supernatant, cells were 
resuspended in the appropriate media. A sample of cells was diluted into trypan blue, by a 
dilution factor of 10, to allow visualisation and exclusion of dead cells (trypan blue positive). 
10 µL of trypan blue/cell mixture was transferred to the haemocytometer for counting. The 
number of trypan blue negative cells were counted in at least 2 of the 4x4 corner grids, 
including cells touching the top and left lines and excluding those touching the bottom and 
right lines. The number of cells across grids was averaged, then multiplied by the trypan blue 
dilution factor, then multiplied by 10 to give the number of cells in 1 µL. Cells were then diluted 
into media to the appropriate concentration for seeding. 
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Cells were seeded by either flooding the well (and coverslip) with media containing the 
correct number of cells per well, or by using micro-drop cultures. Micro-drop cultures were 
formed by placing 30-50 µL of medium containing the specified density of cells into the centre 
of a dry coverslip forming a defined drop on the surface. This method allowed for a high-
density cell colony in the centre of the coverslip with all viable cells attached to the coverslip. 
After transferring plates to the incubator for 4 hours allowing cell attachment, wells were then 




2.4 Mouse embryonic stem cell culture  
2.4.1 The 46C cell line 
The mouse embryonic stem cell (mESC) line 46C (a kind gift from Professor Meng Li, 
Neuroscience & Mental Health Research Institute, Cardiff University) was used to study the 
effects of nicotinamide on neuronal differentiation. This cell line contains the green 
fluorescent protein gene (GFP) under the Sox1 promoter allowing for visual identification of 
neural precursors expressing Sox1. This cell line was generated from E14Tg2a.IV cells after 
gene targeting where the open reading frame of Sox1 was replaced with GFPiresPac. This 
allows for accurate recapitulation of in vitro Sox1 signalling with undetectable levels in 
undifferentiated cells, increasing to a significant proportion of cells expressing GFP upon 
neural induction (Ying et al., 2003). This cell line provides a valuable tool for the identification 
of neural precursors within differentiating populations. 
 
2.4.2 Thawing and proliferation of the 46C cell line 
The 46C cell line had been frozen in 10% dimethyl sulfoxide (DMSO) in medium at a 
density of 2 x 106 cells in 800 µL. Vials were removed from liquid nitrogen storage and rapidly 
thawed in warm water. Cells were transferred to a 15 mL tube containing 5 mL warm N2B27 
medium (Table 2.5) and centrifuged at 1000 rpm for 3 minutes. Supernatant was removed and 
cells were resuspended in warm 2i medium (Table 2.5) and transferred to a gelatin coated T25 
flask (described in Chapter 2.3.2). 
Proliferating 46C cells were maintained in 0.1% gelatin coated T25 flasks in 2i media 
(Table 2.5). Cultures were passaged after reaching 80% confluence. Cells were washed with 
warm PBS, then enzymatically detached using warm TrypLE (synthetic trypsin; 2 mins). Cells 
were collected into a 15 mL tube with 10 mL warm N2B27 and centrifuged at 1200 rpm for 3 
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mins. Supernatant was discarded and the pellet resuspended in warm 2i medium. Live cells 
were counted (Chapter 2.3.3) and seeded at 5 x 105 cells per gelatin coated T25 flask with 2i 
medium. Medium was changed every 2-3 days. Cultures were used between passage numbers 




2.5 Use of animals for primary tissue cultures 
Adult Sprague Dawley rats were maintained in appropriate conditions in line with the 
Home Office Code of Practice for the housing and care of animals bred, supplied, or used for 
scientific purposes covered by Keele University site licence X350251A8. Animals were housed 
in the accredited animal facility at Keele University with ad libitum access to food (Special Diet 
Services RM1 (E) 801002) and water, and with controlled temperature (21 ± 2 °C) and 
photoperiod (12 hour light-dark cycle). Each cage was supplied with substrate, hide, chew 
block and bedding. Females were 12-15 weeks old when paired for mating in a mesh bottom 
cage with ad libitum access to food and water. The tray underneath the cage was checked 
daily for the plug ejected by the female once mated. Once the plug was seen, marking Day 0 
of gestation, females were removed and housed with other pregnant dams. Animals were 
killed using licenced Schedule 1 methods in accordance with the Animals (Scientific 
Procedures) Act of 1986. 
 
2.5.1 Dissection and maintenance of E14 rat ventral 
mesencephalon and whole ganglionic eminence cultures 
Primary ventral mesencephalon (VM) and whole ganglionic eminence (WGE) cultures 
were obtained from E14 rat embryos. Pregnant Sprague Dawley rats were sacrificed by 
cervical dislocation at 14 days from the plug date (defined as E0). The abdomen was sprayed 
with 70% ethanol before laparotomy to remove embryos from the uterus. Embryos were killed 
humanely using a standard Schedule 1 procedure appropriate for their gestation 
(decapitation) and the heads collected into dissection media (Table 2.5) kept on ice. The VM 
and/or WGE was then dissected, as described in Dunnett & Björklund (1992) and shown in 
Figure 2.2, from each head individually under sterile conditions using a dissection microscope 
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in a laminar flow hood. The dissected tissue was collected into 1 mL dissection media kept on 
ice. Once dissections were complete, the collected tissue was washed twice with fresh, cold 
dissection media, then TrypLE DNase (consisting of DMEM-F12 with 0.5X TrypLE and 50 U/mL 
DNase) was added and cells were incubated at 37°C for 20 mins. TrypLE DNase was removed 
and tissue pieces were washed 3 times with cold DMEM DNase (DMEM-F12 with 50 U/mL 
DNase). Tissue pieces were then resuspended in 200 µL DMEM DNase and were mechanically 
dissociated using a P200 pipette. Cell density was calculated (Chapter 2.3.3) whilst cells were 
centrifuged at 1200 rpm for 3 mins at 4 °C. The pellet was then resuspended in room 
temperature NCM (Table 2.5) and cultures were seeded at 5-6 x 104 cells in 50 µL micro-drop 
cultures onto PEI and PDL coated coverslips (described in Chapter 2.3.2). Micro-drop cultures 
were allowed to attach for 4 hours before wells were flooded with warm NCM. At this point, 
cultures were described as 0 days in vitro (DIV). 
Primary rat E14 VM and WGE cultures were maintained in NCM in an incubator at 37 
°C with 5% CO2 and humidified atmosphere. The initial full media change took place at 3 DIV, 
with full media changes thereafter every 2-3 days to ensure removal of debris and 
replenishment of any media components or vitamins in treatment conditions. 
 
2.5.2 In vitro PD model using 6-OHDA 
To create an in vitro PD model, 6-OHDA was used to selectively destroy dopaminergic 
neurons within VM cultures. To prevent rapid oxidation of 6-OHDA, an ascorbic acid (AA) 
solution was used as a vehicle. To ensure continuity across experimental repeats, a stock 
solution of 100 mM 6-OHDA in 85 mM AA (stored at -80 °C) was used. For cell application, 100 
mM 6-OHDA (in 85 mM AA) was diluted into 85 mM AA to 2.5 mM 6-OHDA concentration. 
This solution (2.5 mM 6-OHDA in 85 mM AA vehicle) was then diluted 1:100 into NCM resulting 
in cells receiving final concentrations of 25 µM 6-OHDA in 850 µM AA.  
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At 7 DIV, media was aspirated and replaced with NCM containing 25 µM 6-OHDA or 
vehicle control (850 µM AA) for 4 hours. After treatment, 6-OHDA/AA media was aspirated 
and cells were washed twice with warm NCM and left to recover in NCM for 48 hours.  
 
Figure 2.2 Diagram showing the dissection of VM and WGE tissue. A) Diagram showing dissection of 
VM tissue from E14 rat. An initial cut was made above the eye to remove the brain. A series of cuts, as 
shown, were then made to dissect the VM B) Diagram showing dissection of WGE from E14 rat. An 
initial cut above the eye was made to remove the brain and the cortices were removed from the mid- 
and hindbrain. Cuts were then made along the dorsal, medial cortex and folded aside to reveal the 
lateral ventricular cavity. The WGE appears as a heart-shaped bulge which can then be removed with 
a superficial horizontal cut. This was then repeated on the second hemisphere. E: embryonic day; VM: 




2.6 Derivation of pure microglial cultures from mixed glial 
cultures 
Pure microglial cultures were obtained from rat mixed glia cultures. Mixed glial 
cultures were derived from postnatal day 0-3 (P0-3) Sprague Dawley rats. Animals were killed 
using a standard Schedule 1 procedure (overdose of pentobarbital) and the brains dissected 
out. Under sterile conditions, the cerebellum and olfactory bulbs were removed, the cerebral 
cortices isolated, and gently rolled on autoclaved handtowel to remove meninges. The 
cerebral cortices were then mechanically dissociated, seeded into PDL coated flasks, and 
maintained in D10 media (Table 2.5) for 7-10 days allowing cultures to become confluent, and 
for stratification of the cell layers, such that oligodendrocyte precursor cells and microglia 
were displaced above a confluent bedlayer of astrocytes. 
Shaking was used to separate floating and loosely adherent microglia from mixed glia 
cultures. Flasks had their headspace sealed to maintain 5% CO2, then were placed in a 37 °C 
rotary shaker at 220 rpm for 1.5-2 hours. This process detaches microglia from the monolayer 
culture keeping them suspended in the media. Media was then collected from the flasks and 
centrifuged at 1200rpm for 3 mins. The supernatant was discarded and the cell pellet 
resuspended in warm D10 media. Cell density was calculated (Chapter 2.3.3) and cells were 
seeded at the required density for each experiment onto PDL coated coverslips or wells and 




2.7 Preparation of flow cytometry samples 
To prepare cells for flow cytometry analysis, media was removed and cells were 
washed with warm PBS. TrypLE was applied for 2 mins to enzymatically detach cells which 
were collected into warm N2B27 in a 15 mL tube and centrifuged at 1200 rpm for 3 mins. The 
supernatant was discarded and cells were resuspended in 1 mL of cold PBS and transferred to 
a 1.5 mL Eppendorf tube. Cells were centrifuged again at 1200 rpm for 3 mins, the supernatant 
was discarded and cells resuspended in 500 µL cold PBS. Once again, cells were centrifuged at 
1200 rpm for 3 mins, the supernatant discarded, and cells resuspended in 200 µL of cold PBS. 
This cycle of washes ensured removal of media. Samples were kept on ice to minimise any 
enzymatic activity and degradation of cells until use. Cells were passed through the flow 
cytometer using Incyte software and data was later analysed using FlowJo software (Table 2.4). 
For excitation of fluorophores the blue (488 nm) laser was used alongside green (525/30 nm) 
and red (695/50 nm) emission filters for detection of GFP and propidium iodide (PI) 




2.8 Fixation and Immunocytochemistry 
Cells on coverslips or in wells were fixed using 4% paraformaldehyde (PFA) for 15 
minutes then washed 3 times with PBS. Samples remained in PBS at 4 °C until staining. 
Blocking solution (5% normal goat or donkey serum in PBS, 0.3% Triton X-100) was applied for 
1 hour to limit non-specific antibody binding. Primary antibodies (Table 2.2) in blocking 
solution were applied and left at 4 °C overnight. Samples were washed 3 times for 3 mins with 
PBS and blocking solution was applied again for 30 mins. Corresponding secondary antibodies 
(Table 2.3) in blocking solution were applied and samples were incubated in the dark at room 
temperature for 2 hours. Samples were then washed 3 times for 3 mins and coverslips were 
mounted with mounting medium containing 4',6-diamidino-2-phenylindole (DAPI). The 
outside of mounted coverslips were sealed with clear nail varnish for preservation of samples. 
The primary antibodies and dilution used in this PhD thesis are shown in Table 2.2. β-
III-tubulin is a microtubule present almost exclusively in neurons (Lee et al., 1990) with 
exceptions discussed in Chapter 3.4.1. Here it has been used to identify neuronal populations 
in both VM and 46C cultures.  
Tyrosine Hydroxylase (TH) is the rate-limiting enzyme that catalyses the hydroxylation 
of tyrosine to L-DOPA (Figure 1.4) and is expressed exclusively in catecholaminergic neurons 
(Daubner, Le and Wang, 2011). In this PhD thesis TH was used to identify dopamine neurons 
in VM cultures. Although some serotonergic neurons may be included in cultures, dependent 
on the positioning of the caudal cut during dissection (Dunnett and Björklund, 1992), later 
examination for serotonin staining revealed the presence of a couple of serotonin+ neurons 
within some coverslip cultures (data not shown). This allowed the belief that the majority of 
TH+ neurons within these cultures were dopaminergic.  
Neuroectodermal stem cell protein (Nestin) is a cytoskeletal protein expressed in NSCs 
and some non-neural cells. Here it is used to identify NSCs in VM cultures, which do not 
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contain the non-neural cells (e.g. heart, skeletal muscle) also known to express Nestin (Bernal 
and Arranz, 2018).  
GFAP is an intermediate filament present in astrocytes and is involved in pro-
inflammatory activation of astrocytes in response to injury or insult (McKeon and Benarroch, 
2018). It has been used to identify astrocytes in VM cultures in this PhD thesis.  
Ionized calcium binding adaptor molecule 1 (Iba1) is found to be exclusively expressed 
in microglia (Ito et al., 1998). Involved in cytoskeletal reorganisation, it is uniformly expressed 
throughout the cytoplasm (Korzhevskii and Kirik, 2016). It was used here to identify microglia 





2.9 Acquisition of cell images for analysis 
Microscopy was performed on either a Nikon Eclipse 80i or Nikon Eclipse Ti 
microscope. Images were captured using a black and white digital camera (Hammamatsu) and 
NiS Elements software. The same exposure settings were used for each fluorescence stain 
within each experimental repeat. Images were exported from NiS Elements software in Tag 
Image File Format (TIFF). Each TIFF contained a ‘stack’ of images termed ‘slices’ for each 
fluorescence channel used. TIFFs were analysed and transformed (e.g. colour application, 
scale bar addition etc.) using Image J software (Schneider, Rasband and Eliceiri, 2012). Lookup 
tables (LUTs) within Image J were used to apply relevant colours to each slice and to merge 
colour channels to show co-localisation of stains within images. 
Images taken at 10X magnification defined a 1.16 mm2 field of interest (FOI). 
Magnification at 20X equalled an FOI of 0.29 mm2. Images taken at 40X magnification had an 
FOI of 0.073 mm2. FOIs were taken randomly across the culture moving from left to right and 
top to bottom with no overlapping fields. To obtain representative images of cells of interest, 
the edges of VM cultures, which typically contain mostly proliferating cells, were avoided 
where possible. In order to reliably count cells of interest, large clumps of cells (identified as 
large numbers of DAPI+ nuclei, visible across multiple focal panes in the z axis), which would 
be difficult to quantify, were also avoided (FOI was rejected, and new FOI tested). Although 
all imaging followed the above guidelines, slightly differing techniques of imaging and analysis 
were utilised dependent on which cell type was to be analysed. Details of the technique used 




2.10 Measuring optical density 
Optical density measurements were used to quantify the expression of markers within 
cultures. This technique was used when counting was either not possible due to 
crowded/clumped cell distributions, or to provide further quantitative data about expression 
levels. 
To prepare images for optical density analysis, an Image J macro was used to transform 
TIFF stacks into individual images for each fluorescence channel slice. The slices were then 
colour inverted (high intensity staining originally shaded as white was changed to black) 
meaning that higher optical density measurements corresponded to higher levels of 
expression. 
The optical density of images was measured using the Image J Measure function. 
Measurements were calibrated using the step tablet (which provides steady gradations from 
white to black) and protocol supplied by the National Institutes of Health (NIH), Image J 
website (NIH, no date). The mean grey value was measured for each step on the tablet and 
entered into the ‘Calibrate’ dialog box alongside calibration values supplied by NIH. “Rodbard” 
was selected from the “Function” dropdown menu, and O.D. was entered in the “Unit” field. 
The mean grey value was then measured for each image as a whole resulting in values 




2.11 Normalisation of results with variation across 
experimental repeats 
Due to the nature of working with the dissection of biological tissue, variation was 
observed across some experimental repeats. This could arise from biological differences in the 
tissue used, due to variables such as: exact time between plug formation and dissection (which 
could easily vary by ~ 12 hours), variations in litter number (which can affect rate of 
development for individual pups), and variation in embryo/pup size (which may be related to 
individual rate of development, and could also influence accuracy of dissection and yield of 
desired tissue). Differences could also arise from the size of the dissected tissue with no way 
to replicate the exact accuracy of tissue dissection, yield, or purity across experimental 
repeats. 
Data sets were normalised if variations in cell counts were observed across 
experimental repeats. Trends across treatment conditions were conserved with 
normalisation. To normalise, the average quantified value/measurement from each technical 
replicate was divided by the average number of the control condition of that experimental 
repeat, then multiplied by 100 to give the percentage, relative to the average control. This is 




2.12 Statistical analysis using GraphPad Prism software 
Prism software was utilised for all statistical analysis. One-way and two-way ANOVA, 
t-tests and linear regression were utilised. The statistical analysis used for each set of data is 
outlined in the relevant chapter. Post-hoc analysis for ANOVA was utilised for more detailed 
statistical information across treatment groups. Bonferroni’s multiple comparisons test was 
used to compare two selected treatments within an ANOVA. Tukey’s multiple comparisons 
test was used to compare every treatment with every other treatment within an ANOVA. 
Dunnett’s multiple comparisons test was used when comparing each treatment against the 
control within an ANOVA. 
All data described within text and displayed in graphs is mean ± SEM (standard error 
mean) unless otherwise stated. Statistical significance is displayed as follows: * = p < 0.05, ** 





3 Nicotinamide in directing neuronal differentiation 
3.1 Introduction 
3.1.1 Nicotinamide has been used in differentiation protocols 
Cell replacement therapy has the potential to reverse, and offer long-term relief, from 
the motor symptoms of PD, through the replacement of lost dopaminergic neurons. However, 
researchers are still in pursuit of a reliable source of specific midbrain dopaminergic neurons. 
Stem cells may provide readily available and consistent neurons for grafts, with low 
immunogenicity. However, a suitable protocol for large scale, reproducible production of 
dopaminergic neurons, which survive transplantation in required numbers, is yet to be fully 
established (Chapter 1.6.3). Further enhancement of protocols for the differentiation of 
dopaminergic neurons and their survival in vitro may benefit from the addition of 
nicotinamide. 
Protocols have shown the use of nicotinamide in the differentiation of pluripotent cells 
(specifically ESCs and iPSCs) into insulin-secreting (Vaca et al., 2008), cardiac (Parsons et al., 
2011), motoneuron (Y. Zhang et al., 2011), and retinal pigmented epithelium (Idelson et al., 
2009; Buchholz et al., 2013) cells. 
Specifically, nicotinamide has shown effectiveness in promoting neural differentiation 
(Cimadamore et al., 2009; Idelson et al., 2009; Y. Zhang et al., 2011; Buchholz et al., 2013; 
Griffin et al., 2013, 2017). The application of 10 mM nicotinamide has been shown to promote 
neuronal differentiation of the mESCs used in this PhD thesis. Both numbers, and the 
percentage neurons of total DAPI+ cells, were significantly, and dose-dependently increased 
with the application of 5 and 10 mM nicotinamide (Griffin et al., 2013). Application of 10 mM 
nicotinamide during early differentiation also increased neuronal maturation of differentiated 
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mESCs and reduced the number of undifferentiated stem cells determined by Oct4 expression 
(Griffin et al., 2017). Reduced levels of NANOG and Oct4 mRNA in nicotinamide treated hESCs 
also suggest that nicotinamide promotes differentiation; whilst inhibition of meso-endoderm 
marker expression and induction of ectoderm marker expression further suggests that 
nicotinamide promotes neural differentiation (Meng et al., 2018). Cimadamore et al. (2009) 
found that addition of 5 mM nicotinamide to hESCs increased neuralisation and cell viability. 
Alongside differentiation, studies have also suggested that nicotinamide has roles in stem cell 
pluripotency, survival, and proliferation (Meng et al., 2018). 
 
3.1.2 Nicotinamide inhibits proliferation in a number of 
different cell types 
Nicotinamide dose dependently promoted hESC survival, and concentrations of 10 mM 
reduced cell growth over 4 days (Meng et al., 2018). Nicotinamide has also been shown to 
inhibit proliferation in some cancer-related cell lines, although the mode of action is debated 
(Audrito et al., 2011; Petin et al., 2019; Malesu et al., 2020). The addition of 10 mM 
nicotinamide to D3-ES cells (an mESC line) reduced proliferation by 70% when directed 
towards an insulin-secreting cell fate (Vaca et al., 2008). However, concentrations of 1 mM 
and below have been shown to increase proliferation and maintenance of pluripotency in 
human ESCs and iPSCs (Son et al., 2013). As discussed in Chapter1.10, nicotinamide could 






3.1.3 Nicotinamide’s mode of action includes Sirt1, PARP-1 and 
kinase inhibition 
Studies exploring the mechanisms of nicotinamide often refer to the inhibitory effects 
that nicotinamide exerts on Sirt1 and PARP-1 (discussed in Chapters 1.10.4 and 1.10.5). 
Inhibition of Sirt1 has been suggested as a mechanism in nicotinamide-induced neural 
differentiation (Y. Zhang et al., 2011; Liu et al., 2014). Levels of Sirt1 are higher in foetal, 
compared to adult, brain (Michishita et al., 2005), and Sansone et al. (2013) found reduced 
levels of Sirt1 in neuronally differentiated NG108-15 cells (a rodent neuroblastoma/glioma 
hybrid cell line with neuronal growth properties) compared to proliferating cells. Inhibition of 
Sirt1, through application of sirtinol, induced cell death in proliferating NG108-15 cells; whilst 
cell death was significantly lower in neuronally differentiated cells. Sirt1 overexpression also 
resulted in decreased expression of the neuronal marker MAP5, whilst Sirt1 silencing 
promoted neuronal net formation (Sansone et al., 2013). This suggests that nicotinamide-
induced Sirt1 inhibition may contribute to the accelerated neuronal 
differentiation/maturation described above.  
Nicotinamide also acts as a PARP-1 inhibitor and this is often cited as a mechanism for 
nicotinamide-induced effects. PARP-1 knockout mice show reduced brain weights, and NSCs 
derived from these mice show decreased proliferation rates and increased apoptosis, showing 
that PARP-1 is involved in NSC proliferation and survival (Hong et al., 2019). Cimadamore et 
al. (2009) found that addition of 5 mM nicotinamide to hESCs increased neuralisation and also 
increased cell viability through nicotinamide-induced PARP-1 inhibition, resulting in decreased 
cell death. They found that PARP-1 is strongly expressed in human neural progenitor cells, but 
it’s expression in hESCs is significantly lower (Cimadamore et al., 2009) suggesting that 
inhibition of PARP-1 may help to protect differentiating neural progenitor cells. However, 
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PARP-1 knockout mouse NSCs showed decreased neuronal, and increased astrocyte (GFAP+) 
and oligodendrocyte (Olig2+) differentiation (Hong et al., 2019). PARP inhibition supressed the 
formation of neurospheres in a concentration dependent manner and reduced the viability of 
neural stem/progenitor cells (Okuda et al., 2017).  
Although nicotinamide has been shown to inhibit PARP-1 activity, and this may have a 
role in the effects observed, complete inhibition may not be responsible for the nicotinamide-
induced neurogenesis discussed above. The assessment of 5 different PARP inhibitors (not 
including nicotinamide) showed variability in their effects on proliferation, differentiation and 
survival with mouse neural stem/progenitor cells (Okuda et al., 2017), highlighting the 
complexity of downstream effects caused by PARP inhibition and other regulatory influences 
that PARP inhibitors may exhibit.  
Nicotinamide may also exert neuroprotective effects through inhibition of Rho-
associated protein kinase activity and other kinase cascades (Meng et al., 2018). Although this 
is relatively new research, it provides another potential avenue for therapeutic applications 
of nicotinamide in neurodegeneration. This research also shows the wide-ranging effects that 




3.1.4 Aims of Chapter 3 
The use of nicotinamide in stem cell cultures could help to advance the development 
of dopaminergic differentiation protocols for CRT to provide treatment for PD. As previously 
discussed, nicotinamide has been used in the development of a number of differentiation 
protocols and has been shown to enhance neuronal differentiation whilst limiting stem cell 
proliferation. There is potential for CRT in the treatment of neurodegenerative conditions, 
however, one of the obstacles to CRT for PD is the need for protocols that can reliably and 
efficiently generate cells suitable for grafting. Therefore, this chapter aims to ascertain how 
nicotinamide may be used in the differentiation of stem cells for CRT for PD by assessing the 
effects of nicotinamide on 46C mESCs using immunocytochemistry and flow cytometry. The 
specific aims of this work were to: 
I. Assess the effect of nicotinamide on proliferation of 46C cells during a pro-
neuronal differentiation protocol. 





3.2.1 Mycoplasma testing of 46C cell line 
Mycoplasma are a type of bacteria, commonly found to infect cells in culture, that can 
interfere with normal cell functions, such as metabolism, compromising experimental data 
(review: Drexler & Uphoff, 2002). To confirm that the cells used in these experiments were 
mycoplasma-free prior to differentiation, the 46C cell cultures were tested for presence of 
mycoplasma using the MycoAlert PLUS kit (Lonza).  
The reagent and substrate were reconstituted as instructed. Supernatant from cells 
grown in Glasgow’s minimum essential medium (GMEM) for at least 24 hours was used to test 
cultures for mycoplasma. GMEM, rather than complex culture media was used, to simplify the 
experiment, removing extraneous media components, in order to rule out the cells as a source 
of contamination. GMEM supernatant was centrifuged at 1200 rpm for 3 minutes to remove 
cells and debris, then mixed with the reagent. Luminescence was read by a plate reader 
(Promega Glomax Multi detection system) after 10 minutes of reagent addition. The substrate 
was then added and the plate was read 10 minutes later. Results were calculated by dividing 
the second luminescence reading (substrate) by the initial luminescence reading (reagent). If 
this ratio is < 1, the sample is negative for mycoplasma. 
 
3.2.2 Neuronal differentiation of the 46C cell line 
For neuronal differentiation of 46C cells, proliferating cells (Chapter 2.4.2) were 
washed with warm PBS then enzymatically detached using warm TrypLE for 2 mins. Cells were 
collected in warm N2B27 media, centrifuged at 1200 rpm for 3 mins. The supernatant was 
discarded, the pellet resuspended in warm N2B27, and cell density calculated (Figure 3.1). 
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Cells were seeded into gelatin coated 6 well plates at a density of 1 x 105 cells per well, in 
warm N2B27 media (day 0) with full media changes every 2-3 days.  
On day 7, differentiating cells were washed with warm PBS, enzymatically detached 
using warm TrypLE for 2 mins, collected in 10 mL warm N2B27 and centrifuged at 1000 rpm 
for 3 mins. The supernatant was discarded and the pellet resuspended in warm N2B27. Cells 
were counted and seeded on to PDL and laminin coated glass coverslips in 30 µL micro-drop 
cultures containing 3 x 104 cells. Micro-drop cultures were allowed to adhere for 4 hours 
before flooding the well with warm N2B27 media. Cultures were maintained for a further 7 









3.2.3 Analysis of cells over the initial 7 days of differentiation 
The effects of nicotinamide on the neural differentiation of the 46C cell line was 
explored. Cells were plated into the differentiation protocol as described in Chapter 3.2.2. 
Nicotinamide concentrations of 5 and 10 mM were applied to cells in N2B27 media with full 
media changes every 2-3 days. Cells were fixed each day between day 1-7 and analysed by 
immunocytochemistry for GFP and β-III-tubulin expression (Chapter 2.8). Micrographs were 
obtained at 10X magnification using an inverted microscope to allow imaging of the cells in 
the 6-well plate. Efforts were made to plate the cells on gelatin coated glass coverslips at the 
same plating density, however, cells did not attach. It was deemed most appropriate to grow 
and image the cells in the 6 well plates. GFP expression in fixed samples across days 1-7 was 
analysed using OD (Chapter 2.10), and β-III-tubulin+ cells were manually quantified at day 7.  
Cells were also analysed by flow cytometry everyday between day 1-7 of the 
differentiation protocol. Flow cytometry samples were prepared as described in Chapter 2.7. 
 
3.2.4 Gating of cell populations within flow cytometry samples 
Flow cytometry is a method in which particles within liquid samples can be processed 
individually. With cells, this is obtained by forcing the liquid into a thin stream over a detection 
point in which only single cells can pass. At the detection point, variables including 
fluorescence, forward scatter (forward deflection of light; indicative of size) and side scatter 
(indicative of granularity) of each “event” are measured. Due to the nature of cell culture and 
the flow cytometry sample preparation, cell samples likely contain debris from dead cells 
which is also detected by the flow cytometer. Therefore, within flow cytometry samples, 




PI and Triton X-100 were used to identify the cell population within these flow 
cytometry samples, and to distinguish cells from debris. PI binds to DNA, an interaction which 
enhances the fluorescence of PI (~20-30 fold). However, PI cannot permeate into live cells, 
meaning that PI fluorescence is an indicator of membrane permeability and, therefore, cell 
death. This means it is commonly used to detect irreversibly compromised cells within a 
population. In this experiment PI was used at a concentration of 10 µg/mL to detect dead cells 
within flow cytometry samples.  
Triton X-100 is a detergent commonly used to permeabilise cells (Borner et al., 1994; 
Ahn et al., 1997). In this experiment 0.01% Triton X-100 was used to permeabilise cells, 
inducing cell death, within flow cytometry samples. By using PI and Triton X-100 it is possible 
to identify the cell population within samples. 
In this experiment, 46C cells were harvested after 3 days in either proliferation 
conditions (2i media) or differentiation conditions (N2B27 media). Cells were processed as 
described in Chapter 2.7. Proliferating and differentiating flow cytometry samples were then 
split into conditions containing PI alone or PI with 0.01% Triton X-100 (PI + Triton) and were 
left on ice for 15 mins before flow cytometry analysis. 
 
3.2.5 Gating of GFP+ cells within cell populations 
To assess the GFP+ population, gating needed to be set to discern GFP- and GFP+ 
populations. Possible gates were placed at 101.2, 102 and 102.2 on the green fluorescence log 
scale. These gates were chosen based on a search of the literature showing gates placed across 
these points for differentiating 46C cultures (Aubert et al., 2003; Ying et al., 2003; Diogo, 
Henrique and Cabral, 2008; Incitti et al., 2014). All three gates showed similar trends in GFP 
expression in these 46C control cultures over 7 days of differentiation (Figure 3.2). The 
percentage of GFP+ cells given at each timepoint within these gates was used to determine 
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the most appropriate gating strategy. Gating GFP+ populations as those above 102 in the green 
fluorescence log scale was deemed the most accurate gating strategy. This was based on a 
low GFP+ population at day 1 (4.32 ± 0.96 SEM) and a plateauing in GFP+ cells at days 5, 6, and 
7 reaching a maximum of 77.49% (± 3.02 SEM) at day 7, similar to results seen by Ying et al. 
(2003).  
 
Figure 3.2 Graph showing the percentage of GFP+ cells in flow cytometry samples (cell population gated 
as described in 3.2.4). Initially, three gates were set at 101.2, 102 and 102.2 in green fluorescence to 





3.3.1 46C cultures tested negative for mycoplasma 
As detailed in Chapter 3.2.1, supernatant from 46C cell culture was tested for the 
presence of mycoplasma prior to culturing of this cell line for this PhD thesis. Results were 
calculated by dividing the substrate luminescence reading (15383) by the reagent 
luminescence reading (22799) providing a ratio of 0.67 (Table 3.1). As this ratio is < 1, the 
sample was classed as negative for mycoplasma.  
Another simple test for mycoplasma contamination is the presence of extra-nuclear 
fluorescence resulting from mycoplasma DNA. Extra-nuclear DAPI fluorescence was not 
observed in differentiated 46C cultures during immunocytochemical analysis of fixed cultures 
(Figure 3.3). All cultures were routinely assessed using this method, with no signs of extra-
nuclear DAPI observed. 
Table 3.1 Table showing mycoplasma kit test results. Luminescence readings taken after addition of 
reagent and substrate to cell supernatant. The ratio of substrate to reagent is < 1 indicating a negative 
mycoplasma result. 
Reagent luminescence Substrate luminescence 𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒
𝐑𝐑𝐒𝐒𝐒𝐒𝐑𝐑𝐒𝐒𝐑𝐑𝐒𝐒
 
22799 15383 0.67 
 
 
Figure 3.3 Image showing DAPI staining of differentiated 46C cells. No extra-nuclear staining is visible 
indicating absence of mycoplasma. 
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3.3.2 Validating the production of β-III-tubulin+ cells in the 
neuronal differentiation protocol for 46C cells 
To determine whether nicotinamide has effects on the differentiation of stem cells to 
a neuronal fate, a testbed differentiation protocol was established (Chapter 3.2.2). 
Micrographs taken from 4 experimental repeats, each with 2-3 technical replicates, were 
counted to ascertain the percentage of β-III-tubulin+ neurons within differentiated cultures. 
Differentiation of the 46C cell line, using this 14 day protocol, resulted in β-III-tubulin+ cell 
populations comprising an average of 16.33% ± 4.15 of the total cell population (Figure 3.4, A-
C). β-III-tubulin+ cells displayed typical neuronal morphology with small somas and extending 
neurites (Figure 3.4, D). This indicates that the differentiation protocol is able to produce β-
III-tubulin+ neurons from the 46C cell line. 
 
Figure 3.4 Representative images of 46C cultures after the 14 day differentiation protocol. A) DAPI. B) 
β-III-tubulin. C) Merge of DAPI and β-III-tubulin. D) Magnified image showing typical neuronal 






3.3.3 Nicotinamide reduced 46C Sox1-GFP expression over the 
initial 7 days of differentiation 
Having validated a model of neuronal differentiation, cultures were treated with 
nicotinamide across the first 7 days, based on previous work showing the effects of 
nicotinamide occurring within the early days of differentiation (Griffin et al., 2013). Expression 
of GFP was quantified indicating Sox1 expression which is indicative of neural precursors. GFP 
expression was not visible in control cultures at day 1 of differentiation (Figure 3.5 A), however 
expression was widespread at day 7 (Figure 3.5 B).  
Due to the high density of cells observed over increasing days, it was not possible to 
identify individual cells to perform cell counts to quantify GFP expression. Therefore, optical 
density (OD) was used to assess GFP expression. 
OD measurements provided a simple assessment for immunocytochemistry. The mean 
grey value of 10X magnification micrographs showing GFP+ cells was measured. The changes 
in OD levels with time in culture could be the result of changes in cell numbers, morphology 
and/or GFP expression levels. Four images were taken from each of 3 technical replicates 
across 3 experimental repeats. As there was variation between experimental repeats, mean 
OD values of each technical replicate were normalised to the average day 1 control value of 
each experimental repeat.  
Two-way ANOVA of GFP OD data, normalised to control day 1, showed that GFP 
expression was affected by time in culture (F(6, 168) = 16.49, p <0.0001), nicotinamide treatment 
(F(2, 168) = 12.06, p < 0.0001), and showed an interaction effect of these parameters (F(12, 168) = 
9.481, p < 0.0001). Post-hoc analysis using Dunnett’s multiple comparison test revealed a 
significant increase in GFP OD in control cultures at days 5 (103 ± 0.46, p < 0.01), 6 (106 ± 0.96, 
p < 0.001) and 7 (110 ± 1.45, p < 0.001) of differentiation compared to day 1 (100 ± 0.06; Figure 
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3.6 A, E). Cultures treated with 5 mM nicotinamide also showed a significant increase in GFP 
OD at day 5 of differentiation compared to day 1 (104 ± 0.76 vs. 101 ± 0.22, p < 0.001; Figure 
3.6 B, E). Treatment of cultures with 10 mM nicotinamide did not show any significant 
difference in GFP OD over 7 days (Figure 3.6 C, E). These results show a significant increase in 
GFP expression that increases over days 5-7 of differentiation in control cultures. Cultures 
treated with 5 mM nicotinamide showed a significant increase in GFP OD only at day 5 
compared to day 1, whilst cultures treated with 10 mM nicotinamide did not show any 
significant differences in GFP OD throughout differentiation.  
Further post-hoc analysis showed significant differences between control and 
nicotinamide treated cultures. The addition of 5 mM nicotinamide to differentiating 46C 
cultures resulted in significantly lower GFP OD measurements at days 6 and 7 compared to 
control cultures (103 ± 0.27 vs. 106 ± 0.96, 102 ± 0.29 vs. 110 ± 1.5; Tukey’s p < 0.01; Figure 
3.6 D). The addition of 10 mM nicotinamide to differentiating cultures also resulted in lower 
GFP OD compared to control cultures at days 6 and 7 (102 ± 0.19 vs. 106 ± 0.96, 102 ± 0.5 vs. 
110 ± 1.5;Tukey’s p < 0.001; Figure 3.6 D). These results show that cultures treated with 
nicotinamide, at both 5 and 10 mM, resulted in lower GFP expression, measured by OD, than 
control cultures at days 6 and 7 of differentiation. 
A significant interaction of time and nicotinamide treatment was also observed. 
Further post-hoc analysis showed that differentiating cultures treated with 5 mM 
nicotinamide showed a significant increase in GFP OD at days 5 (Dunnett’s p < 0.001) and 6 
(Dunnett’s p < 0.05) compared to day 1 control cultures (Figure 3.6 D). A significant increase 
in GFP OD was also observed in 10 mM nicotinamide treated cultures at day 5 of 
differentiation compared to day 1 control cultures (Dunnett’s p < 0.05; Figure 3.6 D). This 
shows an interaction effect with Sox1-GFP expression significantly increased between days 5-
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7 in control conditions, at days 5 and 6 with 5 mM nicotinamide treatment, and at day 5 with 
10 mM nicotinamide treatment, when compared to day 1 control cultures. 
 
Figure 3.5 Representative images of GFP expression in 46C control cultures.  
A) Day 1 of differentiation showing fewer DAPI+ nuclei and few GFP+ cells. Inset shows faint GFP 
expression associated with nuclei. 
B) Day 7 of differentiation showing higher numbers of DAPI+ nuclei and GFP+ cells showing clear GFP 








Figure 3.6 Nicotinamide affected GFP expression in differentiation 46C cultures.  
A) Graphs showing the optical density measurements normalised to control day 1 cultures. A 
significant increase in GFP expression was observed at days 5, 6, and 7, compared to day 1 of 
differentiation.  
B) Graph showing the optical density measurements normalised to control day 1 in 5 mM nicotinamide 
treated cultures. A significant increase in GFP expression was observed at day 5 compared to day 1 of 
differentiation.  
C) Graph showing the optical density measurements normalised to control day 1 in 10 mM 
nicotinamide treated cultures. No significant increase in GFP expression was observed across 
differentiation. ** p < 0.01; *** p < 0.001.  
D) Graph showing the optical density measurements normalised to control day 1 in all treatment 
conditions. A significant ANOVA interaction effect was observed in control (blue), 5 mM nicotinamide 
(red), and 10 mM nicotinamide (green) treated cultures compared to day 1 control cultures; * p < 0.05; 
** p < 0.01. A significant difference in GFP expression in nicotinamide treated cultures compared to 
control cultures was also observed at days 6 and 7; ## p < 0.01; ### p < 0.001.  
E) Representative inverted, greyscale images (with blue DAPI inserts) used for optical density 
measurements. Images show how optical density measurements from each treatment condition at 
days 1, 5, 6 and 7 reflect cell numbers in these cultures. 
 
These results show that the addition of nicotinamide at concentrations of 5 and 10 
mM significantly altered GFP OD measurements compared to control over 7 days of 
differentiation. Control cultures showed an increase in GFP OD over 7 days, whilst 5 mM 
nicotinamide showed a peak at day 5 which decreased and plateaued at days 6-7, and 10 mM 
nicotinamide showed a slight peak at day 5 although levels remained low compared to control. 
The use of OD measurements for GFP fluorescence here provides an estimate of GFP 
expression but cannot consider the percentage of GFP+ cells as DAPI+ cell counts were not 
possible due to high density populations. 
 
3.3.4 Numbers of β-III-tubulin+ cells at day 7 of differentiation 
are affected by nicotinamide concentrations 
Next, β-III-tubulin expression was assessed as an indicator of neuronal differentiation. 
Numbers of β-III-tubulin+ cells were counted from micrographs taken at 10X magnification to 
assess neuron numbers at 7 days of differentiation. However, not all β-III-tubulin+ cells showed 
a neuronal morphology of small cell soma and presence of neurites with higher expression 
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intensity, a minority (observed in some micrographs) displayed a large, flat shape with lower 
expression intensity (Figure 3.7 A, B). In this experiment, the number of β-III-tubulin+ neurons 
was of interest, therefore, only β-III-tubulin+ cells with a neuronal morphology (as displayed 
by * in Figure 3.7 A, C) were counted and analysed.  
Numbers of β-III-tubulin+ cells with neuronal morphology were counted within 4 
images across 3 technical replicates and 3 experimental repeats. Due to variation in numbers 
of β-III-tubulin+ cells across experimental repeats (control averages ranging from 14-43), the 
number of β-III-tubulin+ neurons was normalised to the control as described in Chapter 2.11). 
One-way ANOVA showed an effect of nicotinamide treatment (F(2, 24) = 4.49, p < 0.05). Tukey’s 
multiple comparisons test showed no significant difference in the number of β-III-tubulin+ cells 
(with neuronal morphology) at 7 days of differentiation between control and nicotinamide 
treated cultures (Figure 3.7 D, E). However, neuron numbers were slightly higher in 5 mM 
nicotinamide treated cultures compared to controls, and were lower in 10 mM nicotinamide 
treated cultures compared with controls, at 7 days in culture. Therefore, when nicotinamide 
treated cultures were compared directly, there were significantly lower numbers of neurons 
in 10 mM nicotinamide treated cultures compared to 5 mM nicotinamide treated cultures at 







Figure 3.7 The number of β-III-tubulin+ cells did not differ between control and nicotinamide treated 
cultures. 
A) Micrograph showing merge of DAPI and β-III-tubulin staining in 46C cultures at day 7 of 
differentiation. * Indicates examples of neuronal β-III-tubulin staining with a small cell soma, extending 
neurites, and high intensity expression. # Indicates non-neuronal β-III-tubulin staining with large, 
flattened cell soma and low intensity expression.  
B) Magnified example of non-neuronal β-III-tubulin staining with large, flattened cell soma and low 
intensity expression.  
C) Magnified example of neuronal β-III-tubulin staining with a small cell soma, extending neurites, and 
high intensity expression.  
D) Graph showing numbers of β-III-tubulin+ neurons at day 7 of differentiation normalised to control 
cultures. A significant decrease in neuron numbers was observed between 5 mM and 10 mM 
nicotinamide treatment conditions (p < 0.05).  
E) Representative micrographs showing DAPI and β-III-tubulin staining across treatment conditions at 
day 7 of differentiation. Inserts show neuronal morphology.  
 
3.3.5 Gating of cell populations within 46C flow cytometry 
samples and representation of data 
Flow cytometry was used to provide a more detailed analysis of the effects of 
nicotinamide on differentiating 46C cultures, in particular, addressing numbers/proportion of 
cells expressing GFP, which was not possible to derive accurately using micrographs of fixed 
cultures. For accurate analysis, gating parameters needed to be established to distinguish cells 
from debris within the flow cytometry sample. Propidium iodide (PI) and Triton X-100 were 
used to identify the cell populations within samples of proliferating and differentiating 46C 
cell cultures as described in Chapter 3.2.4. Cells grown in both proliferation and differentiation 
media showed similar trends. As differentiating samples were to be analysed for GFP 
expression, only results from differentiating cells are described below. 
Addition of PI to flow cytometry samples resulted in the formation of two peaks in the 
red fluorescence channel which were classed as PI- and PI+, respectively, as separated by a 
gate placed at 101, in between the peaks (Figure 3.8 A, B). In cell samples from differentiation 
medium, 26% of total events were PI+ (Figure 3.8 A). As a positive control, 0.01% Triton X-100 
was added to a parallel differentiating cell sample. This increased PI+ events to 61% of total 
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events (Figure 3.8 B), consistent with the anticipated effects of Triton X-100: increased plasma 
membrane permeability of cells within the sample, allowing PI to bind to DNA and 
subsequently fluoresce. By applying this PI+/PI- gate of red fluorescence against forward 
scatter (which provides an estimate of the size of the event), it was possible to identify the 
shift in red fluorescence predominantly occurring in events above 102.3 in forward scatter in 
both PI only and PI with Triton X-100 samples (Figure 3.8 C, D). That is, the bottom right 
quadrant (PI+, Forward Scatter <102.3) showed an extremely low number of events, consistent 
with PI staining being associated with cells whose membranes are compromised, rather than 
fragments/debris. From this it was decided that events above 102.3 in forward scatter would 
be considered as the cell population of the sample (i.e. excluding debris). This data was then 
plotted as forward scatter vs. side scatter (a general measure of granularity) to show the cell 
population without the use of fluorescence markers and channels (Figure 3.8 E, F).  
When events were gated to limit analysis to the cell population, the percentage of PI+ 
cells in differentiating samples without triton was 35.4% (Figure 3.8 G), which increased to 
90.7% in samples treated with Triton X-100 (Figure 3.8 H). Fluorescence microscopy confirmed 
PI staining within cells (Figure 3.8 I, J) showing a larger proportion of PI+ cells within samples 
with Triton X-100 compared to samples with PI alone. These images also confirm a greater 
presence of debris in samples with Triton X-100. This is also observed in graphs E and F with a 
lower percentage of events classed as whole cells in samples treated with Triton X-100 (66%) 









Figure 3.8 Flow cytometry gating for cell population.  
A) Histogram of red fluorescence showing flow cytometry samples of differentiating cells with PI only. 
A gate separating PI+ and PI- events in red fluorescence was set at 101.  
B) Histogram of red fluorescence showing flow cytometry samples of differentiating cells with PI and 
0.01% Triton X-100. A gate separating PI+ and PI- events in red fluorescence was set at 101.  
C) Scatter graph showing forward scatter (y; used as a relative measure of size) and red fluorescence 
(x) for samples with PI only. A shift in red fluorescence is observed mostly in events above 102.3. This 
indicates the cell population.  
D) Scatter graph showing forward scatter (y; used as a relative measure of size) and red fluorescence 
(x) for samples with PI and 0.01% Triton X-100. A shift in red fluorescence is observed mostly in events 
above 102.3. This indicates the cell population. 
 E) Scatter graph showing forward scatter (y) against side scatter (x; representative of granularity) for 
differentiating cells with PI only.  
F) Scatter graph showing forward scatter (y) against side scatter (x; representative of granularity) for 
differentiating cells with PI and 0.01% Triton X-100.  
G) Histogram of red fluorescence of the “cell” gated population shown in E with gate indicating PI- 
(below 101) and PI+ (above 101) staining for PI only differentiating samples.  
H) Histogram of red fluorescence of the “cell” gated population shown in F with gate indicating PI- 
(below 101) and PI+ (above 101) staining for PI with Triton X-100 differentiating samples.  
I) Brightfield and fluorescence microscopy showing PI staining (red) within cells (*) in differentiating PI 
only conditions.  
J) Brightfield and fluorescence microscopy showing PI staining (red) within cells (*) in differentiating PI 
with Triton X-100. # shows an increase in debris in samples with Triton X-100. 
 
This established the methodology used for the gating of cell populations within flow 
cytometry samples in the following experiments exploring the effects of nicotinamide on 
proliferation and GFP expression in 46C cultures. 
To assess cell numbers, results, measured in forward scatter, are presented as cells 
(based on the gate set at log 102.3 to include cells and exclude debris) as a percentage of total 
events (which include both cells and debris). Representing results this way was deemed most 
appropriate, as absolute numbers of cells could be affected by changes in the processing of 
the flow cytometry samples (e.g. the amount of sample processed). To check the validity of 
this measure, absolute cell numbers were checked within each experimental run and data 
showed the same trends as the percentage of total events measure used when analysing the 




3.3.6 The number of cells in cultures over 7 days of 
differentiation were lower with nicotinamide treatment 
Flow cytometry samples were analysed from differentiating 46C cell cultures across 
days 1-7, treated with either 5 or 10 mM nicotinamide, with a full media change every other 
day. The results were gated as described in Chapter 3.3.5 allowing for analysis of the cell 
population within the sample.  
Two-way ANOVA revealed significant differences in the percentage of cells out of total 
events across nicotinamide treatment (F(2, 125) = 60.68, p < 0.0001) and day of differentiation 
(F(6, 125) = 9.36, p < 0.0001) with a significant interaction (F(12, 125) = 5.302, p < 0.0001). 
Nicotinamide treatment significantly reduced the cell population compared to control 
cultures. Control cultures reached a peak of cells at 95 ± 1.8 percent at day 7 of differentiation, 
whilst cultures treated with 5 mM nicotinamide peaked at 40 ± 8.5 percent at day 3, and 
cultures treated with 10 mM nicotinamide peaked at 25 ± 10 at day 3. These results show a 
significant decrease in cells with nicotinamide treatment compared to control; with the 
percentage of cells peaking at day 3 in nicotinamide treated cultures compared to day 7 in 
control cultures.  
An increase in the percentage of cells across days in differentiation was observed in 
control cultures. Post-hoc analysis showed a significant increase in the percentage of cells in 
control flow cytometry samples between day 1 and days 3, 4, 5, 6, and 7 (Dunnett’s p < 0.001; 
Figure 3.9 A). No significant difference in the percentage of cells across days in differentiation 
was observed for cultures treated with 5 mM or 10 mM nicotinamide (Figure 3.9 B, C 
respectively). These results indicate that numbers of cells increased across 7 days of 





Figure 3.9 Numbers of cells were lower in nicotinamide treated cultures compared to control.  
A) Graph showing the percentage cells of total events across days 1-7 of differentiation in control 
cultures. A significant increase was observed at days 3, 4, 5, 6, and 7 compared to day 1 (*** p < 0.001).  
B) Graph showing the percentage cells of total events across days 1-7 of differentiation in 5 mM 
nicotinamide treated cultures. No significant difference was observed across 7 days of differentiation. 
 C) Graph showing the percentage cells of total events across days 1-7 of differentiation in 10 mM 
nicotinamide treated cultures. No significant difference was observed across 7 days of differentiation. 
D) Graph showing the percentage cells of total events across days 1-7 of differentiation in control (blue 
circle), 5 mM nicotinamide (red square), and 10 mM nicotinamide (green triangle) treatment 
conditions. Treatment with 5 mM nicotinamide resulted in a significantly lower percentage cells of 
total events compared to control at days 4, 5, 6, and 7. Treatment with 10 mM nicotinamide also 
resulted in a significantly fewer cells as a percentage of total events at days 3, 4, 5, 6 and 7 compared 
to control (## p < 0.01; ### p < 0.001). 
 
The application of 5 mM nicotinamide resulted in a significantly lower percentage of 
cells in samples compared to control between days 4 -7 of differentiation (Tukey’s p < 0.01; 
Figure 3.9 D). Similar results were observed with the application of 10 mM nicotinamide with 
a significant decrease in the percentage of cells compared to control at days 3 to 7 of 
differentiation (Tukey’s p < 0.01; Figure 3.9 D). These results show that 5 mM nicotinamide 
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significantly reduced the number of cells in 46C cultures compared to control from day 4 of 
differentiation, whilst 10 mM nicotinamide significantly reduced cell numbers from day 3. 
 
3.3.7 Nicotinamide treatment reduced the GFP+ cell population 
detected by flow cytometry over 7 days of differentiation 
Flow cytometry was used to detect GFP+ cells within differentiating 46C cultures over 
7 days. Two-way ANOVA showed significant differences across nicotinamide treatment (F(2, 
125) = 181.2, p < 0.0001), days (F(6, 125) = 36.52, p < 0.0001), and a significant interaction (F(12, 
125) = 21.66, p < 0.0001).  
Nicotinamide treatment, at concentrations of both 5 and 10 mM, showed a 
significantly lower percentage of GFP+ cells compared to control cultures. Control cultures 
reached a GFP+ peak of 77.5 ± 3.0 percent at day 7, whilst cultures treated with 5 mM 
nicotinamide reached a peak of 24.3 ± 4.8 percent at day 5, and cultures treated with 10 mM 
reached a peak of 10.4 ± 1.9 percent at day 3 (Figure 3.10 D). These results show that control 
cultures contained the highest percentage of GFP+ cells peaking at day 7, whilst 5 and 10 mM 
nicotinamide treated cultures showed lower percentages of GFP+ cells with peaks at days 5 




Figure 3.10 The percentage of GFP+ cells was reduced in nicotinamide treated cultures  
A) Graph showing the percentage of GFP+ cells across 7 days of differentiation in control 46C cultures. 
A significant increase in GFP+ cells was observed between day 1 and days 3, 4, 5, 6, and 7.  
B) Graph showing the percentage of GFP+ cells across 7 days of differentiation in 5 mM nicotinamide 
treated 46C cultures. A significant increase in GFP+ cells was observed between day 1 and days 3, 4, 5, 
and 6 (** p < 0.01).  
C) Graph showing the percentage of GFP+ cells across 7 days of differentiation in 10 mM nicotinamide 
treated 46C cultures. No significant differences were observed across days in differentiation.  
D) Graph showing the percentage of GFP+ cells across 7 days of differentiation in control, 5 mM and 10 
mM treated 46C cultures. Treatment with 5 mM nicotinamide significantly reduced numbers of GFP+ 
cells at days 4, 5, 6, and 7 when compared to control cultures. Treatment with 10 mM nicotinamide 
also significantly reduced GFP+ cell numbers compared to control at days 3, 4, 5,  6, and 7 (# p < 0.05, 
## p < 0.01, ### p < 0.001).  
 
An increase in GFP+ cells was observed across 7 days of differentiation in control 
cultures. Post-hoc analysis revealed a significant increase in the percentage of GFP+ cells in 
control cultures comparing day 1 with days 3, 4, 5, 6, and 7 (Dunnett’s p <0.01; Figure 3.10 A). 
These results show that Sox1-GFP expression increased over 7 days of differentiation in these 
46C control cultures. 
An increase in GFP+ cells was also seen in differentiating cultures treated with 5 mM 
nicotinamide. A significant increase in the percentage of GFP+ cells in 5 mM treated cultures 
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was observed between day 1 and days 3, 4, 5, and 6 (Dunnett’s p < 0.01; Figure 3.10 B). No 
significant difference in the percentage of GFP+ cells was found in cultures treated with 10 
mM nicotinamide (Figure 3.10 C). These results show that nicotinamide dose-dependently 
affects Sox1-GFP expression in these 46C cultures. 
Application of 5 mM nicotinamide to differentiating 46C cells significantly reduced the 
percentage of GFP+ cells compared to control at days 4 to 7 of differentiation (Dunnett’s p < 
0.01; Figure 3.10 D). Application of nicotinamide at 10 mM significantly reduced the 
percentage of GFP+ cells compared to control at days 3 to 7 of differentiation (Dunnett’s p < 
0.05; Figure 3.10 D). This shows that 5 mM nicotinamide significantly reduced Sox1-GFP 
expression in 46C cultures from day 4 of differentiation, whilst 10 mM nicotinamide 





3.4.1 Validity of the neuronal differentiation model using 46C 
cells 
The differentiation protocol validated here generated neurons, identified as β-III-
tubulin+ cells. As well as expression of this neuronal marker, cells also displayed the typical 
neuronal morphology of a small cell soma with extending neurites. These cells accounted for 
16% of the total cell population. The 46C cell line has also been reported to produce both 
astrocytes and oligodendrocytes, using the N2B27 medium (Ying et al., 2003). Although the 
full differentiation protocol took 14 days, in the current study, β-III-tubulin+ cells with neuronal 
morphology were present in cultures at day 5. Other studies have also assessed the neural 
commitment of these cells over the initial 6/8 days of differentiation (Ying et al., 2003; Diogo, 
Henrique and Cabral, 2008) with neuronal morphology and marker expression also apparent 
at day 5 (Ying et al., 2003). 
In mESC cultures assessed at day 7 of differentiation, the antibody for β-III-tubulin used 
in this PhD thesis also showed some reactivity with cells that did not have a neuronal 
morphology. These cells were distinctive from neurons, possessing a large nucleus and large 
flattened cell body with low intensity staining, and accounted for approximately 20% of β-III-
tubulin+ stained cells. β-III-tubulin expression has also been observed in non-neuronal cells 
including: embryonic lens, caudal-ventral somites, and ectodermal cells of the amnion (Lee et 
al., 1990). Given that cultures in the present study were generated from ESCs, it is possible 
that non-neuronal cells were present in differentiated cultures. Ying et al. (2003) also 
observed large, flattened cells in cultures differentiated in N2B27 on laminin. High 
concentrations of 20 mM nicotinamide have been shown to affect cell morphology (Wang et 
al., 2012). However, in the current study, non-neuronal β-III-tubulin+ cells were also observed 
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in control cultures, and numbers did not increase with nicotinamide treatment (data not 
shown), suggesting that this is not an effect of nicotinamide treatment. Although non-specific 
staining is not desirable, in this instance, the obvious difference in morphology meant that 
non-neuronal cells showing weakly positive staining could be readily excluded and therefore 
did not interfere with analysis or results. 
The validation of the neuronal differentiation protocol, discussed in Chapter 3.3.2, 
confirmed the suitability of the 46C cell line, and the differentiation protocol, to assess the 
effects of nicotinamide on neural differentiation from ESCs for this PhD thesis.  
Human ESCs or iPSCs would provide a more easily clinically translatable tool and the 
experimental processes described here could be transferred to a human cell line for further 
assessment and to provide data for more immediate translation to the clinic. However, the 
use of non-human cell lines and animal models still provides a valuable tool for basic research. 
The use of yeast, drosophila, zebrafish, rodents and primates still hold a prominent position 
in research with advantages including detailed characterisation, simplicity and availability. 
Although not every discovery in non-human cells is translatable, many are, and the 
understanding of these differences still provides value to research. Mouse and human ESCs 
share a number of similarities and differences in morphology, gene expression, and 
electrophysiological properties (Ginis et al., 2004; Wang et al., 2005), although cell-type 
specific gene expression in midbrain development appears to be conserved (La Manno et al., 
2016). Protocols for neuronal differentiation have been translated from mouse to human ESCs 
and iPSCs (Jaeger et al., 2011; Zhang et al., 2018). Sox1 expression has also been shown to 
identify neural progenitors in both human and mouse cell lines (Zhang et al., 2018). This 
supports the possibility that the effects of nicotinamide found in this PhD thesis may be 




3.4.2 Flow Cytometry is a valid measure to assess the 
differentiation of 46C cells 
Immunocytochemistry was initially used to assess the neuronal differentiation of the 
46C cell line. However, this method required a long differentiation protocol (14 days) and 
time-consuming analysis to study the effects of nicotinamide, which has shown to induce 
neuralisation during the first 7 days of differentiation (Griffin et al., 2013). Therefore, flow 
cytometry was used to assess the Sox1-GFP expression in these cells over the differentiation 
period. The use of flow cytometry allowed for a more encompassing analysis of cell cultures 
with the identification of higher numbers of cells in a short timeframe when compared to 
microscopic analysis. 
Initial experiments included the analysis of cells after re-plating at day 7 of 
differentiation. However, cell numbers and thus GFP expression were dramatically reduced in 
samples after replating. This was thought to be due to neuronal differentiation within cell 
cultures, producing neuronal cells that may not have survived the enzymatic detachment and 
dissociation process used for flow cytometry sample preparation (Barker et al., 1995; Fricker 
et al., 1996).  
Flow cytometry required gating of the cell population to provide an estimate of cell 
numbers. Gating of the cell population utilised PI and Triton X-100 to distinguish cells from 
debris within the sample. This experiment utilised PI, in which fluorescence is dramatically 
enhanced upon DNA binding, as a nuclear marker. However, PI cannot penetrate the intact 
cell membrane, meaning that it can be used to identify membrane-compromised cells, an 
indicator of cell death. The use of Triton X-100 to permeabilise cell membranes (Borner et al., 
1994; Ahn et al., 1997) alongside addition of PI, allowed for the identification of the cell 
population which was represented as a shift in fluorescence found only in events above a 
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specific threshold in forward scatter. Gating events above this threshold allowed for 
identification of the cell population based solely on forward scatter analysis. 
After gating of the cellular population, it was then possible to gate for the GFP+ 
population within this. Ideally a GFP- cell line similar to 46C would be used as a negative 
control. Other researchers have used the E14tg2a cells (Veraitch et al., 2008; Incitti et al., 
2014) from which 46C cells are derived, however, this option was not available. 
Undifferentiated 46C cells have also been used as a negative GFP control (Diogo, Henrique 
and Cabral, 2008) which could have provided a viable option for these PhD experiments. 
Although ideally a GFP- population would have served to show a fluorescence baseline for 
each time point and each experimental repeat, the analysis of cells from 1-7 days of 
differentiation showed a measurable and relative change in GFP expression in control 
cultures, providing validity in the methods used. 
PI could have been used alongside GFP expression to show the proportion of live cells 
during differentiation. However, to gain accurate cell death data from differentiating flow 
cytometry samples, more rigorous optimisation would have been required to ensure sample 
preparation did not affect cell viability. Without this, it would be difficult to ensure that cell 
death was a result of the treatment condition, rather than sample preparation. Further cell 
specific markers would also be required to assess whether changes in cell viability were a 
direct effect of nicotinamide treatment, or an indirect effect due to nicotinamide-induced 
changes in cell-type populations. Although this may present an interesting aspect to further 
explore; the assessment of cell viability was not considered as a necessary element in this 





3.4.3 Cell numbers were lower over 7 days of differentiation in 
nicotinamide treated cultures 
Results from flow cytometry analysis revealed that numbers of cells within control 
cultures significantly increased from day 3, with cell numbers appearing to plateau from day 
5. This increase suggests proliferation within these cultures. Cultures treated with 5 or 10 mM 
nicotinamide did not show a significant increase compared to day 1 across 7 days of 
differentiation. Numbers of cells were significantly lower compared to control cultures from 
day 3 with 10 mM nicotinamide, and from day 4 with 5 mM nicotinamide. This suggests that 
nicotinamide limited proliferation within these cultures. This is an effect of nicotinamide that 
has been observed across cell cultures (Audrito et al., 2011; Petin et al., 2019; Malesu et al., 
2020) including hESCs which also showed reduced cell growth with application of 10 mM 
nicotinamide over 4 days (Meng et al., 2018). Lower cell numbers quantified by DAPI staining 
were also observed in 46C cultures after the 14 day differentiation protocol with nicotinamide 
applied during the initial 7 days (Griffin et al., 2013). These lower cell numbers and decreased 
Oct4 expression were still observed on withdrawal of nicotinamide from days 8-14 (Griffin et 
al., 2017). Nicotinamide has also been shown to downregulate genes associated with stem 
cell pluripotency (Meng et al., 2018). This suggests that 10 mM nicotinamide reduces the 
number of proliferating cells within cultures from as early as 3 days into treatment and is not 
reversible upon removal.  
Further assessment of the 46C cultures used in this PhD thesis would be to confirm if 
nicotinamide increased cell death or decreased proliferation. The numbers of cells staying 
steady across time in nicotinamide treated cultures suggests a limitation of proliferation, as 
numbers did not decrease over time. Application of 20 mM nicotinamide has shown cytotoxic 
effects and wide-spread cell death in 46C cells after 3-4 days (Griffin et al., 2013), however, 
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the use of 10 mM has not shown toxicity in a number of studies (Vaca et al., 2008; Griffin et 
al., 2013; Meng et al., 2018). The reduction in cell numbers shown in this PhD thesis may be a 
result of nicotinamide-induced proliferating cell death through Sirt1 inhibition. Treatment of 
NG108-15 cells with sirtinol (a Sirt1 inhibitor) killed 79.5% of proliferating cells but only 32.1% 
of neuronally differentiated cells (Sansone et al., 2013). This suggests that proliferating cells 
may be vulnerable to nicotinamide-induced Sirt1 inhibition and may explain the reduction in 
cell numbers shown in this PhD thesis. 
The application of PARP inhibitors has been shown to increase apoptosis in a 
concentration dependent manner (Okuda et al., 2017), therefore this possible effect of 
nicotinamide should not be excluded without confirmation. However, PARP inhibitors have 
also decreased cell death with no change in Ki67 expression during the neuralisation process 
(Cimadamore et al., 2009). These differences highlight the complexity of PARP inhibition and 
its downstream effects. Although nicotinamide is known to inhibit PARP-1 activity, this may 
not be the mechanism responsible for the results observed in the 46C cultures used here. 
Therefore, further analysis of the mechanistic action(s) of nicotinamide is required.  
Increased programmed cell death is also observed alongside increased neuralisation, 
suggesting heightened vulnerability of differentiating cells compared to proliferating ESCs 
(Cimadamore et al., 2009). This may provide an additional explanation for the lower 
percentage of cells measured by flow cytometry in nicotinamide treated cultures. Vulnerable 
cells, that may be more likely to be damaged through sample preparation as a consequence 
of increased neuralisation or differentiation, would lead to increased debris and thus a 
decrease in the proportion of cells observed in the flow cytometry data. Therefore, 
nicotinamide may induce more vulnerable cell populations in these cultures, especially if 
nicotinamide is able to accelerate differentiation or neuralisation (further discussed in 
Chapter 3.4.5). If nicotinamide also restricts proliferation, with proliferating cells being less 
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vulnerable, this may account for the higher in cell numbers in control cultures, but lower cell 
numbers in nicotinamide treated cultures.  
The results presented here suggest that nicotinamide caused a decrease in 
proliferation of cells within differentiating mESC cultures, however, further analytical 
techniques to assess proliferation and cell death would assist confirmation of this. 
 
3.4.4 Sox1-GFP expression was reduced in nicotinamide treated 
cultures 
GFP expression, measured by OD, increased with days of differentiation in these 46C 
cultures. OD measures recorded in the current study were generalised marker expression 
levels across multiple cells, which could be indicative of intensity/expression of GFP per cell, 
number of cells expressing GFP in the FOI, or size of cells expressing GFP within the FOI.  
In control cultures, OD measurements showed an increase in GFP expression, rising 
steeply between days 5-7 with a significant increase compared to day 1 (Figure 3.6 A). Cultures 
treated with 5 mM nicotinamide showed a significant increase at day 5 compared to day 1, 
which peaked, then decreased slightly and plateaued over days 6-7 (Figure 3.6 B). Treatment 
of cultures with 10 mM nicotinamide showed only a small peak at day 5, with no significant 
increase in GFP expression, which remained low compared to control cultures (Figure 3.6 C). 
Lower levels of GFP expression, measured by OD, have also been observed with application of 
10 mM nicotinamide, compared to control, in 46C cultures (Griffin et al., 2017). 
In this PhD thesis, treatment with 5 mM nicotinamide showed a significant increase at 
days 5 and 6 when compared to control cultures at day 1 (Figure 3.6 D). The application of 10 
mM nicotinamide also showed a significant increase in GFP OD at day 5 compared to control 
day 1 (Figure 3.6 D). This shows an interaction effect of nicotinamide treatment and days of 
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differentiation. A slight but not significant increase in GFP OD in nicotinamide treated cultures 
at day 1 off-set the increases observed in nicotinamide treated cultures when compared 
within treatment at later days of differentiation. This suggests that nicotinamide may 
influence the neural differentiation of 46C cultures from as early as 24 hours after application. 
This is in agreement with Griffin et al. (2017) who observed promotion of neuronal 
differentiation of 46C cultures in the initial 2 days of differentiation with nicotinamide 
application. 
The increase in GFP expression observed in these 46C cultures is indicative of an 
increase in Sox1-GFP expression as cells become neural progenitors. This expression is then 
downregulated after neural differentiation. Nicotinamide treated cultures showed lower GFP 
expression compared to control cultures at days 6 and 7. This decrease in expression may be 
a result of decreased cell numbers which is evident from DAPI staining. The OD technique was 
not able to compensate for the decreased cell numbers observed in the cultures treated with 
nicotinamide (confirmed by flow cytometry Figure 3.9 D). Therefore, flow cytometry was used 
to provide more detailed analysis of the cell populations and Sox1-GFP expression throughout 
the initial 7 days of differentiation.  
When Sox1-GFP expression was analysed by flow cytometry, control cultures showed 
increased GFP expression at day 3 of differentiation (Figure 3.9 A), corresponding with other 
reports of GFP expression in differentiating 46C cultures (Ying et al., 2003; Incitti et al., 2014). 
In this PhD thesis, GFP expression in control cultures continued to increase reaching a plateau 
between days 5-7 with 73-77% of the cell population classed as GFP+. This is comparable to 
other studies with GFP+ 46C cells reaching a maximum of 60% (Incitti et al., 2014) and 
approximately 75% (Ying et al., 2003) of the population at day 4-5 of differentiation.  
In these cells, Sox1-GFP expression is associated with neural progenitors, therefore an 
increase in GFP expression is indicative of neural differentiation. Sox1 expression is 
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subsequently downregulated upon neural differentiation (Pevny et al., 1998). A decrease in 
GFP expression was observed in nicotinamide treated cultures in this PhD thesis, with 5 mM 
treated cultures reaching a maximum of 24% of cells expression GFP, whilst 10 mM 
nicotinamide treated cultures reached a maximum of 10% of cells expressing GFP compared 
to 77% of control cultures. One explanation for reduced GFP expression would be that 
nicotinamide promoted more non-neural differentiation or inhibited neural differentiation. 
However, this is unlikely as nicotinamide treated cultures had lower cell numbers compared 
to control cultures (Figure 3.9 D), without reduced neuronal populations at day 7 (Figure 3.7 
D). Suggesting that nicotinamide did not inhibit neuronal differentiation. Another explanation 
is that nicotinamide inhibited proliferation across cell types, including those expressing GFP. 
Therefore, GFP expressing cells may have been more proliferative in control cultures, 
increasing the numbers of GFP+ cells. Whilst proliferation was inhibited in nicotinamide 
treated cultures, cell numbers appeared to remain steady, maintaining a balance across 
proliferation, apoptosis, and differentiation.  
In this PhD thesis, control cultures showed an increase in GFP expression (measured 
by flow cytometry) over 7 days of differentiation, with a plateauing of expression between 
days 5-7. Incitti et al. (2014) observed a peak of GFP expression at day 5, however, Ying et al. 
(2003) observed a plateau in GFP expression from day 4-7 (consistent with the observations 
of this PhD thesis) with a reduction observed from day 8. In this PhD thesis, maximum 
expression of GFP was reached at day 7 in control cultures, day 5 in 5 mM nicotinamide treated 
cultures, and day 3 in 10 mM nicotinamide treated cultures. The results described here 
suggest that maximum GFP expression peaks earlier with nicotinamide treatment. This could 
be indicative of earlier neural differentiation of these 46C cultures and is further discussed in 
Chapter 3.4.5.  
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In these cells, GFP expression is driven by the expression of the Sox1 gene, however, 
GFP fluorescence is not simply switched on/off as a result of altered gene expression. Whilst 
the Sox1 gene is downregulated with differentiation, GFP protein, with a half-life in 
mammalian cells of approximately 26 hours, may continue to be expressed for a protracted 
period. Therefore, a decrease in GFP protein expression may be delayed after downregulation 
of Sox1, resulting in prevailing GFP fluorescence that is not representative of 
contemporaneous Sox1 expression. 
The expression of Sox1 is not synchronised across cells within in the culture (Ying et 
al., 2003), and fluorescence intensity of the GFP protein may vary throughout its presence 
within the cytoplasm. This may account for some of the difficulties encountered when gating 
the GFP+ population (discussed in Chapter 3.2.5). Other papers have described GFP expression 
as negative, low, and high (Veraitch et al., 2008). Differences in GFP intensity have also been 
observed across treatment conditions of 46C cultures, with 10 mM nicotinamide treated 
cultures being devoid of “strong” GFP expressing cells (Griffin et al., 2017).  
 
3.4.5 Nicotinamide increased the β-III-tubulin+ neuronal 
population 
β-III-tubulin+ cells with neuronal morphology were observed in cultures across 
treatments at day 4 of differentiation, although numbers were extremely low, with only a few, 
solitary, neurons with short processes identified across experimental repeats. However, 
neurons were more obviously visible across all treatment conditions at day 5. This corresponds 
with Ying et al. (2003) who also observed neuronal morphology and marker expression 5 days 
into the differentiation protocol. 
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The number of β-III-tubulin+ cells with neuronal morphology did not differ significantly 
between control and nicotinamide treated cultures (Figure 3.7), however, a slight increase 
with 5 mM treatment and a decrease with 10 mM treatment led to a measurable and 
significant difference in neuron numbers between these nicotinamide concentrations at day 
7.  
Numbers of total cells were shown to be significantly lower in nicotinamide treated 
cultures, although numbers of β-III-tubulin+ neurons were not significantly different. This 
suggests an increase in the neuronal population within the cultures, with neurons constituting 
a higher percentage of the total cell population. This is consistent with other reports of 
nicotinamide-induced neuralisation (Cimadamore et al., 2009) and neuronal differentiation 
and maturation (Griffin et al., 2013, 2017).  
The increase in neuronal differentiation could be an indirect effect of nicotinamide-
induced reduction in cell numbers, as lower plating densities have shown an increase in neural 
commitment quantified by Sox1-GFP expression in the 46C cell line (Diogo, Henrique and 
Cabral, 2008). However, treatment with nicotinamide did not show an increase in GFP 
expression in this PhD thesis. Therefore, the increased neuronal differentiation may be a direct 
effect of nicotinamide on these cells, rather than an indirect effect through a decreased cell 
numbers. 
Nicotinamide may exert neuronal differentiation/maturation through inhibition of 
Sirt1 or PARP-1. Sirt1 silencing in NG108-15 cells increased neuronal MAP5 expression 
(Sansone et al., 2013), whilst PARP-1 inhibitors (including nicotinamide) have shown enhanced 
ESC neuralisation (Cimadamore et al., 2009). However, NSCs derived from PARP-1 knockout 
mice showed decreased neuronal, and increased astrocyte (GFAP+) and oligodendrocyte 
(Olig2+) differentiation (Hong et al., 2019), suggesting that complete PARP-1 inhibition may 
not be responsible for the increased neuralisation observed in these 46C cultures. 
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Cimadamore et al. (2009) found that nicotinamide alone did not potentiate 
neuralisation, but did with the addition of basic fibroblast growth factor and epidermal growth 
factor. These results together suggest that nicotinamide may be a beneficial addition to 
differentiation protocols for CRT. Further analytical techniques would be required to explore 
the mechanisms behind the effects observed in this PhD thesis.  
 
3.4.6 Conclusions and future work 
The results observed in this PhD thesis show lower levels of GFP, with earlier maximum 
expression, in nicotinamide treated cultures compared to control. Nicotinamide also limited 
46C cell proliferation but did not significantly alter numbers of β-III-tubulin+ neurons at day 7 
of differentiation. The results discussed here are consistent with the possibility that 
nicotinamide may reduce proliferation and enhance cell-cycle exit from ESCs through 
neuralisation to mature neural differentiation (Griffin et al., 2017).  
Although the mechanisms for the effects of nicotinamide observed in this PhD thesis 
were not explored, decreased proliferation and increased neuralisation have been described 
through Sirt1 and PARP-1 inhibition. Therefore, nicotinamide may exert these effects through 
Sirt1 inhibition, which has been shown to increase cell death in proliferating cultures and 
increase neuronal marker expression (Sansone et al., 2013). Analysis of these cultures using 
western blot for Sirt1 would reveal changes in Sirt1 expression with nicotinamide treatment. 
 PARP-1 inhibition has also been shown to decrease NSC proliferation (Hong et al., 
2019) and increase neuralisation (Cimadamore et al., 2009). Different PARP inhibitors have 
also shown variability in their effects on proliferation, differentiation and survival with mouse 
neural stem/progenitor cells (Okuda et al., 2017). Whilst this highlights the complexity of 
downstream effects caused by PARP inhibition, it also suggests that nicotinamide-induced 
PARP-1 inhibition may be a factor in a number of cumulative effects of nicotinamide on a range 
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of cellular mechanisms. Immunocytochemistry for PARP-1 would confirm whether 
nicotinamide treatment reduced PARP-1 expression in these cultures and provide insight into 
this potential mechanism. 
Further assessment of these cultures could include the use of proliferation markers 
such as Ki67 and BrdU to confirm nicotinamide-induced limitation of proliferation in these 
cultures. Another potential mechanism could be that nicotinamide induced cell death, 
therefore, viability assays such as TUNEL staining or the MTT assay would able to provide 
clarification on cell death within these cultures.  
Further exploration of Sirt1 and PARP-1 expression in differentiating 46C cultures may 
assist to elucidate the mechanisms behind the decreased proliferation and increased 
neuralisation observed in this PhD thesis. It may also be interesting to assess whether 
nicotinamide is involved in the upregulation of any vital transcription factors involved in 
dopaminergic differentiation and/or maturation such as sonic hedgehog (Shh), Lmx1b, Nurr1, 
or Pitx3 (discussed in Chapter 1.3). 
The effects observed here, and well-established safety profile of nicotinamide, mean 
that nicotinamide could be a beneficial addition to the development of clinically transferable 
protocols for the generation of cells for CRT for PD in line with GMP guidelines. Further work 
to build on conclusions drawn from this data would be: 
I. To assess the effect of nicotinamide on levels of PARP-1 using 
immunocytochemistry during neural differentiation of 46C cultures. 
II. To assess the effect of nicotinamide on the expression of Sirt1 during neural 





4 Nicotinamide and neuroprotection 
4.1 Introduction 
4.1.1 Nicotinamide may have roles in neuroprotection 
It is well known that diet and nutrition are key factors for general health, but there is 
also a growing body of evidence that it could affect the onset, progression and amelioration 
of PD (Seidl et al., 2014; Agim and Cannon, 2015). Research over the last century has 
elucidated the many essential roles that vitamins play in health maintenance, however, their 
exact effects, biological mechanisms and potential medicinal benefits are still being 
discovered.  
Nicotinamide has been identified as an emerging tool for neuroprotection (Maiese et 
al., 2003) although the mechanisms behind this are yet to be defined (Chapter 1.10). Potential 
modes of action for nicotinamide include: mitochondrial function & energy production (NAD+), 
oxidative stress, PARPs, and sirtuins (Li, Chong and Maiese, 2006). 
 
4.1.2 6-Hydroxydopamine in vitro mechanisms 
The inaccessible nature of the brain in general, and more specifically the SNpc, means 
that studying the molecular mechanisms of PD is often not possible until post-mortem once 
cells have already been destroyed. In vitro models of PD provide a way to visualise 
dopaminergic neurons and their response to pathology. They also provide a valuable tool for 
testing potential neuroprotectants that could provide therapy for PD.  
The neurotoxin 6-OHDA is commonly used to generate an in vitro PD model. It is a 
synthetic, organic compound that is taken up by catecholaminergic (dopamine, adrenaline, 
noradrenaline) neurons (Schubert et al., 1973) via the monoamine transporters: serotonin 
142 
 
transporter, noradrenaline transporter (Lin et al., 2011), and in the use of PD models, the 
dopamine transporter (DAT) present on dopaminergic neurons (Ding et al., 2004; González-
Hernández et al., 2004; Redman et al., 2006). Once inside the cell, a series of reactions take 
place to induce cell death, however, the exact mechanisms behind 6-OHDA toxicity are highly 
debated. The ability of glial cells to also internalise synaptic dopamine is becoming an area of 
research, although it is thought that whilst dopamine taken up by neurons is stored, once it is 
internalised by glia it is broken down by MAO and COMT activity which is higher in glial cells 
(Meiser, Weindl and Hiller, 2013; Winner et al., 2017; Petrelli et al., 2020). If glial cells are able 
to internalise dopamine, then 6-OHDA uptake may not be specific to dopamine neurons, 
however the processing of this toxin may differ between cell types, explaining the selective 
toxicity. 
Cells receiving 6-OHDA treatment undergo apoptosis through a caspase-dependent 
mechanism (Ding et al., 2004), rather than cell death through necrosis (Lotharius, Dugan and 
O’Malley, 1999; Callizot et al., 2019). This differs to the toxins  MPTP and rotenone which work 
through other mechanisms to cause toxicity as described in Chapter 1.5. 
Some of the proposed mechanisms of 6-OHDA toxicity are highlighted in Figure 4.1. 
These include mitochondrial dysfunction, production of toxic compounds through auto-
oxidation, and oxidative stress resulting from ROS production. The accumulation of these 
damaging events culminate in cell death (González-Hernández et al., 2004).  
Studies have shown that 6-OHDA causes mitochondrial dysfunction (Lotharius, Dugan 
and O’Malley, 1999; Hanrott et al., 2006) by inhibiting the mitochondrial respiratory chain 
complexes I and IV (Glinka and Youdim, 1995). Mitochondrial complex I (NADH 
dehydrogenase) transfers electrons from NADH (producing NAD+) to coenzyme Q10 in the first 




Figure 4.1 Potential toxin mechanisms of 6-hydroxydopamine (6-OHDA).  
A) Auto-oxidation of 6-OHDA occurs rapidly under physiological conditions to form hydrogen peroxide 
(H2O2), the reactive oxygen species (ROS) super oxide (O2-) and hydroxyl radical (•OH), and 1,4-
benzoquinone (commonly known as para- or p-quinone; Graham et al., 1978; Soto-Otero et al., 2000). 
This reaction can happen intra- and/or extracellularly. 
B) Due to it structural similarity to dopamine, 6-OHDA enters dopaminergic neurons via the dopamine 
transporter (DAT; Luthman et al., 1989). Once inside the cell autoxidation of 6-OHDA (A) can occur. 
Blocking DAT activity can protect dopaminergic neurons from 6-OHDA toxicity (Ding et al., 2004).  
C) 6-OHDA has been shown to inhibit complexes I and IV of the mitochondrial respiratory chain (Glinka 
and Youdim, 1995). Mitochondrial complex I is the enzyme NADH dehydrogenase which transfers 
electrons from NADH (producing NAD+) to coenzyme Q10 in the first step of the mitochondrial 
transport chain (Wirth et al., 2016). Mitochondrial complex IV is the enzyme cytochrome c oxidase 
which catalyses the transfer of electrons from reduced cytochrome c to O2 alongside the translocation 
of H+ for ATP production (Mansilla et al., 2018). The inhibition of these complexes leads to 
mitochondrial dysfunction resulting in a series of damaging events including production of O2- 
(Pelicano et al., 2003) contributing to increasing levels of ROS. 
D) Mitochondrial dysfunction leads to a reduction in ATP synthesis (Marques, Massari and Tasca, 
2019). ATP-dependent pumps maintain a steep concentration gradient of low intracellular Ca2+ levels 
compared to high extracellular levels (Surmeier et al., 2011). A reduction in ATP levels could result in 
an influx of Ca2+ into the cell. 
E) Ca2+ increases the inhibitory potency of 6-OHDA for mitochondrial complex I. This may cause a 
feedback amplification with mitochondrial dysfunction resulting in elevated levels of Ca2+ which 
further disrupt mitochondrial function (Glinka, Gassen and Youdim, 1997). 
F) Increased intracellular Ca2+ can also induce mitochondrial swelling (Kobayashi et al., 2003) and 
permeability of the mitochondrial membrane (Norenberg and Rama Rao, 2007). Surmeier et al. (2011) 
provide a review on the potential roles of Ca2+ in dopaminergic neuron death. 
G) H2O2 has been cited as highly cell permeable (Ramasarma, 1982; Halliwell, 1992; Nagatsu and 
Sawada, 2006; Dias, Junn and Mouradian, 2013), however, diffusion rates have been shown to differ 
across cell types and membranes (Antunes and Cadenas, 2000; Hashida, Sakakura and Makino, 2002; 
Makino et al., 2004). There are also proposals of channels and aquaporins that may facilitate 
transportation of hydrogen peroxide across membranes (Bienert et al., 2007; Avola et al., 2018). 
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H) Intracellular H2O2 reacts with Fe2+ and Fe3+ in the Fenton reaction to produce the ROS hydroxyl 
radical (•OH), hydroxide ion (OH-), and hydroperoxyl radical (•OOH; Valko et al., 2007). 
I) Increased levels of ROS lead to damage of mitochondrial DNA and disruption of mitochondrial Ca2+ 
regulating proteins (Guo et al., 2013). 
J) ROS also lead to lipid peroxidation which consists of damage to lipid membranes including the outer 
cell membrane and mitochondrial membranes. Lipid peroxidation can lead to structural damage of 
membranes and production of neurotoxic products (Montine et al., 2002; Guo et al., 2013; Lima et al., 
2018). 
K) Involvement of the mitochondrial bound enzyme monoamine oxidase (MAO) in 6-OHDA toxicity is 
debated (Blum et al., 2001). Under normal conditions, MAO breaks down amines such as dopamine 
and 6-OHDA. MAO inhibitors can increase the toxicity of 6-OHDA by preventing it’s breakdown, 
thereby requiring a lower dose of 6-OHDA for toxicity (Duty and Jenner, 2011). However, MAO 
inhibitors have also shown protection of TH+ neurons against 6-OHDA toxicity in vivo (Salonen et al., 
1996; Cutillas, Ambrosio and Unzeta, 2002). These differences cited in the literature could be due to 
the specificity of the inhibitor as well as the different 6-OHDA models used. The action of MAO may 
enhance the toxicity of 6-OHDA as the breakdown of dopamine and 6-OHDA by MAO results in the 
production of H2O2 as a by-product (Blum et al., 2001). 
L) H2O2 is potentially an important signalling molecule with cellular mechanisms maintaining non-toxic 
intracellular levels (Armogida, Nisticò and Mercuri, 2012). It is typically inactivated by the action of 
cytosolic glutathione peroxidase with the co-factor glutathione (GSH) to produce glutathione 
disulphide (GS-SG) and water (H2O). 
M) GSH levels can be reduced in 6-OHDA treated cell models (Villa et al., 2013; Magalingam, 
Radhakrishnan and Haleagrahara, 2014) and can also be diminished as a result of lipid peroxidation (J) 
due to increased levels of ROS (Guo et al., 2018). This results in lower levels of GSH and therefore a 
reduction in glutathione peroxidase activity to neutralise H2O2 (L). Higher levels of H2O2 could then lead 
to further production of ROS (H). 
N) Damage to mitochondria arising from C, E, F, I, and J results in a decrease in mitochondrial 
membrane potential (ΔΨm; Ly, Grubb and Lawen, 2003). 
O) Mitochondrial swelling (F), ROS mediated damage (I, J) and reduction in ΔΨm (N) lead to the release 
of cytochrome c (Kobayashi et al., 2003; Gomez-Lazaro et al., 2008; Guo et al., 2013).This in turn 
activates caspases which are central in apoptotic signalling leading to cell death (Ly, Grubb and Lawen, 
2003). 
P) Production of ROS resulting from autoxidation of 6-OHDA (A), mitochondrial dysfunction (C) and the 
Fenton reaction of H2O2 (H) causes widespread damage throughout the cell including damage to 
nuclear DNA and cytosolic RNA (Sanders and Greenamyren, 2013). 
Q) Intracellular p-quinone produced from autoxidation of 6-OHDA (A) is proposed to disrupt protein 
folding and impair proteome function contributing to cell death (Farzam et al., 2020). 
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Mitochondrial complex IV (cytochrome c oxidase) catalyses the transfer of electrons 
from reduced cytochrome c to O2 alongside the translocation of H+ for ATP production 
(Mansilla et al., 2018). Dysfunction of the mitochondrial respiratory chain caused by inhibition 
of complexes I and IV by 6-OHDA results in increased production of ROS (Figure 4.1 C; Pelicano 
et al., 2003; Wirth et al., 2016), decreases in mitochondrial membrane potential (ΔΨm; Figure 
4.1 N; Ly, Grubb and Lawen, 2003) and reduced ATP levels (Figure 4.1, C; Villa et al., 2013; 
Marques, Massari and Tasca, 2019). 
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A reduction in ATP levels could result in an influx of Ca2+ (Figure 4.1 D) further inhibiting 
mitochondrial complex I (Figure 4.1 E; Glinka, Gassen and Youdim, 1997). Increased 
intracellular Ca2+ can also induce mitochondrial swelling (Figure 4.1 F) leading to the release 
of cytochrome c (Kobayashi et al., 2003). Cytochrome c release activates caspases which are 
central to apoptotic signalling leading to cell death (Figure 4.1 O; Ly, Grubb and Lawen, 2003). 
MAO breaks down amines including dopamine and 6-OHDA, and its involvement in 6-
OHDA toxicity is debated (Blum et al., 2001). A potential contribution of MAO to toxicity is 
through the production of hydrogen peroxide (H2O2) resulting from the breakdown of amines 
(Figure 4.1 K). 
Hydrogen peroxide production is a normal part of cell functioning and it can be 
considered as a signalling molecule, with cellular mechanisms maintaining non-toxic 
intracellular levels (Figure 4.1 L; Armogida, Nisticò and Mercuri, 2012). Its toxicity arises from 
ROS production by interaction with Fe2+ and Fe3+ in the Fenton reaction (Figure 4.1H; Valko et 
al., 2007). ROS production and subsequent damage can be further propagated by a reduction 
in neutralising mechanisms resulting from other toxic compounds involved in 6-OHDA toxicity 
(Figure 4.1M; Guo et al., 2018). Glutathione (GSH), protects cells against 6-OHDA toxicity 
(Shimizu et al., 2002), perhaps by reducing H2O2 production. Treating cultures with 6-OHDA 
decreases levels of GSH in RCSN-3 cells (a cell line derived from rat SN; Villa et al., 2013). 
Increased ROS is both directly (auto-oxidation; Figure 4.1 A) and indirectly 
(mitochondrial dysfunction and increased H2O2; Figure 4.1 C, H) caused by 6-OHDA, resulting 
in cell death through oxidative stress (Lotharius, Dugan and O’Malley, 1999). Excessive ROS 
production leads to lipid peroxidation (Figure 4.1 J; Montine et al., 2002; Guo et al., 2013; Lima 
et al., 2018), damage to mitochondrial DNA and calcium regulating proteins (Figure 4.1 I; Guo 
et al., 2013), and damage to nuclear DNA and cytosolic RNA (Figure 4.1 P; Evans, Dizdaroglu 
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and Cooke, 2004; Sanders and Greenamyren, 2013). This ROS production can occur 
intracellularly and/or extracellularly resulting in damage to cells.  
Auto-oxidation of 6-OHDA occurs rapidly under physiological conditions to form H2O2, 
super oxide (O2-), hydroxyl radicals (•OH), and 1,4-benzoquinone (commonly known as para-
quinone or p-quinone; Figure 4.1 A; Graham et al., 1978; Soto-Otero et al., 2000). Intracellular 
p-quinone is proposed to alter protein expression and disrupt protein folding, contributing to 
cell death (Farzam et al., 2020). 
Blocking DAT rescues cells from intracellular 6-OHDA toxicity both in vitro (Ding et al., 
2004) and in vivo (González-Hernández et al., 2004), whilst forced expression of DAT induces 
vulnerability to 6-OHDA toxicity in cortical neurons (Redman et al., 2006). However, 6-OHDA 
can also induce toxicity extracellularly: i.e. induce damage in cells in the absence of uptake. If 
ROS production occurs outside of the cell, then non-specific toxicity can occur. For instance, 
in PC12 cells, 6-OHDA toxicity remained evident even when DAT was blocked (Hanrott et al., 
2006). Extracellular production of H2O2 could also contribute to toxicity, with suggestions that 
H2O2 is highly cell permeable (Ramasarma, 1982; Halliwell, 1992; Nagatsu and Sawada, 2006; 
Dias, Junn and Mouradian, 2013). There are also proposals of channels and aquaporins that 
may facilitate transportation of hydrogen peroxide across membranes (Bienert et al., 2007; 
Avola et al., 2018). This could contribute to instances of non-specific 6-OHDA toxicity. 
Non-specific toxicity, shown by a reduction in cell numbers, has been reported in VM 
cultures at concentrations of 6-OHDA between 10 and 100 µM (Michel and Hefti, 1990). This 
toxicity is not restricted to neurons, with concentrations of 100 µM 6-OHDA for 24 hours 
resulting in death of approximately 90% of cultured primary rat microglia (Takai et al., 1998). 
Concentrations as low as 10 µM 6-OHDA have also been shown to induce a range of pro-
inflammatory effects on astrocytes including increased expression of iNOS (inducible nitric 
oxide synthase) and GFAP in the C6 rat astrocyte cell line (Gupta et al., 2015).  
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The staging of 6-OHDA auto-oxidative events is dependent on the propagating 
intermediates, substrates and products available throughout auto-oxidation (Gee and 
Davison, 1989). When 6-OHDA is carried in an ascorbic acid (AA) vehicle this auto-oxidation to 
neurotoxic metabolites is reduced (Ding et al., 2004). 10 mM AA reduces the rate of oxygen 
consumption and production of H2O2 (Soto-Otero et al., 2000). Production of p-quinone is also 
reduced by AA (Sullivan and Stern, 1981; Soto-Otero et al., 2000). This suggests that the 
addition of AA to 6-OHDA could help to prevent non-specific toxicity caused by extracellular 
auto-oxidation. 
Methods to create in vitro 6-OHDA PD models, and the resulting outcomes, vary across 
the literature (Table 4.1). Due to the variation described by laboratories across the world, a 
robust and reproducible 6-OHDA in vitro model needed to be developed and specified for the 
VM cultures used in this PhD research. Once a standardised model was developed it could 




Table 4.1 Table highlighting some in vitro PD models using 6-OHDA in primary rodent VM cultures. VM: ventral mesencephalon; E#: embryonic day; P# postnatal 
day; AA: ascorbic acid. Article reference: 1) Batelli et al. (2015) 2) Lotharius, Dugan and O’Malley (1999) 3) Cerruti et al. (1993) 4) Rodriguez-Pallares et al. (2007) 
5) Michel and Hefti (1990) 6) Callizot et al. (2019) 7) Izumi et al. (2005) 8) Bronstein et al., (1995) 9) Masaki et al. (2017) 10) Ding et al. (2004) 11) Sun et al. (2018) 
Conclusion 6OHDA conc. Vehicle Exposure 
duration and 
fixation 
















 cells from 9.5% to 8% 
50 μM and 6.5% 100 μM 











TH Not stated 1 
15 μM reduced TH
+
 neurons by 
approximately 55% 




















10 nM Not stated 48 hr exposure, 
fixed at 9 DIV 
E14 VM rat 300,000 cells 
per dish 
2 or 7 Not stated Dopamine Not stated 3 
40 μM reduced TH
+
 cell 
numbers by about 60% 
10, 40 μM 0.02% saline 
ascorbate 




 6 Not stated TH Not stated 4 
10-100 μM resulted in a dose 
dependent reduction in TH+ 
neurons 
10-100 μM 20 μM AA 
40 μM α-
tocopherol 
Did not affect 
response to 
toxin 
24 h then 
fixed/assessed 
E15 VM rat Density after 1 
week in vitro = 
1.0 to 1.4 x 10" 










30 μM 24 hr reduced TH
+
 
numbers by about 30% 
10-30 μM  Not stated 24 or 48 h, tests 
run immediately 
E 15 rat VM 40,000 per 96 
well 
225,000 per 24 
well 












100 μM reduced TH
+
 neurons by 
about 80% 










9 Not stated TH Not stated 7 
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6OHDA treatment killed 89 ± 8% 
TH+ cells 
(10μM ineffective, 100μM killed 
non-catecholaminergic cells) 
30 μM 0.1% Ascorbate 48 h then fixed E16 rat VM 100,000 
cells/well 
4-6 Not stated TH Treatment 
killed 30% TH- 
neurons 
8 








9 Not stated TH Not stated 9 
40 μM reduced TH
+
 cell 
numbers by 53% 





acid; 0.15% AA; 
flushed with N2 
15 min then 3-
48 hr recovery 






 of total 
cells at 4DIV 




















4.1.3 Direct effects of nicotinamide through inhibition of PARP-
1 and Sirt1 
PARP-1 can be considered as cytoprotective due to its role in DNA repair, however 
overactivation through mechanisms including oxidative stress can lead to depletion of cellular 
NAD+ and ATP, and activation of cell death pathways (Virág and Szabó, 2002). One of the main 
modes of cell death due to 6-OHDA toxicity is through oxidative stress, which could lead to 
overactivation of PARP-1 as a mediator of this toxicity. However, Callizot et al. (2019) found 
no protection of a specific PARP-1 inhibitor against 6-OHDA, suggesting that PARP-1 is not 
central to 6-OHDA mediated toxicity. 
Sirt1 is often cited as neuroprotective with Sirt1-overexpressing mice showing life span 
extension and enhanced neural activity (Satoh et al., 2013). Resveratrol has been shown to 
upregulate Sirt1 providing neuroprotection (Wan et al., 2016; Zhuo Zhang et al., 2019), and 
has also shown effectiveness in PD models reviewed by Tang (2017). However, a number of 
the studies showing neuroprotection in this review article use cell lines that may not be 
considered representative of dopaminergic neurons (as discussed in Chapter 1.5.2). Sirt1 has 
been found to be crucial in neuroprotection induced by NAMPT overexpression in primary 
neuronal cultures and transgenic mice (Wang et al., 2011). However, transgenic mice 
overexpressing Sirt1 did not show alleviation of MPTP-induced loss of TH+ neurons (Kitao et 
al., 2015).  
Other studies have shown that inhibition of Sirt1 can be neuroprotective. Inhibition of 
Sirt1 by application of sirtinol or 5 mM nicotinamide, or knockdown of Sirt1, increased survival 
of cultured cortical neurons exposed to oxidative stress through application of H2O2 (Li et al., 
2008). However, 6-OHDA significantly reduced Sirt1 activity in PC12 cells (Zou et al., 2016). 
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Therefore, if 6-OHDA alone inhibits Sirt1 activity, the addition of nicotinamide as a Sirt1 
inhibitor may not exert neuroprotective effects through this mechanism in a 6-OHDA model. 
 
4.1.4 Indirect effects of nicotinamide through nicotinamide 
derivatives 
As described in Chapter 1.10, nicotinamide and associated compounds have shown 
neuroprotective properties across a variety of neurodegenerative diseases. It has therefore 
been hypothesised that nicotinamide could provide neuroprotection for dopaminergic 
neurons. Consistent with this, nicotinamide has shown protection in models of PD. Schulz, 
Henshaw, Matthews, & Beal (1995) suggest that nicotinamide, given prior to (0.5 hours) and 
after (every 8 hours for 48 hours) MPTP administration (discussed in Chapter 1.5), in an in vivo 
mouse model reduces neurotoxicity through improved mitochondrial energy production.  
However, it is not clear whether such protective effects are mediated by nicotinamide 
itself, or by one or more derivative molecules. Figure 1.10 described the interconversion of 
various nicotinamide-related metabolites. Several of these molecules, and the enzymes 
involved in NAD+ pathways, have been associated with neuroprotective effects; but, as with 
nicotinamide, it is often unclear whether these effects are directly attributable to the 
delivered molecule or depend on generation of a derivative molecule.  
Nicotinamide could confer this protection to dopaminergic neurons through increases 
in pyridine nucleotide levels (NAD+, NADH, NADP+, NADPH). Administration of NAD+ in the in 
vivo 6-OHDA mouse model significantly reduced the loss of TH+ neurons in the SN (Shan et al., 
2019). Therefore, it is possible that nicotinamide could exert protective effects by increasing 
levels of NAD+. In PC12 cells, NAD+ levels and Sirt1 activity are reduced by 6-OHDA treatment. 
Treatment of PC12 cells with the nicotinamide derivative NMN (Figure 1.10) rescues 6-OHDA 
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induced cell viability attenuating the Sirt1 activity decrease (Zou et al., 2016), and increased 
cell survival and attenuated rotenone-induced intracellular ATP depletion (Lu et al., 2014). 
6-OHDA may decrease levels of GSH (Villa et al., 2013) an important antioxidant 
(detailed in Chapter 4.1.2). NADPH is utilised by glutathione reductase in the reduction of GS-
SG to GSH. Therefore, increases in NADPH could help to maintain levels of GSH, conferring 
protection against oxidative stress. 
Despite evidence of neuroprotection conferred by nicotinamide and associated 
compounds, there is the potential for nicotinamide to exacerbate neurodegenerative 
conditions. For example the increase in meat consumption in populations across the globe 
(and consequently vitamin B3) correlates with increased incidence of PD (Williams and 
Ramsden, 2005a), whilst vegan diets are associated with a lower risk (McCarty, 2001). The 
increased risk with meat intake may be through increased production of N-
methylnicotinamide which is toxic to dopaminergic neurons (Williams and Ramsden, 2005b). 
Also, Harrison, Powell, & Dexter (2019) found that nicotinamide dose-dependently 
exacerbated behavioural motor defects in the lactacystin rat model of PD. In this study, 
nicotinamide dose-dependently increased ventricular enlargement induced by lactacystin and 
exacerbated the loss of TH+ neurons in the SNpc. They suggest that this could be due to a 
synergistic inhibitory effect of lactacystin and nicotinamide on proteasome activity and/or 
nicotinamide-induced inhibition of Sirt1.  
 
4.1.5 Calcitriol and neuroprotection 
As discussed in Chapter 1.8, vitamins have widely been shown to promote 
neuroprotection. One of the most predominantly studied for its neuroprotective properties is 
vitamin D3. Calcitriol, the active metabolite of vitamin D3 (discussed in Chapter 1.9), has shown 
protection of dopamine neurons from 6-OHDA toxicity in both in vitro and in vivo models 
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(Wang et al., 2001; Sanchez et al., 2009; Orme, Bhangal and Fricker, 2013; Lima et al., 2018) 
and also causes an increase in the release of dopamine in the striatum and SN of rats (4-5 
months old; Cass et al., 2014), however, this positive response was not seen in aged (22 
months) rats (Cass and Peters, 2017). 
Calcitriol has been shown to have a protective effect on dopamine neurons through 
upregulation of GDNF (Sanchez et al., 2009; Orme, Bhangal and Fricker, 2013) an important 
factor in dopamine neuron survival and maintenance (Hidalgo-Figueroa et al., 2012; 
d’Anglemont de Tassigny, Pascual and Lopez-Barneo, 2015). Calcitriol may also offer 
protection by decreasing oxidative stress and the resulting damage from this change in cell 




4.1.6 Aims of Chapter 4 
As described above, there is uncertainty in the potential neuroprotective effects of 
nicotinamide and its potential roles in the development of PD. The cause of dopaminergic 
degeneration remains unknown for the majority of PD cases and there are no treatments that 
can prevent the continual degeneration. Treatments that may halt or slow this 
neurodegeneration could improve the quality of life for many people with PD. 
Neuroprotective treatments may also benefit other therapies such as CRT which may be 
vulnerable to disease progression after initial recovery. This chapter aims to assess the 
potential of nicotinamide to incite neuroprotection in a PD model. The objectives of this 
chapter are: 
I. The development of an effective in vitro model of PD using E14 rat VM cultures 
treated with 6-OHDA. 
II. Assessment of the effects of nicotinamide on dopaminergic neurons (TH+ 
populations) within control VM cultures. 
III. Assessment of the potential for nicotinamide to provide neuroprotection of 
TH+ neurons in the developed in vitro 6-OHDA PD model; and comparison with 
the protective effects of calcitriol and possible combined neuroprotection of 





4.2.1 Assessing neuroprotection of nicotinamide and calcitriol 
in an in vitro 6-OHDA PD model 
The in vitro PD model described in Chapter 2.5.2 was used to assess potential 
neuroprotective activity of nicotinamide. Calcitriol was used as a positive, neuroprotective 
control. VM cultures were obtained as described in Chapter 2.5.1 and plated on to PEI/PDL 
coated coverslips (0 DIV). Cultures were grown for 7 DIV in their treatment condition, either 
control (NCM), 10 mM nicotinamide (Griffin et al., 2013), 10 nM calcitriol (Orme, Bhangal and 
Fricker, 2013), or 10 mM nicotinamide + 10 nM calcitriol. At 7 DIV, 6-OHDA or AA vehicle 
control was applied as described in Chapter 2.5.2, for 4 hours, and after removal the cells were 
maintained for a further 48 hours ‘recovery’. Cells received their treatment conditions 
(vitamins) prior to, throughout, and during recovery from 6-OHDA treatment (Figure 4.2). 
Cultures were assessed using fluorescence microscopy. Cells were fixed at 9 DIV and stained 






Figure 4.2 Diagram showing the protocol for the in vitro 6-OHDA PD model developed here. Cultures were obtained from E14 rat VM and were seeded in micro-
drop cultures (Day 0). Cultures received the vitamin treatment conditions displayed in the table throughout the protocol with media changes every 2-3 days. 6-
OHDA or AA vehicle was applied on day 7 for 4 hours, after which cultures were washed with NCM and then left for a 48 hour ‘recovery period’ in their treatment 
condition. Cells were fixed on day 9 and analysed using immunocytochemistry for β-III-tubulin and tyrosine hydroxylase, with nuclei counterstained with DAPI. 6-




4.2.2 Acquisition of images for 6-OHDA treated culture analysis 
Varying techniques were used to identify and quantify TH+/ β-III-tubulin+, TH-/β-III-
tubulin+, and TH-/β-III-tubulin- cells within VM cultures treated with 6-OHDA. Initial 
assessment during development of the 6-OHDA model utilised images taken at 40X and 20X 
magnification (detailed in Chapter 2.9). For final assessment of the effects of vitamins and 6-
OHDA on TH+ cells within VM cultures, images were taken at 10X magnification and the total 
number of TH+ cells were quantified within each image.  
As TH+ cells composed a small percentage of cells within each culture, but were usually 
aggregated within small areas, micrographs taken at 10X magnification ensured 
representative TH+ populations were imaged across coverslips. This avoided having many 
images with zero TH+ cells, and a few images with a high density of TH+ cells (observed with 
20X and 40X magnifications), which would be likely to skew analyses. FOI were chosen as 
described in Chapter 2.9, using the DAPI fluorescence channel. Experimental design followed 
that described in Chapter 2.2, with 3 experimental repeats, 3-4 technical replicates per 





4.3.1 Development of the 6-OHDA model 
Pilot experiments based on protocols from the literature (Table 4.1), and protocols 
previously used in the lab, were required to achieve an appropriate and reproducible in vitro 
6-OHDA model with the primary VM cultures. Based on the literature, concentrations of 25 
µM, 50 µM, and 100 µM, and application times of 20 minutes, 2 hours, and 24 hours were 
tested. Due to time constraints, only one experimental repeat was carried out, therefore, 
statistical tests were not performed on preliminary 6-OHDA results. 
The rapid oxidation of 6-OHDA requires it to be carried in a vehicle to reduce auto-
oxidation and subsequent reduction in biological activity and production of p-quinone. The 
vehicle used for this in vitro model was AA, the antioxidant effects of which are described 
above (Chapter 4.1.2). To determine whether there was any effect of AA on TH+ cells in culture, 
control cells received either 850 µM AA vehicle or remained untreated, receiving only a media 
change and subsequent washes. The total number of TH+ neurons present in 4 micrographs, 
taken across 3-4 technical replicates, was normalised to the untreated cultures for each 
experimental repeat (n = 3). Cultures receiving 850 µM AA vehicle showed no significant 
difference in TH+ cell numbers compared to untreated cultures (93.7 ± 19.3 vs. 100.0 ± 12.9 in 
untreated cultures; values normalised; t = 0.28, n.s.; Figure 4.3). Therefore, the addition of AA 




Figure 4.3 Application of ascorbic acid vehicle did not affect TH+ numbers. Graph showing the total 
number of TH+ neurons normalised to control, in untreated cultures (media change only; green circle) 
and cultures receiving ascorbic acid vehicle control (850 µM; blue square). No significant difference 
was observed.  
 
The initial pilot experiment compared application of 6-OHDA at 25 µM, 50 µM and 100 
µM (in 850 µM AA vehicle) for 20 minutes, 2 hours and 24 hours.  
The 20-minute treatment with 25 µM and 50 µM 6-OHDA did not appear to reduce 
numbers of TH+ cells whilst cultures treated with 100 µM 6-OHDA for 20 minutes reduced 
numbers (Figure 4.4 A). However, it was considered unlikely that pipetting could be performed 
rapidly enough when applying and removing/washing away 6-OHDA across multiple cultures, 
to reliably replicate this 20-minute timeframe.  
Application of 100 µM 6-OHDA reduced numbers of TH+ cells dramatically, with very 
few remaining across cultures at all timepoints (Figure 4.4 A). The toxic effects of 100 µM 6-
OHDA also appeared to be non-specific, with total cell numbers (DAPI+ nuclei counts) 
obviously diminished at 2 hour and 24 hour treatments (Figure 4.4 A). 
6-OHDA treatment for 2 hours appeared most effective at reducing numbers of TH+ 
cells without affecting total cell numbers. Four images from 4 technical replicates were taken 
at 40X magnification to analyse TH+ and TH- cell numbers. At 2 hours, TH+ numbers were lower 
across all concentrations of 6-OHDA (Figure 4.4 B). Total cell numbers appeared reduced at 50 
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µM and 100 µM 6-OHDA suggesting non-specific toxicity, whilst total cell numbers at 25 µM 
appeared unchanged (Figure 4.4 C). From this pilot data, 25 µM for 2 hours was chosen as the 
most effective application for an in vitro 6-OHDA model for future experiments.  
However, when this concentration and exposure time was used for the next 
experiment, rather than selectively killing TH+ cells, a large proportion of β-III-tubulin+/TH- 
neurons were also destroyed (Figure 4.4 D). As part of troubleshooting it was suspected that 
small inconsistencies weighing the small amount of 6-OHDA powder (2.5 mg) needed for each 
experimental repeat could produce inaccuracies in the concentration of 6-OHDA that cells 
were exposed to, leading to problems in reproducibility. Therefore, a 100 mM 6-OHDA stock 
in 85 mM AA vehicle was created, aliquoted and stored at -80℃. All future experiments were 
drawn from these aliquots ensuring more reliable replication of 6-OHDA treatment, compared 







Figure 4.4 Pilot test of 6-OHDA toxicity.  
A) Representative 10X images showing merge of DAPI and TH immunocytochemistry in VM cultures 
treated with vehicle control (850 µM AA), or 6-OHDA at concentrations of 25, 50, or 100 µM, for either 
20 minutes, 2 hours, or 24 hours. Scale bars hold for all images.  
B) Graph showing the average number of TH+ neurons per 40X micrograph across 6-OHDA treatment 
conditions for 2 hours.  
C) Graph showing the average number of nuclei per 40X micrograph across 6-OHDA treatment 
conditions for 2 hours. (Graph error bars show SEM of technical replicates).  
D) Representative 10X images for vehicle control and 25 µM 6-OHDA treatment for 2 hours. 
Immunocytochemistry showing DAPI, TH, and β-III-tubulin shows the substantial loss of β-III-tubulin+ 
neurons in 6-OHDA treated cultures. 
 
As 6-OHDA oxidises in solution it becomes brown/black, due to the production of p-
quinone, and loses biological effectiveness. To ensure storage was reliable, stock aliquots (100 
mM 6-OHDA in 85 mM AA) were left at room temperature and imaged at 1 hour, 48 hours, 1 
week and 2 weeks. Only after 2 weeks at room temperature was there a change in colour 
perceptible by eye (Figure 4.5 A). It was assumed that if thawed 6-OHDA aliquots did not 
appear transparent and colourless, then degradation had occurred and they would not be 
used. However, this appearance did not present and no aliquots needed to be discarded. 
Stock 6-OHDA was then diluted and tested on VM cultures at 25 µM, 50 µM and 100 
µM for 2, 6 and 24 hours. Results showed that 50 µM and 100 µM concentrations, at all time 
points, reduced TH+ numbers, with very few remaining across all technical replicates. These 
concentrations also obviously reduced β-III-tubulin+ and total cells (DAPI) indicating non-
specific toxicity (Figure 4.5 B). 
To analyse this pilot data, numbers of TH+/β-III-tubulin+, TH-/β-III-tubulin+ and TH-/β-
III-tubulin- cells were quantified from 4 micrographs taken at 20X magnification for 3 technical 
replicates. These results showed a decrease in the percentage TH+ neurons of all neurons (i.e. 
TH+/β-III-tubulin+ divided by β-III-tubulin+), between vehicle control and 25 µM 6-OHDA 
treated cultures, at both 2 and 6 hours (Figure 4.5 C). The 6 hour 25 µM treatment also showed 
a drop in the percentage of β-III-tubulin+ neurons relative to total cells (Figure 4.5 D) 
suggesting the possibility of non-specific toxicity. It was decided that 25 µM 6-OHDA for 4 
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hours would be the most suitable option to consistently and significantly reduce TH+ numbers 






Figure 4.5 Application of 25 µM 6-OHDA (from frozen aliquots) for 4 hours was chosen to create a VM 
6-OHDA model.  
A) Images of a thawed 6-OHDA aliquot imaged immediately after removal from -80°C storage (0), then 
1 hour, 48 hours, 1 week, and 2 weeks left at room temperature. Discolouration was perceptible by 
eye after 2 weeks.  
B) Representative 10X micrographs of VM cultures treated with ascorbic acid vehicle control (850 µM) 
or 6-OHDA (from freshly thawed aliquot) at concentrations of 25, 50, or 100 µM for 2, 6 or 24 hours. 
Immunocytochemistry shows DAPI (blue), TH (red), and β-III-tubulin (green). Scale bars hold for all 
images.  
C) Graph showing % TH+ neurons of total neurons in VM cultures treated with 25 µM 6-OHDA for 2 or 
6 hours, compared to cultures receiving vehicle control for 6 hours.  
D) Graph showing % β-III-tubulin+ neurons of total cells in VM cultures treated with 25 µM 6-OHDA for 
2 or 6 hours, compared to cultures receiving vehicle control for 6 hours. Error bars represent SEM 
between technical replicates. 
 
4.3.2 Numbers of TH+ cells in VM cultures across 14 DIV were 
higher with nicotinamide treatment 
In images taken at 40X magnification, DAPI counts showed that nicotinamide 
treatment was associated with significantly lower numbers of cells in VM cultures at 7 DIV 
compared to control cultures (220.1 ± 17.81 vs. 283.1 ± 18.8; t-test p < 0.05; Figure 4.6). This 
prompted a more thorough characterisation of other cell types (GFAP+ astrocytes, Nestin+ 
neural stem cells, Iba1+ microglia) present in these cultures. Analyses of VM cultures across 
multiple experiments were compiled to estimate cell populations, details are described in 
Chapters 5.2.1 and 5.3.1. This analysis found that TH+ cells make up approximately 0.66% of 
control cultures and 1.2% of nicotinamide treated cultures. 
 
Figure 4.6 Numbers of DAPI+ nuclei were lower in nicotinamide treated VM cultures. Graph showing 
the average number of DAPI+ nuclei quantified in control (blue circle) and 10 mM nicotinamide (red 
square) treated VM cultures Nicotinamide treated cultures had significantly lower numbers of nuclei 
than control after 7 days in vitro, * p < 0.05. (FOI = 0.073 mm2). 
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Micrographs taken at 10X magnification were used to assess numbers of TH+ neurons 
within cultures at 1, 4, 7 and 14 DIV. Numbers showed variation across experimental repeats, 
therefore, the average number of TH+ cells was normalised to the control at 1 DIV, within each 
experiment. The number of TH+ cells varied with both nicotinamide treatment (two-way 
ANOVA F(1, 78) = 27.6, p < 0.001) and time in culture (two-way ANOVA F(3, 78) = 37.16, p < 0.001), 
with no interaction effects detected (two-way ANOVA F(3, 78) = 0.69, n.s.). Post-hoc analysis 
using Bonferroni’s multiple comparison revealed significantly higher numbers of TH+ neurons 
in nicotinamide treated cultures compared to control cultures at 1 DIV (166.6 ± 11.3 vs. 100.0 
± 5.7; p < 0.05), 4 DIV (302.1 ± 28.2 vs. 206.3 ± 19.9; p < 0.01), and 7 DIV (212.4 ± 21.2 vs. 145.0 
± 25.2; p < 0.05) with no significant difference at 14 DIV (87.3 ± 14.4 vs. 43.4 ± 9.5; n.s.; Figure 
4.7).  
Post-hoc analysis using Tukey’s multiple comparisons revealed significant differences 
within control cultures between 1 and 4 DIV (100.0 ± 5.7 vs. 206.3 ± 19.9; p <0.001), and 
between 7 and 14 DIV (145.0 ± 25.2 vs. 43.4 ± 9.5; p < 0.01). In nicotinamide treated cultures, 
significant differences were found between 1 and 4 DIV (166.6 ± 11.3 vs. 302.1 ± 28.2; p < 
0.001), between 4 and 7 DIV (302.1 ± 28.2 vs. 212.4 ± 21.2; p < 0.01), and between 7 and 14 
DIV (212.4 ± 21.2 vs. 87.3 ± 14.4; p < 0.001; Figure 4.7). 
The morphology of TH+ cells appeared to change over time in culture (Figure 4.8) with 
cells exhibiting small somas with few, short processes at 1 DIV. At 4 DIV, TH+ cells showed a 
neuronal morphology with small somas and extending, complex processes. This morphology 
was maintained through to 14 DIV with some TH+ neurons showing extensive neurites. The 
addition of nicotinamide to cultures did not appear to effect TH+ neuron morphology although 
no quantitative analysis was carried out. 
The above results show that TH+ cell numbers increased between days 1 and 4, and 
then decreased between days 4-14 in both control and nicotinamide treated VM cultures. 
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Also, VM cultures treated with nicotinamide contained significantly higher numbers of TH+ 
cells than control cultures at days 1, 4 and 7, but not at day 14. 
 
Figure 4.7 Numbers of TH+ neurons were higher in nicotinamide treated cultures and changed 
significantly over days in vitro (DIV). A) Graph showing the average number of TH+  cells per 10X 
micrograph across days 1, 4, 7, and 14 DIV. * Numbers of TH+ cells were significantly higher in 
nicotinamide treated cultures (red square) compared to control (blue circle) at 1, 4, and 7 DIV. # 
Numbers of TH+ cells also changed across DIV in treatment conditions with a significant increase in TH+ 
numbers between days 1 and 4, in both control and nicotinamide treated cultures, a significant 
decrease was observed between 4 and 7 DIV in nicotinamide treated cultures, and a significant 
decrease between 7 and 14 in both control and nicotinamide cultures. * p < 0.05; ** p < 0.01; # p < 
0.05. B) Representative 10X micrographs of VM cultures in control and nicotinamide treatment 




Figure 4.8 Morphology of TH+ neurons changed over days in vitro (DIV). Micrographs showing the 
morphology of TH+ cells at days 1, 4, 7, and 14 DIV in both control and nicotinamide treated VM 
cultures. Scale bar holds across all images. 
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4.3.3 Numbers of TH+ cells were also higher in nicotinamide-
treated AA vehicle control cultures 
For the 6-OHDA treatment experiments, control cultures at 7 DIV were treated for 4 
hours with the vehicle used to carry the 6-OHDA, namely NCM containing 850 µM AA. These 
cultures are referred to as vehicle controls below. Total numbers of TH+ neurons were counted 
across 4 micrographs taken at 10X magnification from each technical replicate across 4 
experimental repeats. Due to variation across experimental repeats, TH+ cell counts were 
normalised to the vehicle control within each experimental repeat. 
Firstly, the effects of nicotinamide were investigated within vehicle treated cultures. 
Cultures treated with nicotinamide and AA vehicle contained significantly more TH+ cells than 
control cultures with vehicle (154.2 ± 13.7 vs. 100.0 ± 10.5; t = 3.15, p < 0.01; Figure 4.9 A).  
Numbers of β-III-tubulin+ neurons were also analysed across 10X micrographs and 
normalised to control due to variation across experimental repeats. Results showed no 
statistically significant difference in β-III-tubulin+ numbers between vehicle control and 
nicotinamide treated cultures (100.0 ± 4.1 vs. 90.8 ± 4.3; t = 1.54, n.s.; Figure 4.9 B). 
These results show that the application of 10 mM nicotinamide also increased 
numbers of TH+ neurons within these AA vehicle treated VM cultures, with no significant 





Figure 4.9 Nicotinamide treatment increased numbers of TH+ neurons, but not total β-III-tubulin+ 
neurons.  
A) Graph showing the number of TH+ neurons in control (blue circle) and nicotinamide (red square) 
treated cultures at 9 DIV (with addition of AA, the vehicle control for 6-OHDA). Nicotinamide treated 
cultures contained significantly higher numbers of TH+ neurons; ** p < 0.01.  
B) Graph showing the number of β-III-tubulin+ neurons in control and nicotinamide treated cultures at 
9 DIV (with addition of AA, the vehicle control for 6-OHDA).  
 
4.3.4 Calcitriol did not increase numbers of TH+ cells in cultures 
To assess the effects of calcitriol alone and in combination with nicotinamide on TH+ 
neurons, total numbers of TH+ cells were counted across 4 images taken at 10X magnification 
for each experimental repeat. Numbers were normalised to the vehicle control as described 
in Chapter 2.11. Results showed no significant difference in the number of TH+ cells in VM 
cultures between control and calcitriol alone (Figure 4.10, A). There was also no significant 
difference in numbers of TH+ cells in VM cultures treated with nicotinamide alone and 
nicotinamide in combination with calcitriol when normalised to control (Figure 4.10 A). These 
results were unexpected due to previous studies showing a positive effect of calcitriol on 
numbers of TH+ neurons in VM cultures derived from E12 rat (Orme, Bhangal and Fricker, 
2013).  
Calcitriol is reported to be air and light sensitive (Sigma-Aldrich, 2009). It was possible 
that this lack of increase in TH+ cells could be due to a reduction in biological activity of this 
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batch of calcitriol over time in storage. Therefore, a new batch of calcitriol was generated. 
Normalised numbers of TH+ cells were compared between calcitriol batch 1 (n=3, 4 technical 
replicates) and calcitriol batch 2 (new calcitriol, n=1, 3 technical replicates). Results showed 
no statistically significant difference in numbers of TH+ cells across vehicle control and 
calcitriol batch 1 or batch 2 (100.0 ± 10.4 vs. 87.4 ± 8.3 vs. 73.9 ± 21.1; one way ANOVA F(2,23) 
= 0.93, n.s.; Figure 4.10 B). 
 
Figure 4.10 Addition of calcitriol did not alter numbers of TH+ neurons in VM cultures.  
A) Graph showing the number of TH+ neurons normalised to the vehicle control (blue circle), for 
calcitriol (green triangle), nicotinamide (red square), and combined nicotinamide and calcitriol (purple 
diamond). No significant difference was observed between control vs. calcitriol, or nicotinamide alone 
vs. nicotinamide and calcitriol treated cultures.  
B) Graph showing the numbers of TH+ neurons normalised to the vehicle control (blue circle), for batch 
1 (orange triangle) and batch 2 (red square) of calcitriol. No significant differences were observed.  
 
4.3.5 Neither nicotinamide nor calcitriol protected TH+ neurons 
against 6-OHDA toxicity 
The potential protective effects of nicotinamide and/or calcitriol were tested using the 
6-OHDA model described in Chapter 2.5.2. As previously described, TH+ cell numbers were 
counted in 10X micrographs and normalised to vehicle control. Two-way ANOVA revealed 
significant effects on numbers of TH+ cells due to vitamin treatment (F(3, 111) = 8.7, p < 0.001), 
6-OHDA treatment (F(1, 111) = 107.4, p < 0.001), and with an interaction effect (F(3, 111) = 4.46, p 
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< 0.01). Post-hoc analysis using Bonferroni’s multiple comparisons showed significant 
decreases in numbers of TH+ cells due to 6-OHDA treatment in control (AA vs. 6-OHDA: 100.0 
± 10.5 vs. 49.1 ± 7.1, p < 0.01), nicotinamide (154.2 ± 13.7 vs. 46.1 ± 10.0, p < 0.001), calcitriol 
(84.4 ± 7.7 vs. 38.8 ± 5.0, p < 0.01), and combined nicotinamide-calcitriol (148.6 ± 13.8 vs. 62.0 
± 8.0, p < 0.001) treated cultures (Figure 4.11 A). These results show that neither nicotinamide 
nor calcitriol were able to protect TH+ neurons from 6-OHDA toxicity. There was no significant 
difference in TH+ numbers between 6-OHDA treated control, nicotinamide, calcitriol, and 
combined nicotinamide and calcitriol treated cultures; despite elevated TH+ numbers in 
nicotinamide and combined nicotinamide-calcitriol treated vehicle cultures, and no change in 
calcitriol treated vehicle cultures.  
As shown in Figure 4.6, the total number of cells was decreased at 7 DIV in 
nicotinamide treated cultures. This may affect the toxicity of 6-OHDA in nicotinamide treated 
cultures. Therefore, the protective potential of 10 mM nicotinamide was also tested when 
applied only during 6-OHDA treatment and recovery period (i.e. not applied prior to 6-OHDA 
treatment). One-way ANOVA showed no significant difference between control 6-OHDA, 
nicotinamide 6-OHDA, or 6-OHDA + nicotinamide with no nicotinamide pre-treatment (Figure 
4.11 B). 
These results show that 6-OHDA application significantly reduced TH+ cells numbers in 
these VM cultures and that the application of the vitamins nicotinamide and calcitriol, both 






Figure 4.11 6-OHDA treatment reduced numbers of TH+ neurons.  
A) Graph showing the number of TH+ neurons normalised to the control in AA vehicle (blue circle) vs. 
6-OHDA (pink square treatment across vitamin treatments. Significantly lower numbers of TH+ neurons 
were observed in 6-OHDA treated cultures compared to AA in all vitamin treatment conditions 
(nicotinamide, calcitriol, combined nicotinamide and calcitriol); ** p < 0.01; *** p < 0.001.  
B) Graph showing the number of TH+ neurons normalised to the control in 6-OHDA cultures with no 
nicotinamide (control; pink square), nicotinamide from day 0 (orange diamond), and nicotinamide 
during and after 6-OHDA treatment (green triangle). No significant differences were observed. AA: 
ascorbic acid; 6-OHDA: 6-hydroxydopamine. 
 
4.3.6 Application of 6-OHDA also reduced numbers of β-III-
tubulin+ cells 
The effect of 6-OHDA on β-III-tubulin+ cells was also assessed. For this, the number of 
β-III-tubulin+ cells in images taken at 10X magnification was quantified and normalised to 
control as described in Chapter 2.11. Two way ANOVA showed differences in β-III-tubulin+ 
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numbers related to 6-OHDA (F(1, 79) = 135.2, p <0.001) and vitamin (F(3, 79) = 5.82, p < 0.01) 
treatments, but with no interaction effects (Figure 4.12).  
Post-hoc analysis using Bonferroni’s multiple comparison revealed significant 
decreases in the number of β-III-tubulin+ cells in 6OHDA treated cultures compared to AA 
treated cultures in control (54.1 ± 6.4 vs. 100.0 ± 4.1, p < 0.001), nicotinamide (23.8 ± 8.2 vs. 
90.8 ± 4.3, p < 0.001), calcitriol (41.4 ± 6.6 vs. 100.0 ± 7.3, p < 0.001), and nicotinamide-
calcitriol combined (33.4 ± 6.0 vs. 74.3 ± 7.8, p < 0.001) treated cultures (Figure 4.12 *). 
A significant effect of vitamin treatment was also observed. Post-hoc analysis using 
Tukey’s multiple comparison revealed significantly lower numbers of β-III-tubulin+ cells in 
nicotinamide-calcitriol combined compared to control (74.3 ± 7.8 vs. 100.0 ± 4.1, p <0.05) and 
nicotinamide-calcitriol combined compared to calcitriol (74.3 ± 7.8 vs. 100.3 ± 7.3, p < 0.05) in 
AA vehicle treated cultures. Significantly lower β-III-tubulin+ cell numbers were also observed 
between control and nicotinamide treated cultures with 6-OHDA application (54.1 ± 6.4 vs. 
23.8 ± 8.2, p < 0.01; Figure 4.12 #). However, with 6-OHDA treatment, no significant difference 
was observed in numbers of β-III-tubulin+ neurons between calcitriol and nicotinamide-
calcitriol combined compared to control. This suggests a slight neuroprotective effect of 





Figure 4.12 6-OHDA treatment reduced numbers of β-III-tubulin+ neurons. Graph showing numbers of 
β-III-tubulin+ cells normalised to control AA. *Significantly lower numbers of β-III-tubulin+ cells were 
observed with 6-OHDA (pink square) application compared to AA vehicle (blue symbols) in control, 
nicotinamide, calcitriol, and combined nicotinamide-calcitriol cultures. #AA vehicle cultures showed 
significantly lower β-III-tubulin+ cell numbers in combined nicotinamide-calcitriol cultures compared 
to control and calcitriol alone. 6-OHDA treated cultures showed significantly lower numbers of β-III-
tubulin+ cells in nicotinamide compared to control cultures. (***p <0.001; # p < 0.05; ## p < 0.01). 
 
Treatment of cultures with 6-OHDA did not affect the average numbers of cells, 
counted by DAPI staining at 40X magnification (FOI = 0.073 mm2), compared to AA in vehicle 
control or nicotinamide treated cultures (Figure 4.13). These results show that treatment of 
cultures with 6-OHDA significantly reduced the number of β-III-tubulin+ cells but did not 
significantly reduce total cell numbers. As previously discussed in Chapter 4.3.2, the number 
of DAPI+ nuclei was significantly lower in nicotinamide treated cultures compared to control 
in AA vehicle cultures (221 ± 23.7 vs. 309 ± 23.4), an effect that was also replicated in 6-OHDA 
treated cultures (189 ± 12.8 vs. 305 ± 13.6). A lack of effect observed in calcitriol treated 
cultures meant that micrographs for DAPI analysis were only collected for an n of 2, therefore 




Figure 4.13 Numbers of DAPI+ nuclei were not changed by 6-OHDA treatment. Graph showing average 
number of DAPI+ nuclei (per 40X micrograph FOI = 0.073 mm2) in AA vehicle (blue symbol) and 6-OHDA 
(pink symbol) in control, nicotinamide, calcitriol, and combined nicotinamide-calcitriol treated 
cultures. No significant difference was observed between AA vehicle and 6-OHDA treatment within 
control and nicotinamide treated cultures. However, significantly lower numbers of DAPI+ nuclei were 
observed in nicotinamide treated cultures to control within AA vehicle and 6-OHDA treatments (p < 
0.05). No statistical analysis was performed on calcitriol and combined nicotinamide-calcitriol cultures 





4.4.1 Optimising the 6-OHDA in vitro model 
The results of 6-OHDA toxicity in vitro can be highly variable. As discussed in Chapter 
4.1.2, the rapid auto-oxidation, and variability of this process dependent on molecular 
availability, can make 6-OHDA an unpredictable chemical to work with. Another source of 
variation can arise from the accuracy with which midbrain regions are identified and dissected, 
and the growth profiles of subsequent cultures. 
The final in vitro 6-OHDA PD model protocol established and used in this PhD research 
utilised E14 VM cultures grown for 7 DIV, treated with 25 µM 6-OHDA in an 850 µM AA vehicle 
for 4 hrs, with cultures fixed 48 hours after removal of the toxin. Results showed a 50% 
decrease in TH+ neurons present within cultures treated with 6-OHDA compared to vehicle 
control. This protocol shares similarities with other 6-OHDA in vitro models cited in the 
literature (Table 4.1). A 50% decrease with 6-OHDA treatment should provide a reasonable 
testbed for detecting effects of experimental treatments, whether protective, or toxic. 
Rat VM from E14-16 is commonly used, and typically cultured for 6-9 DIV before 
treatment with 6-OHDA. VM cultures contain TH+ cells/progenitors from the developing SN 
and VTA. Dissection of the VM at E14 allows for larger numbers of TH+ cells to be generated 
in culture as the cells are less developed and can better survive the dissection and culturing 
process. However it does mean the inclusion of developing VTA TH+ neurons which are less 
susceptible to damage than TH+ cells from the SN (Grant and Clarke, 2002; Healy-Stoffel et al., 
2014; Alberico, Cassell and Narayanan, 2015). This could account for the TH+ population that 
was resistant to 6-OHDA toxicity found throughout all treatment conditions in preliminary 
experiments. This type of pattern was also observed by Lotharius et al. (1999) using E14 mouse 
VM, with a plateau in TH+ cell numbers at around 70% lower than control despite more than 
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tripling the 6-OHDA concentration, which generated non-specific toxicity. To avoid the 
inclusion of VTA dopamine neurons, Ding et al. (2004) used P0 tissue from the SN, meaning 
that their TH+ cell population was likely derived solely from the SN. Although this technique 
may provide a more accurate representation of TH+ SN neurons, it is a more complicated 
model to derive and dopaminergic viability may be compromised due to axotomy prior to 
toxin exposure. 
In the literature (Table 4.1), 6-OHDA is typically used at concentrations between 10 
and 100 µM. Therefore, the 25 µM concentration used here is reasonable in comparison. Most 
studies utilise a longer application time, typically 24-48 hours, compared to the 4-hour 
treatment window used here. However, the majority of studies fix or analyse cells 
immediately after 6-OHDA exposure, with no recovery window equivalent to the 48 hours 
used in this research. Rationale for inclusion of a recovery window include a model that may 
resemble PD more closely, with a singular toxic insult followed by neurodegeneration, 
compared to prolonged exposure alongside neurodegeneration. It also allows for studying 
potential neuroprotective effects before, during, and after toxin exposure, rather than 
neuroprotective effects that can arise from pre-treatment, a treatment method that would be 
difficult to apply clinically due to the pre-clinical aspect of PD (Chapter 1.1.3). A short exposure 
combined with removal of the toxin may also reduce non-specific toxicity. Ding et al. (2004) 
relied on a short time frame (15 minutes) to allow the uptake of 6-OHDA into 
catecholaminergic neurons, with removal of non-internalised toxin before auto-oxidation 
within the media and consequently, non-specific toxicity. Cultures were fixed up to 48 hours 
after removal of 6-OHDA, allowing cells to succumb to toxicity induced by internalised 6-
OHDA. In this method, Ding et al., (2004) abolished 6-OHDA toxicity by blocking DAT and 
preventing internalisation of 6-OHDA. This shows that cell death in their cultures resulted from 
6-OHDA toxicity occurring within the cell.  
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In this PhD research, using the short time frame of 20 minutes 6-OHDA exposure did 
not induce sufficient loss of TH+ cells after a further 48 hours in vitro. The use of this time 
frame was also considered to be potentially inconsistent due to pipetting limitations. 
Application of 25 µM for just 6 hours showed non-specific toxicity of TH-/β-III-tubulin+ 
neurons. A number of models within the literature fix cells immediately, but after a longer 
period of treatment (6-OHDA exposure). This means that extracellular toxicity arising from 
auto-oxidation of 6-OHDA occurs throughout treatment, and may affect all cell types, rather 
than restricting toxicity to cells that have internalised it (predominantly DAT+ cells). Such non-
specific toxicity could arise from the formation of toxic compounds such as H2O2, p-quinone, 
and ROS within the media, external to cells. For instance Lotharius et al. (1999) found non-
specific neurotoxicity at early timepoints after 6-OHDA treatment for 6 hours. Also, Cerruti et 
al. (1993) found a reduction, but not abolition, of 6-OHDA (10 nM for 48 hours) toxicity in TH+ 
neurons when DAT was blocked suggesting toxicity arising externally. Only a small proportion 
of papers report on non-specific toxicity, and in many cases the effects of 6-OHDA on TH- 
neurons and non-neuronal cells are not discussed (Table 4.1).  
Results from this thesis showed a 50% reduction in TH+ neurons after 6-OHDA 
treatment. This reduction was deemed appropriate to study the potential for neuroprotection 
with a statistically significant decrease in TH+ neurons that could potentially be rescued by 
addition of a neuroprotective agent. Other 6-OHDA in vitro models have shown reductions in 
TH+ populations between 30-90% (Table 4.1).  
Reliable replication of 6-OHDA toxicity was not initially possible in this PhD research. 
This was proposed to be due to the difficultly in reliably weighing the small amount of 6-OHDA 
powder on each repeat. Similar variability in neuronal response to 6-OHDA treatment was also 
observed by Ding et al., (2004), who hypothesise that this is due to variations in the actual 
amount of 6-OHDA in the culture medium. The difficult nature of using in vitro 6-OHDA models 
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can be seen by the variety of methods described in the literature, differing in culture type, 
concentration of 6-OHDA and exposure time, and the resulting decrease in TH+ neurons 
observed. Many reports do not state whether a vehicle was used to decrease auto-oxidation 
of 6-OHDA, do not declare their starting TH+ population size, and fail to comment on the 
absence or presence of non-specific toxicity. Therefore, establishing a protocol for use in this 
PhD research was necessary.  
This protocol and the outcome are comparable to other 6-OHDA in vitro models within 
the literature and was suitable for this research. Although improvements could be made in 
the selection of SN specific TH+ neurons and in the reduction of non-specific toxicity, these 
elements are present across the literature and are difficult to avoid. 
 
4.4.2 Nicotinamide increased numbers of TH+ neurons 
In this thesis, TH was used to identify dopaminergic neurons. However, TH, the rate 
limiting enzyme required in the synthesis of dopamine (Figure 1.4) is also present in other 
catecholaminergic neurons (adrenaline, noradrenaline). Adrenaline and noradrenaline 
neurons arise in the rhombencephalon (Goridis and Rohrer, 2002; Robertson et al., 2013) and 
therefore should not have been included in VM dissection, allowing for the assumption that 
the TH+ cells in these cultures were dopaminergic. TH is a commonly used and reliable marker 
to identify dopaminergic neurons, especially within VM cultures (Table 4.1). To further confirm 
dopaminergic neuron populations other markers including DAT, VMAT, Calbindin and GIRK2 
could have been used. This would also assist in the identification of SNpc and VTA 
dopaminergic neurons, further assisting in the translation of results to PD. 
Protocols for VM dissection cite TH+ populations ranging from ‘up to 1%’ (Michel and 
Hefti, 1990; Liu and J. Hong, 2003), 2-4% (Gaven, Marin and Claeysen, 2014), to 17-21% 
(Shimoda et al., 1992) of the total cell population. This variability arises from different 
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techniques in the obtainment of tissue and culture conditions (such as media) used. This thesis 
reports a TH+ population of approximately 0.66% of total cells in control cultures, increasing 
to 1.2% with nicotinamide treatment. These numbers are low compared to some reported in 
the literature. This lower number could be the result of the manual dissociation process which 
can damage dopaminergic cells (Pruszak et al., 2009). However, reducing the intensity of the 
manual dissociation process led to clumped populations, with β-III-tubulin+ and TH+ neurons 
typically growing within spheres, making visual analysis of cell populations more difficult and 
less accurate (Figure 4.14). Therefore, it was deemed more appropriate to have cultures with 
a lower dopaminergic density, but that could be analysed effectively. Although avoiding 
clumped areas during imaging allowed for more accurate analysis of cells within each FOI, it 
may have led to bias against imaging of neuronal populations: neuronal densities may have 
been greater in areas that were rejected on the grounds of being difficult to distinguish 
individual cells. However, the TH+ populations observed in these VM cultures were still 




Figure 4.14 Neurons, including TH+ neurons, tend to grow in clumps or spheres. Fluorescence 
micrographs of VM cultures with immunocytochemistry for β-III-tubulin (green), tyrosine hydroxylase 
(TH; red), and DAPI (blue).  
 
Variations in tissue selection (Shimoda et al., 1992), media components, seeding 
densities, addition of growth factors and decreasing oxygen conditions can be utilised to 
increase the TH+ yield (Pruszak et al., 2009). These additional factors were not explored as this 
thesis focussed on the effects of nicotinamide and calcitriol on the TH+ populations within 
these VM cultures. Using a basic medium (NCM) allowed for clarification that the effects were 
due to the addition of these vitamins, although combining these vitamins with growth factors 
may provide further increases in TH+ yield and could be explored for the generation of high 
yield dopaminergic populations for use in in vitro models. 
To address the low TH+ yield found here, different imaging techniques were applied to 
accurately analyse the TH+ population. The most effective imaging method to assess the 
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population spread of TH+ neurons in these VM cultures was to use a larger FOI for analysis by 
imaging cultures at 10X magnification.  
The number of TH+ neurons in these VM cultures increased between 1-4 DIV, then 
decreased between days 4-14 in both control and nicotinamide treatment conditions. This 
initial increase in TH expression is also reported within the literature. Pruszak et al. (2009) 
state that maturing dopamine cultures can be observed from 1 to 3 DIV when using E14 rat 
VM tissue. Gaven, Marin, & Claeysen (2014) found the presence of TH+ cells in VM cultures 
derived from E13.5 mouse from 1 DIV with numbers increasing up to 6 DIV, numbers then 
plateaued until 13 DIV. Bollimpelli & Kondapi (2015) found TH+ neurons from 3 DIV with 
maximum expression of TH between 7 and 14 DIV using E14 rat VM, also showing an initial 
increase in TH expression. Shimoda et al. (1992), using stringent dissection of what they term 
the mesencephalic dopaminergic region of E14 rats, reported their highest TH+ densities at 5 
DIV, with the percentage of TH+ cells remaining between 17% and 21% from 4 hours after 
plating to 10 DIV. However, they state a decrease in the absolute number of cells by 50% and 
80% at 7 and 10 DIV respectively, suggesting that they also witnessed a decrease in the 
number (but not percentage) of TH+ cells during this time period. VM cultures have been 
maintained for up to 48 days, however, this protocol used glial feeders and did not report on 
the numbers of TH+ neurons at this time point (Lautenschläger et al., 2018). 
The initial increase followed by decrease in TH+ neurons observed in this thesis may be 
a form of programmed cell death. Neuronal programmed cell death is involved in normal 
vertebrate brain development and is thought to occur as a result of neurotrophic cell death. 
The neurotrophic theory is that neurons are overproduced and cell survival is dependent on 
active cellular connections being made (Dekkers, Nikoletopoulou and Barde, 2013). The 
changing morphology observed in these VM cultures showed TH expression restricted to small 
somas after 1 DIV, with neurite extension appearing to increase in number and length at 4 DIV 
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and stabilising through to 14 DIV. This corresponds with other work showing the development 
of extensions and further branching and ramification at days 4 and 7 with mouse TH+ neurons 
(Gaven, Marin and Claeysen, 2014). Therefore, if TH+ neurons in these VM cultures did not 
form suitable synaptic connections, they may have undergone a form of programmed cell 
death, which could account for decreasing numbers of TH+ neurons in maturing cultures. The 
removal of these cells from the embryo, placement into an ‘alien’ environment, and the 
absence of the specific striatal neurons that SNpc neurons target (Holmes, Angharad Jones 
and Greenfield, 1995), would have disrupted signalling and correct formation of the specific 
synaptic connections required to fully maintain healthy SNpc dopaminergic neuron 
populations. 
The application of 10 mM nicotinamide to these VM cultures significantly increased 
the number of TH+ neurons observed, compared to control, at 1, 4 and 7 DIV. The increase in 
TH+ neurons did not correspond with an increase in β-III-tubulin+ neurons. This suggests that 
the effect of nicotinamide could be specific to dopaminergic neurons (TH+ cells in these 
cultures).  
The observation of a significant effect of both nicotinamide treatment and time on the 
number of TH+ neurons with no interaction (Figure 4.7) suggests that an effect of nicotinamide 
on TH+ neurons takes place prior to the initial assessment at 1 DIV; however, it is unclear 
whether this effect could occur pre- and/or post-differentiation. Further exploration of these 
results using markers of proliferation would help to ascertain whether this increase in TH+ 
neurons is due to proliferation and maturation of dopaminergic neuron precursors, or 
whether this result has arisen from a protective effect of nicotinamide on dopaminergic 
neurons present in cultures immediately after the plating process. 
To the best of my knowledge, the assessment of nicotinamide on TH+ cells in VM 
cultures has not been commented on in the literature. However, intraperitoneal injection of 
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100 mg/kg nicotinamide every 2 days into p1 to p21 mice resulted in a decrease in TH+ neurons 
in the SN, with levels of dopamine reduced in the hypothalamus but not striatum (Lee et al., 
2009). The differences observed between that report and the results of this thesis potentially 
arise from vast differences in models used, including in vivo/in vitro, postnatal/embryonic, and 
dosage.  
 
4.4.3 Calcitriol did not increase numbers of TH+ neurons or 
provide TH+ neuroprotection against 6-OHDA treatment 
Treatment of VM cultures with calcitriol did not increase numbers of TH+ cells despite 
previous work in the lab showing an increase in TH+ cells in VM cultures treated with calcitriol 
(Orme, Bhangal and Fricker, 2013). These results also did not show a protective effect of 
calcitriol against 6-OHDA treatment which is contrary to a number of studies which show 
neuroprotective effects of calcitriol on TH+ neurons (Wang et al., 2001; Sanchez et al., 2009; 
Orme, Bhangal and Fricker, 2013; Lima et al., 2018). 
The difference observed between this thesis and the work by Orme, Bhangal and 
Fricker (2013) may be due to the use of different donor ages with E14 used here and E12 used 
previously. Obtainment of rat VM cultures from E12, E13, and E14 have shown different 
differentiation potential, after an initial expansion period, with E12 neurospheres generating 
higher numbers of dopaminergic neurons after differentiation for 6 days (O’Keeffe and 
Sullivan, 2005). However, tissue derived from older embryos (E14) showed greater neurogenic 
potential after a longer differentiation period (Hegarty et al., 2014). These studies highlight 
the effects that donor age and DIV can have on cell populations observed in VM cultures and 
may account for the differences observed in the effects of calcitriol between this thesis and 
previous work. However, the vitamin D receptor is expressed in the nucleus of TH+ cells 
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between E12-15 and increases after this period, in the rat VM, suggesting that an effect of 
calcitriol should have been observed in these VM cultures. When comparing β-III-tubulin+ 
numbers in vehicle control (AA) treated cultures, significantly lower numbers were observed 
in combined nicotinamide and calcitriol cultures when compared to calcitriol alone (but not 
compared to control or nicotinamide treated cultures). In 6-OHDA treated cultures, a 
significant decrease in numbers of β-III-tubulin+ cells was observed in nicotinamide treated 
cultures compared to control, but not in calcitriol or combined nicotinamide-calcitriol 
cultures. These results suggest that there may have been an effect of calcitriol on β-III-tubulin+ 
neurons. However, the meaning and mechanisms of these results are difficult to decipher and 
would need further exploration. 
Due to the inconsistencies between these results and the literature, it was suspected 
that the calcitriol used could have been degraded in storage. Calcitriol is degraded under 
hydrolytic, oxidative, thermal and photolytic conditions in as little as 24 hours (Temova and 
Roškar, 2016). Confirmation of degradation could be ascertained using high performance 
liquid chromatography. Although care was taken to reduce light and heat exposure during 
preparation, and final storage was at -80°C; for future work concerning the use of calcitriol, 
other preparation and storage options could be explored such as storage under inert gas to 
decrease the risk of oxidation. 
 
4.4.4 Nicotinamide did not provide neuroprotection against 6-
OHDA toxicity 
Treatment of these VM cultures with 10 mM nicotinamide produced a significant 
decrease in total cell numbers at 7 DIV (details are further discussed in Chapter 5.3.1). As 
previously described, 6-OHDA toxicity can vary across different cultures. Reducing cell 
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numbers could make cells more susceptible to 6-OHDA toxicity by increasing the amount of 
6-OHDA that each cell is exposed to, and/or concentration of auto-oxidation-generated toxins 
per cell. Higher doses of 6-OHDA have a more detrimental effect on the TH+ population 
(González-Hernández et al., 2004). To address this and assess the effect of nicotinamide 
application alongside 6-OHDA application, control cultures were treated with 6-OHDA + 
nicotinamide starting at 7 DIV, with addition of nicotinamide during the 48-hour recovery 
process. Using this method allows for observation of the effects of nicotinamide on 6-OHDA 
toxicity and recovery, without the effects of nicotinamide on VM cultures from exposure 
during the initial 7 DIV growth period. The number of TH+ cells at 9 DIV results did not differ 
significantly from control and nicotinamide 6-OHDA treated cultures. This provided further 
evidence that nicotinamide was unable to provide neuroprotection against 6-OHDA toxicity 
for TH+ cells in VM cultures. 
6-OHDA has been found to reduce NAD+ levels, reduce the NAD+/NADH ratio and 
decrease Sirt1 activity, which is attenuated by the addition of NMN (precursor to NAD+; Zou 
et al., 2016). However, this was in PC12 cells which (as described in Chapter 1.5.2) do not 
represent either dopaminergic neurons, or a PD model, as closely as VM cultures do. Also, if 
6-OHDA causes toxicity by inhibiting complex I of the electron transport chain (Glinka, Gassen 
and Youdim, 1997), and therefore the process which converts NADH to NAD+, then perhaps 
this process results in the decrease in NAD+ levels and NAD+/NADH ratio seen by Zou et al. 
(2016). Administration of NAD+ in an in vivo 6-OHDA mouse model showed protection of TH+ 
neurons in the SN (Shan et al., 2019). Although administration of nicotinamide has been 
shown to increase levels of NAD+ (Klaidman, Mukherjee and Adams, 2001; Schöndorf et al., 
2018), this mechanism was either not active or was ineffective in the VM 6-OHDA model used 
in this PhD thesis. 
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Oxidative stress is another mechanism of the toxic effects of 6-OHDA which can 
increase levels of H2O2 both intra- and extra-cellularly through auto-oxidation (Graham et al., 
1978; Soto-Otero et al., 2000). Blocking Sirt1 using 5 mM nicotinamide showed protection of 
cortical neurons from oxidative stress induced by H2O2 (Li et al., 2008). However, this cell 
model is also not closely comparable to the 6-OHDA VM model used in this thesis. Mechanisms 
other than oxidative stress also contribute to cell death through 6-OHDA toxicity, therefore, 
Sirt1 inhibition may not be effective against the myriad of toxic events occurring in these 
cultures (discussed in Chapter 4.1.2). 
Overactivation of PARP-1 can lead to cell death through consumption of NAD+ and 
activation of apoptosis and necrosis. Nicotinamide is an inhibitor of PARP-1, although PARP-1 
inhibition has shown protective effects in other models of dopaminergic neuron degeneration 
(Zhang et al., 2000), it has not shown protection from 6-OHDA toxicity (Callizot et al., 2019). 
Nicotinamide has shown neuroprotection through PARP-1 inhibition in an MPTP model of 
neurodegeneration (Mandir et al., 1999). However, Harrison et al. (2019) found an 
exacerbation of toxicity with nicotinamide in the lactacystin model of PD.  
Nicotinamide may increase NADH and/or NADPH which are required for the synthesis 
of tetrahydrobiopterin (BH4), the cofactor essential for TH activity (Thöny, Auerbach and Blau, 
2000). If the addition of nicotinamide is able to increase levels of NADH and NADPH, it could 
allow increased activity of TH. Treatment of PC12 cells with NADH led to increased production 
of dopamine thought to be induced by the regeneration of BH4 (Vrecko et al., 1997). Also, 
NADH and NADPH, but not NAD+ or NADP+, prevent the nitration of tyrosine and subsequent 
inhibition of TH (Kuhn and Geddes, 2002). This suggests a potential role of nicotinamide 
through NADP+ and NADPH in dopamine synthesis (Figure 1.10). However, increased levels of 
cytosolic dopamine may contribute to toxicity (Mosharov et al., 2009), and increased levels of 
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homovanillic acid (a metabolite of dopamine; Figure 1.4) are observed in the cerebrospinal 
fluid of PD patients, correlating with motor symptom severity (Stefani et al., 2017). 
There is still high debate about the mechanisms of cell death in PD. The outcome of 
nicotinamide in neuroprotection may be dependent on the choice of PD model. This variability 
across PD models, and also within the 6-OHDA PD model (described in Chapter 4.4.1) could 
account for differential effects seen using nicotinamide and its derivatives in neuroprotection 
studies. 
 
4.4.5 Conclusions and future studies 
The results discussed in this chapter have shown the development of an in vitro 6-
OHDA PD model using E14 VM rat cultures that was comparable to similar models within the 
literature. This was used to assess potential neuroprotective effects of nicotinamide on TH+ 
cells. Nicotinamide did not show any neuroprotective effects against 6-OHDA in these VM 
cultures. This lack of neuroprotective effect may be due to the 6-OHDA protocol used, 
although this model was comparable to others in the literature, 6-OHDA toxicity may have 
been too effective and therefore irreversible for this neuroprotectant. The use of a positive 
neuroprotective control, calcitriol, was used to analyse this, however, in these experiments 
calcitriol was also unable to provide a neuroprotective effect. Further optimisation of the 6-
OHDA protocol and positive control could be used to further assess the neuroprotective 
potential of nicotinamide. Another possibility for the lack of neuroprotection may be due to 
incompatibilities in the mechanisms of action between 6-OHDA and nicotinamide.  
However, treatment of normal VM cultures with nicotinamide did show a significant 
increase in numbers of TH+ neurons compared to cultures without nicotinamide present. To 
my knowledge, this effect has not been discussed in the literature. Mechanisms of action could 
include direct effects of nicotinamide on TH+ cells by inhibition of PARP-1 or Sirt1, however, 
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increases in these factors typically relate to cell survival mechanisms. Immunocytochemistry 
and western blot techniques could be used to analyse the expression levels of PARP-1 and 
Sirt1 in these cultures.  
Nicotinamide could also have exerted this effect by increasing levels of pyridine 
nucleotides. This mode of action could be explored by assessing the intracellular levels of 
NAD+/NADH through luminescence assays.  
Further analysis of cultures using A9/A10 specific markers (as highlighted in Table 1.5) 
would help to confirm the effects of nicotinamide are on dopaminergic neurons and whether 
this varies between SN/VTA populations. 
This increase in TH+ neurons in cultures treated with nicotinamide could also be an 
indirect effect arising from the interaction of nicotinamide with other cells present in these 
VM cultures. This is further explored in Chapter 5.  
This chapter shows a positive effect of nicotinamide on the number of TH+ cells in these 
cultures, however, the mechanism was not studied. Further experiments would include: 
I. Assessment of TH+ neurons in VM cultures using BrdU to determine whether 
increased numbers were through proliferation of neural precursors. 
II. Analysis of VM cultures using NAD+/NADH luminescence assays to determine 
whether effects could be due to nicotinamide induced increases in NAD+. 




5 Nicotinamide and microglia 
5.1 Introduction 
5.1.1 The in vivo mechanisms involved in microglial 
development are still being elucidated  
As mentioned in Chapter 1.4.1, microglia, the immune cells of the CNS, arise from yolk 
sac, rather than neural plate; and have been cultured from rat embryonic brain tissue as early 
as E10 (Ghosh and Ghosh, 2016). Microglial development in humans, which correlates with 
rat developmental stages (albeit over longer time periods), suggests that microglia enter the 
developing brain from the meninges, choroid plexus and ventricles (Verney et al., 2010). Once 
microglial cells have entered neural tissue they migrate and proliferate to colonise brain 
regions where their numbers then remain stable throughout healthy ageing (Askew et al., 
2017). 
This migration and proliferation is thought to be dependent on a number of signalling 
factors including semaphorins, netrins, macrophage colony stimulating factor (CSF-1), 
monocyte chemoattractant protein 1, macrophage inflammatory protein, and C-X-C motif 
chemokine 12 (Bruttger et al., 2015; Mosser et al., 2017). Studies from knockout mice 
demonstrate the importance of CSF-1 in embryonic development of microglia, with the brains 
of E16 knockout mice showing almost no microglial cells (Elmore et al., 2014). 
Microglia have shown different morphologies and expression patterns dependent on 
their resident brain region (Tan, Yuan and Tian, 2020). The adult mouse SN has one of the 
highest microglial populations (Lawson et al., 1990), with these cells exhibiting differences in 
morphology compared to microglial populations in the bodies of the basal ganglia and in the 
VTA (De Biase et al., 2017). 
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Mechanisms behind the colonisation of brain regions by microglia, the differences in 
homeostatic expression patterns, the maintenance of microglia throughout health, and the 
myriad of responses during neurodegeneration are highly complex and still being investigated. 
 
5.1.2 In vitro models of microglia provide valuable insight, but 
extrapolation to in vivo can be difficult 
Microglia possess complex profiles and behaviours which, as previously discussed 
(Chapter 1.4), are highly responsive to their micro-environment. In vitro models can be 
separated in to three broad categories of stem cell derived, cell lines, and primary cultures, 
each with advantages and drawbacks (review: Timmerman, Burm, & Bajramovic, 2018). This 
project used primary cultures to study microglia both in heterogeneous cultures derived from 
specific brain regions (E14 rat VM and WGE) and in isolated microglial cultures derived from 
rat mixed glial cultures. This provided two environments in which to study the microglial 
response to nicotinamide, allowing for exploration of direct and indirect influences. However, 
it also represented difficulties in the applications of this data as stark differences in microglia 
morphology were observed in each culture system without application of treatment 
conditions. 
Microglia within purified cultures typically display amoeboid and rod-like 
morphologies, often associated with a pro-inflammatory phenotype, rather than the ramified 
morphologies associated with heathy CNS tissue. This is due to the “alien” nature of culture 
conditions (Kettenmann et al., 2011) such as changes in media (which may contain 
components that microglia do not typically contact such as serum), atmosphere and O2/CO2 
balance, pH differences, and 2-dimensional (2D) rather than 3-dimensional (3D) substrate. The 
mixed glial culture system provides relatively easy access to high purity populations of 
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microglia (routinely 95-98% Iba1+) and is widely used for microglial research, however, 
microglial morphologies and behaviours within these cultures may not be representative of in 
vivo, non-pathological microglia. To address part of this problem, 3D culture systems are in 
development which promote more ramified microglial morphologies, predominant in healthy 
CNS, by providing an environment that more closely resembles the brain (Watson et al., 2017). 
These systems attempt to mimic the healthy CNS environment, an important aspect of which 
is the stiffness of the material. Stiff gel materials have shown an increased pro-inflammatory 
response compared to softer gels (Prager et al., 2020). This may also contribute to differences 
observed between microglial cultures grown on a hard glass surface compared to microglia 
grown on a bedlayer, providing a softer extracellular matrix. 
Culturing microglia alongside other neural cell types also increases their ramification 
(Rosenstiel et al., 2001; Rezaie et al., 2002) with factors released from other cell types 
influencing microglial phenotype (Timmerman, Burm and Bajramovic, 2018). 
As with many cell types, the media used to culture microglia can have drastic 
influences on phenotype (Bohlen et al., 2017). The vast majority of microglial research uses 
medium supplemented with 10% foetal bovine serum. Lower serum levels can reduce 
numbers of microglia within mixed glial cultures (Codeluppi et al., 2011). CNS microglia are 
separated from the blood due to the BBB, meaning that they do not typically interact with 
serum components in vivo. Therefore, the addition of serum may affect microglial phenotype, 
essentially simulating haemorrhagic stroke, and serum has been found to disrupt morphology 
and function (Bohlen et al., 2017). 
As discussed in Chapter 1.4.2, a number of markers, which can be associated with 
specific activation states, have been identified in the expression profiles of microglia (Figure 
1.6). These markers can be permanently or transiently expressed, with a number of markers 
showing upregulation in the different activation states of microglia. Although the use of these 
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markers is valuable in the identification and profiling of microglia, there is often debate about 
the phenotypic characterisation of their expression levels. In vitro culturing of microglia can 
contribute to differences in expression patterns meaning that characterisation of microglia 
based on these markers in vitro may not be reliable. 
Culturing microglia can provide insights into factors that can influence their 
phenotype, assisting to identify factors that may able to promote anti-inflammatory or 
regulatory functions. However, in vitro models do not necessarily provide a representative 
microglial phenotype, meaning that data generated through this pathway must be interpreted 
with caution.  
 
5.1.3 A number of factors have been shown to influence 
microglial proliferation 
As discussed in Chapter 1.4.3, microglial proliferation is an indicator of inflammatory 
activation and increased numbers of microglia have been observed at sites of 
neurodegeneration (Gensel and Zhang, 2015; Mathys et al., 2017). Studying the mechanisms 
of microglial proliferation, and pathologies associated with it, could help in understanding 
microglial roles in neurodegeneration. Factors that influence proliferation can also be used in 
the development of protocols allowing large scale generation of microglia for research, or in 
the removal of microglia from other cell cultures. 
Application of inflammatory activators such as LPS have been shown to increase 
microglial proliferation. This increase was shown to be attenuated by inhibition of vascular 
endothelial growth factor (VEGF) signalling (Fukushima et al., 2015). Hydrogen peroxide has 
also been shown to be important in microglial proliferation in response to β-amyloid peptides 
(Jekabsone et al., 2006). Interleukin-1 receptor has shown elevated levels in proliferating 
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microglia with blocking of this receptor impairing proliferation during repopulation after 
ablation (Bruttger et al., 2015). Neurotrophin-3 and IL-5 have also shown influence in the 
proliferation of microglia in vitro and are present in the developing brain (Navascués et al., 
2000). A wide variety of signals can affect microglial proliferation; understanding these 
mechanisms may assist in the development of neuroprotective strategies. 
CSF-1 increases proliferation in microglia, through the upregulation of genes related 
to proliferation and cell cycle. This stimulating factor also upregulates genes Arg1, Fizz1, and 
Ym1 associated with M2 polarisation, showing that increased proliferation is not necessarily 
associated with inflammation (Pepe et al., 2017). Inhibition of microglial proliferation has 
been observed by blocking CSF-1 receptor (Olmos-Alonso et al., 2016) and expression of this 
receptor is required for microglial proliferation in homeostatic maintenance (Askew et al., 
2017). 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that 
induces proliferation and maturation of myeloid progenitors (cells present in bone marrow) 
(Liva et al., 1999) and has also been shown to induce proliferation of microglia (Lee et al., 
1994; Koguchi et al., 2003). Stimulation of astrocyte cultures with factors such as IL-1β, TNF-
α, and LPS induce release of GM-CSF (Aloisi et al., 1992; Lee et al., 1994) suggesting that 
activated astrocytes may release GM-CSF in response to pro-inflammatory stimuli, which is 
then likely to stimulate microglia.  
Treatment of primary microglia with GM-CSF has been shown to increase activation of 
ERK1 and ERK2 (extracellular signal-regulated kinase 1 and 2, which are part of the family of 
mitogen-activated protein [MAP] kinases involved in embryogenesis, differentiation, 
proliferation and cell death). Activation of STAT5A and STAT5B (signal transducer and activator 
of transcription 5A and 5B, are two of 7 proteins activated by cytokines and growth factors, 
and are associated with growth, differentiation, apoptosis and immune responses [Santos & 
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Costa-Pereira, 2011]) is also incurred with GM-CSF treatment, with translocation from 
cytoplasm to nucleus also observed (Liva et al., 1999). Therefore, these pathways likely 
mediate proliferation effects of GM-CSF. 
Understanding the regulation of microglial proliferation may help in controlling 
microglia response to injury or insult and may provide therapeutic potential by reducing 
unwarranted activation or over-activation of microglia which has been implicated in a number 
of neurodegenerative conditions (Pepe et al., 2017). 
 
5.1.4 Nicotinamide and associated compounds influence 
microglial activation and proliferation 
Nicotinamide and NAD+ can modulate immune cell function, influencing physiology 
and pathology in the CNS (Haag et al., 2007). For example, nicotinamide has been shown to 
reduce demyelination and neurofilament loss after spinal cord injury and is proposed to work 
through mediating macrophage responses, converting pro-inflammatory M1 macrophages to 
anti-inflammatory M2 macrophages (Yang, He and Wang, 2016; Montserrat- de la Paz et al., 
2017). Increasing NAD+ levels have also been shown to ameliorate autoimmune mediated 
demyelination in multiple sclerosis (Penberthy, 2009). Alongside this effect, many pathogens, 
and the toxins they release, target NAD+ through the release of NADase (Sharma et al., 2016) 
reducing available levels for host cells, meaning that replenishment is key during illness.  
Administration of NMN, a precursor to NAD+, reduced numbers of Iba1+ microglia, 
NOX1 ( and NADPH oxidase which contributes to generation of intracellular oxidative stress) 
expression and markers of inflammation (TNF-α and IL-6) in an in vivo mouse intracerebral 
haemorrhage model (Wei et al., 2017). 
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Nicotinamide treatment 15 mins, 24 hours and 48 hours after traumatic brain injury in 
juvenile rats reduced the number of Iba1+ microglia cells present 72 hours post-lesion (Smith 
et al., 2019) although the proposed mechanisms are not detailed.  
 
5.1.5 NADPH is involved in microglial activation 
Nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) is an 
extracellular facing, membrane-bound enzyme responsible for the production of free radicals 
(NADPH + 2O2↔ NADP+ + 2O2- + H+) which are involved in cell signalling and pathogen 
destruction (Bedard and Krause, 2007). NOX2, also known as gp91phox, is part of the NADPH 
oxidase enzyme complex found on phagocytes including microglia. NOX2 is expressed by both 
neurons and microglia, and is highly responsive to cortical impact injury with microglia 
increasing and sustaining higher expression levels after injury, whilst neurons decrease 
expression levels with gradual return after injury (Cooney, L Bermudez-Sabogal and Byrnes, 
2013). 
NOX2 expression increases in experimental autoimmune encephalomyelitis (a model 
of CNS demyelinating disease), with microglial activation accompanied by overexpression of 
NADPH oxidase (Filippo et al., 2016). 
NADPH oxidase activation stimulates microglial proliferation (Jekabsone et al., 2006) 
whilst inhibitors of NADPH oxidase prevent microglia proliferation (Mander, Jekabsone and 
Brown, 2006). The NADPH inhibitor apocynin reduced microglial activation (identified as OX-
6+ also known as major histocompatibility complex class II) whilst the NADPH activator 
angiotensin II increased numbers of activated microglia in 6-OHDA treated VM cultures 
(Rodriguez-Pallares et al., 2007). Microglial exposure to neuromelanin results in enhanced 
NADPH oxidase dependent ROS production (W. Zhang et al., 2011) and NADPH oxidase has 
been implicated in PD (Belarbi et al., 2017). Niacin restriction has also been shown to 
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upregulate NADPH oxidase, increasing ROS production (in cultured human keratinocytes), an 
effect that was attenuated by addition of nicotinamide to culture medium (Benavente and 
Jacobson, 2008). 
Administration of NADPH to MPTP treated mice attenuated MPTP-induced elevation 
of Iba1 and levels of inflammasome proteins. The authors suggest that this could be due to 
p38 MAPK inhibition induced by NADPH (Zhou et al., 2018). Nicotinamide may influence 
NADPH oxidase through involvement with the pyridine nucleotides (Figure 1.10) or 
‘consumers’ of these including PARPs and CD38. 
 
5.1.6 PARPs are involved in microglial activation 
PARP1 has been shown to be essential for TNF-α induced microglial proliferation and 
morphological changes associated with inflammatory activation. Microglia derived from 
PARP-1-/- mice showed lower basal levels of MMP-9 (matrix metalloproteinase 9); which is 
released by microglia and degrades extracellular matrix. Blocking of PARP-1 activity by DPQ 
(3,4-dihydro-5-[4-(1-piper-idinyl)butoxy]-1(2h)-isoquinolinone) also reduced expression levels 
of MMP-9 in microglia cultures derived from wildtype mice, and co-cultures of microglia with 
neurons showed that neurotoxicity is mediated by MMP-9 through PARP-1 activity 
(Kauppinen and Swanson, 2005). As previously discussed, nicotinamide is an inhibitor of PARP 
activity (Suzuki et al., 2010) suggesting that nicotinamide may be able to influence microglial 
activation through PARP-1 inhibition. 
 
5.1.7 CD38 is a consumer of NAD+ 
NAD+ is ‘consumed’ by CD38, a transmembrane glycoprotein that catalyses NAD+ into 
nicotinamide, adenosine diphosphate-ribose (ADPR) and cyclic ADPR (Hamblin, 2003). Its 
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expression increases with pro-inflammatory microglial activation (Mayo et al., 2008). CD38 
plays a major role in the age-related decline of NAD+ levels, with expression increasing with 
age and correlated with decreased levels of NAD+ (Camacho-Pereira et al., 2016). CD38 is also 
involved in microglial activation-induced cell death, a mechanism by which microglia reduce 
numbers after a pro-inflammatory response (Mayo et al., 2008). This suggests that NAD+ levels 
may be depleted by microglial activation, which could have adverse effects for other neural 
cells. 
The effects of nicotinamide on microglia is not well covered in the literature, however, 
there appears to be a link between nicotinamide, its derivatives, and pathways inhibited by 
nicotinamide in microglial activation and the immune system in general (Ma et al., 2016; 
Cetina Biefer, Vasudevan and Elkhal, 2017). Given the potential role of microglia in 
neurodegeneration, and more specifically PD; and suggestions of a neuro-immunomodulatory 
effect of nicotinamide, this area of research could assist in the development of novel 




5.1.8 Aims of Chapter 5 
Data presented in Chapter 4.3.2, showed that nicotinamide treated VM cultures had 
significantly lower total numbers of cells, as observed with the nuclear stain DAPI. This led to 
the investigation of the effects of nicotinamide on different cell types present in these 
cultures. Neurons have historically taken precedence in the study of neurodegeneration, and 
more specifically PD. However, it is becoming increasingly apparent that glia may play 
significant roles in both degeneration and protection in neurodegenerative disease, and 
compounds may affect disease progression through these supporting cell types.  
Nicotinamide and associated compounds may also have a role in microglial activation 
and inflammatory response having been shown to reduce inflammation in other disease 
models. Neuroinflammation is implicated in the degeneration of dopaminergic neurons in PD, 
therefore, reducing neuroinflammation could help to slow the progression of PD and may also 
have a role in the outcome of other therapies such as CRT. Due to the wide-ranging influences 
of nicotinamide, both directly and indirectly, the potential mechanisms are not well described. 
Furthermore, due to the adaptive nature of microglia, it is important to analyse their response 
to compounds across multiple culture systems to fully explore the effects it may induce. 
This chapter will discuss: 
I. The identification of cell types within VM cultures derived from E14 rat. 
II. The effects of nicotinamide on GFAP+ astrocytes and Nestin+ cells present 
within VM cultures. 
III. The effects of nicotinamide on microglia in three culture systems (VM, WGE, 





5.2.1 Characterisation and quantification of cell types within 
VM cultures 
To estimate the percentage of each cell type within VM cultures, cell counts were 
collated from multiple experiments following immunocytochemistry for β-III-tubulin, TH, 
Nestin, GFAP and Iba1. Images were taken using different magnifications dependent on the 
cell type analysed and subsequent image analysis technique used. To collate the cell counts, 
data were converted to number of cells per mm2 by multiplying the number of cells per image 
by the area of the micrograph for the magnification at which the image was taken (described 
in Chapter 2.9). The number of cells per mm2 was then averaged across all experiments for 
both control and nicotinamide treated cultures. Since this technique contains different 
imaging techniques and does not allow for normalisation or error representation, the results 
are given as approximate values. 
 
5.2.2 Exploring the effect of nicotinamide on the proliferation 
of microglia within VM cultures 
The effects of nicotinamide on the proliferation of microglia within VM cultures was 
initially assessed by fixing cells at 1, 4, 7, and 14 DIV. The results from this experiment led to 
more detailed analysis of the effects of nicotinamide on microglial proliferation by changing 
the experimental treatment (+/- 10 mM nicotinamide) at 7 DIV. This is explained in Figure 5.1. 
Cultures were grown in control conditions with neural cell media (NCM), or with additional 10 
mM nicotinamide in nicotinamide supplemented NCM (NSM). Cells were then either fixed at 
7 DIV (NCM; NSM), continued with the same media (NCM→NCM; NSM→NSM), or swapped 
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to the other media for the following 7 DIV (NCM→NSM; NSM→NCM), then fixed at 14 DIV. 
Immunocytochemistry for Iba1 and DAPI was performed as described in Chapter 2.8. 
Due to the low quantity and wide-spread distribution of microglia within VM cultures, 
micrographs were taken at 10X magnification, to allow for broad capture of microglia across 





Figure 5.1 Diagram describing the treatment groups used when exploring the effects of nicotinamide on microglial proliferation by switching the addition or 
omission of 10 mM nicotinamide to ventral mesencephalon (VM) cultures. Cultures derived from embryonic day 14 rat VM were grown in control conditions 
(neural cell media; NCM; blue), or with additional 10 mM nicotinamide (NSM; red). Cells were then either fixed at 7 days in vitro (DIV; NCM/NSM; blue/red 
respectively), continued with the same media (NCM→NCM, green; NSM→NSM, orange), or swapped to the other media for the following 7 DIV (NCM→NSM, 






5.2.3 Treatment of pure microglial cultures with nicotinamide 
and GM-CSF 
To observe the effects of nicotinamide and GM-CSF on the proliferation of microglia, 
pure microglial cultures were obtained from mixed glial cultures as described in Chapter 2.6. 
Cells were plated onto PDL coated coverslips (Chapter 2.3.2) in 24-well plates at a density of 
2.2 x 104 cells/well. Cells were immediately exposed to treatment conditions by flooding the 
wells with the appropriate media. Concentrations of 1, 5 and 10 mM nicotinamide were used 
alongside application of 20 ng/mL GM-CSF as outlined in Figure 5.2. These pure microglial 
cultures were maintained for 5 days with full media changes on days 2 and 4 to replenish 
treatment conditions.  
Cultures were fixed and stained for Iba1 using the immunocytochemistry protocol 
described in Chapter 2.8. This experiment contained 3 experimental repeats, with each 
treatment condition containing 3 technical replicates. Results were quantified using cell 
counts and optical density (OD) measurements.  
 
Figure 5.2 Diagram showing treatment conditions of isolated microglial cultures treated with GM-CSF 
(blue) and/or concentrations of nicotinamide (purple/red respectively). Cultures received treatment 
from day 0, had a full media change on days 2 and 4; then were fixed on day 5 for 




For cell counts, 4 micrographs were taken at 10X magnification. Cells were evenly 
dispersed over the coverslip, so this imaging technique allowed capture of representative 
numbers of cells within the culture.  
For OD measurements, 4 micrographs were taken at 40X magnification. This technique 
was deemed more appropriate for analysing Iba1 expression as it provides a more detailed 
image of individual microglial cells. OD measurements were carried out as described in 





5.3.1 Nicotinamide altered VM culture cell populations 
Data presented in Figure 4.6, shows that nicotinamide treated VM cultures had 
significantly reduced total numbers of cells, as observed with the nuclear stain DAPI. This led 
to the investigation of the effects of nicotinamide on different cell types present in these 
cultures. This data is explored in the following sections.  
VM cultures at 7 DIV were assessed for the presence of markers for predominant 
neural cell types: β-III-tubulin (neurons), GFAP (astrocytes), Iba1 (microglia) and Nestin (NSCs). 
The number of nuclei associated with expression of each marker was quantified to 
approximate the number of each specific cell type per mm2 as described in Chapter 5.2.1. 
These values were then used to estimate the proportions of each cell type as shown in Figure 
5.3 A. Under standard conditions, NSCs (identified by Nestin) made up approximately 46% of 
cells. β-III-tubulin+ neurons accounted for approximately 13% of cells. GFAP+ astrocytes for 
2%, and Iba1+ microglia were approximately 0.85% of culture populations. The remaining 38% 
of nuclei were negative for these markers (i.e. could not be accounted for by this technique).  
The equivalent data for VM cultures treated with 10 mM nicotinamide for 7 DIV is 
shown in Figure 5.3 B. Nestin+ NSCs comprised approximately 34% of nicotinamide treated 
cultures, β-III-tubulin+ neurons made up around 14% of cultures. GFAP+ astrocytes were also 
estimated at 2%, with Iba1+ microglia making up 0.15% of nicotinamide treated cultures. The 
remaining 50% of cells did not stain for the above markers.  
Cultures were observed under brightfield and phase contrast microscopy to potentially 
identify unstained cells. Figure 5.3 (C, D) shows phase contrast and fluorescence micrographs 
from VM cultures at 7 DIV grown in control conditions. It was not possible to definitively 
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identify unstained cell types, however, some cells exhibited large nuclei and a flattened 
appearance indicative of astrocytes, although these were negative for GFAP staining. 
 
Figure 5.3 Cell types identified within VM cultures at 7 days in vitro.  
A) Pie chart showing the approximate neural cell proportions of VM control cultures calculated from 
immunocytochemistry for Nestin, GFAP, BIII-tub and Iba1. DAPI only indicates negative for cell-type 
specific markers. 
B) Pie chart showing the approximate make up of VM cultures treated with nicotinamide, calculated 
from immunocytochemistry for Nestin, GFAP, BIII-tub and Iba1.  
C) Phase contrast micrograph of VM cultures showing morphology of the cells.  
D) Immunocytochemistry for DAPI (blue), GFAP (red), and Nestin (green). Some GFAP- cells exhibited 
astrocytic morphology of a larger, dimmer nuclei in phase contrast micrographs (> arrowheads). 
 
5.3.2 Nicotinamide did not affect numbers of GFAP+ astrocytes 
in VM cultures 
GFAP+ astrocytes were quantified within VM cultures at 7 DIV. Numbers of GFAP+ cells 
were counted from micrographs taken at 40X magnification across 3-4 technical replicates 
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from 3 experimental repeats. Results showed no difference in GFAP+ cell numbers between 
control and nicotinamide treated cultures (5.64 ± 1.58 vs. 3.61 ± 1.06; t = 1.06, n.s.; Figure 
5.4). 
 
Figure 5.4 GFAP+ astrocytes did not differ between control and nicotinamide treated VM cultures. A) 
Graph showing the number of GFAP+ astrocytes normalised to control in control (blue square) and 
nicotinamide (red circle) treated cultures at 7 DIV. B) Micrograph showing morphology of astrocytes 
in control cultures. C) Representative micrographs showing numbers and spread of GFAP+ astrocytes 
in control and nicotinamide treated VM cultures. D) Representative micrographs showing morphology 
of GFAP+ astrocytes between control and nicotinamide treated cultures. 
209 
 
Analysis revealed that GFAP+ cells accounted for approximately 2% of the total cell 
population. This number was lower than expected for VM cultures as similar cultures have 
reported 50% GFAP+ cells (Liu and J. Hong, 2003), and phase microscopy of these cultures 
showed GFAP- cells with astrocyte morphology. To assess whether there was a larger 
population of astrocytes present, but not presenting as GFAP+, cultures were co-
immunostained with the originally-used GFAP antibody (supplied by DAKO) and another GFAP 
antibody (supplied by Biolegend). The DAKO GFAP antibody immunostained fewer cells than 
the Biolegend GFAP antibody and co-localisation occurred in some, but not all, Biolegend 
GFAP+ cells Figure 5.5 However, the Biolegend GFAP antibody also appears to have labelled 
fewer cells than anticipated. 
 
Figure 5.5 GFAP antibodies from DAKO and Biolegend show different immunoreactivity. 
Representative micrographs of control VM cultures show the different immunoreactivity of GFAP 
antibodies supplied by DAKO (red) and Biolegend (green). The merge shows some co-localisation, 




5.3.3 Lower numbers of Nestin+ cells were present when VM 
cultures were treated with nicotinamide 
Numbers of Nestin+ cells were counted from 4 micrographs taken at 40X magnification 
across 3-4 technical replicates and 3 experimental repeats. The average number of Nestin+ 
cells for each technical replicate was normalised as described in Chapter 2.11. These results 
showed a significantly lower number of Nestin+ cells in 10 mM nicotinamide treated VM 





Figure 5.6 Numbers of Nestin+ cells were lower in nicotinamide treated cultures.  
A) Graph showing the number of Nestin+ cells normalised to the control in control (blue circle) and 
nicotinamide treated (red square) VM cultures at 7 DIV.  
B) Representative micrographs taken at 10X magnification showing the distribution of Nestin+ cells in 
control and nicotinamide treated cultures.  
C) Representative micrographs taken at 40X magnification showing morphology of Nestin+ cells in 
control and nicotinamide treated cultures.  
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5.3.4 Nicotinamide restricted the proliferation of microglia in 
VM cultures 
As microglia make up < 1% of VM cultures at 7 DIV (Chapter 5.3.1), micrographs were 
taken at 10X magnification, as this was more likely to capture representative proportions of 
Iba1+ cells than micrographs at 40X magnification. The average number of Iba1+ microglia was 
counted from 4 micrographs taken across 3-4 technical replicates from 3 experimental 
repeats. Initial experiments showed obviously lower numbers of Iba1+ microglia in VM 
cultures at 7 DIV (versus control; discussed below). To explore this observation, further 
experiments were performed to quantify Iba1+ microglia at 1, 4 and 14 DIV.  
Cell counts showed an exponential increase in Iba1+ cell numbers in control VM 
cultures across 1, 4, 7, and 14 DIV (Figure 5.7 A). This increase was not seen in nicotinamide 
treated cultures and the growth curves produced from control and nicotinamide treated 
cultures were significantly different (Malthusian growth goodness of fit R2 = 0.84 vs. 0.12; 







Figure 5.7 Nicotinamide restricted proliferation of Iba1+ microglia in VM cultures. A) Graph showing 
the exponential increase in numbers of Iba1+ microglia per 10X micrograph (1.16 mm2) in control (blue 
circle) VM cultures across 14 DIV, whilst numbers of Iba1+ microglia showed very little increase in 
nicotinamide treated cultures (red square). B) Graph showing the number of Iba1+ cells (log scale) per 
10X micrograph (1.16 mm2) in control (blue circle) and nicotinamide (red square) treated cultures. * In 
control cultures, numbers of Iba1+ cells were significantly increased at day 7 vs. day 4, and day 14 vs. 
day 7. # Numbers of Iba1+ cells were significantly lower in nicotinamide treated cultures compared to 
control at days 7 and 14. C) Representative 10X micrographs showing immunocytochemistry for DAPI 
and Iba1 in control and nicotinamide treated cultures at 1, 4, 7, and 14 DIV. Scale bar holds across 
images. * p < 0.05; ** p < 0.01; ## p < 0.01. DIV: days in vitro. 
 
In control cultures, numbers of Iba1+ microglia increased significantly over time (one 
way ANOVA, effects of DIV, F(3, 8) = 24.56, p < 0.001; Figure 5.7 B, C). Individual t-tests showed 
significant increases in numbers of Iba1+ cells between 4 and 7 DIV (6.31 ± 1.97 vs. 35.8 ± 4.58, 
t = 5.9, p < 0.01), and 7 and 14 DIV (35.8 ± 4.58 vs. 290.6 ± 55.7, t = 4.6, p < 0.05). These results 
show that microglia are highly proliferative in these VM cultures over 14 DIV. 
When treated with nicotinamide, one-way ANOVA showed that numbers of Iba1+ 
microglia did not significantly increase over time (DIV; Figure 5.7 B, C). Numbers of Iba1+ 
microglia in control and nicotinamide treated VM cultures did not differ at 1 DIV (2.63 ± 0.13 
vs. 2.18 ± 0.27, t = 1.52, n.s.) or 4 DIV (6.31 ± 1.97 vs. 2.44 ± 0.13, t = 1.97, n.s.). However, 
numbers were significantly lower in nicotinamide treated cultures compared to control 
cultures at 7 DIV (6.08 ± 1.44 vs. 35.8 ± 4.58, t= 6.19, p < 0.01) and 14 DIV (10.9 ± 9.32 vs. 290.6 
± 55.7, t = 4.95 p<0.01; Figure 5.7 B, C). This suggests that nicotinamide inhibits the 
proliferation of microglia in these VM cultures. 
 
5.3.5 VM microglial proliferation was restricted during 
application of nicotinamide 
To further test the effects of nicotinamide on the proliferation of microglia, VM 
cultures were grown in neural cell media (NCM) or nicotinamide supplemented NCM (NSM). 
Cells were then either fixed at 7 DIV (NCM; NSM), continued with the same media 
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(NCM→NCM; NSM→NSM), or swapped to the other media for the following 7 DIV 
(NCM→NSM; NSM→NCM) as described in Chapter 5.2.2. Numbers of Iba1+ microglia were 
counted within 10X micrographs from 3-4 technical replicates and 3 experimental repeats. 
Numbers were then normalised to the 7 DIV NCM as described in Chapter 2.11. 
Results from these VM cultures showed that, consistent with data shown in Chapter 
5.3.4, cultures treated with nicotinamide (NSM) show significantly lower numbers of Iba1+ 
microglia than control (NCM) cultures at 7 DIV (Figure 5.8 A, B, C). 
Also consistent with Chapter 5.3.4, numbers of Iba1+ cells increased significantly from 
7 DIV to 14 DIV in cultures treated with NCM only (Tukey’s: p < 0.0001; Figure 5.8, A, D). 
However, when cultures were swapped to nicotinamide supplemented media at 7 DIV 
(NCM→NSM) and grown to 14 DIV, numbers of Iba1+ microglia did not increase significantly 
compared to control at 7 DIV (NCM; Tukey’s: n.s.; Figure 5.8 A, B, F); that is, a further 7 days’ 
culture did not lead to increased or decreased microglial numbers, when nicotinamide was 
added. At 14 DIV, cultures treated with only NCM (NCM→NCM) had significantly higher 
numbers of Iba1+ microglia than cultures swapped to nicotinamide treatment at 7 DIV 
(NCM→NSM; Tukey’s: p < 0.0001; Figure 5.8 A, D, F).  
Consistent with data shown in Chapter 5.3.4, these results showed no significant 
difference between numbers of Iba1+ microglia in nicotinamide treated cultures at 7 (NSM) 
and 14 DIV (NSM→NSM; Tukey’s: n.s.; Figure 5.8 A, C, E). However, when nicotinamide treated 
cultures were swapped to NCM at 7 DIV and grown to 14 DIV (NSM→NCM), numbers of Iba1+ 
microglia significantly increased compared to nicotinamide treated cultures stopped at 7 DIV 
(NSM; Tukey’s: p < 0.0001; Figure 5.8 A, C, G); that is, a further 7 day’s culture without 
nicotinamide, resulted in increased numbers of Iba1+ cells. Cultures that were swapped from 
NSM to NCM at 7 DIV (NSM→NCM) also had significantly higher numbers of Iba1+ microglia 
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than cultures grown with nicotinamide for 14 DIV (NSM→NSM; Tukey’s: p < 0.0001; Figure 
5.8). 
 
Figure 5.8 Nicotinamide only restricts proliferation during application. A) Graph showing the number 
of Iba1+ cells normalised to control at 7 DIV (NCM; blue circle; B) for the treatment conditions described 
in Figure 5.1. * numbers of Iba1+ cells were lower in nicotinamide treated cultures (NSM; red square; 
C) compared to control (NCM; blue circle; B) at 7 DIV (left of dashed line). Numbers of Iba1+ were 
higher in control cultures at 14 DIV (NCM→NCM; green triangle; D) compared to control at 7 DIV (NCM; 
blue circle; B). NCM→NCM cultures also showed higher numbers of Iba1+ cells at 14 DIV compared to 
control cultures that were swapped to nicotinamide treatment at day 7 (NCM→NSM; purple triangle; 
F). # Nicotinamide treated cultures that were swapped to control media at day 7 and grown to 14 DIV 
(NSM→NCM; black circle; G) showed higher numbers of Iba1+ cells compared to nicotinamide treated 
cultures fixed at 7 DIV (NSM; red square; C). NSM→NCM cultures also showed higher numbers of Iba1+ 
cells than cultures that were treated with nicotinamide for 14 days (NSM→NSM; orange diamond; E). 
*** p < 0.001; ### p < 0.001.  
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These results show that treatment of these VM cultures with 10 mM nicotinamide only 
inhibits microglia proliferation during application and the effects cease once this dose of 
nicotinamide is removed. 
 
5.3.6 The E14 VM contained more microglia than the E14 whole 
ganglionic eminence 
The effects of nicotinamide on microglia were also tested in cultures derived from the 
whole ganglionic eminence (WGE). Four micrographs at 10X magnification were taken from 
each of 3-4 technical replicates, across 3 experimental repeats. Numbers of Iba1+ microglia 
were counted and averaged across each technical replicate. 
Firstly, the WGE was compared to VM in terms of numbers of microglia present. 
Comparisons between cultures grown from E14 VM and E14 WGE at 7 DIV, showed the 
average number of Iba1+ cells was significantly higher in VM than WGE (35.76 ± 4.58 vs. 2.77 
± 2.21; t-test p < 0.01; Figure 5.9 A). 
Comparing numbers of Iba1+ microglia between 7 and 14 DIV in VM and WGE 
suggested a difference in growth rates between cultures grown from these regions. Simple 
linear regression analysis comparing Iba1+ numbers across 7 and 14 DIV for cultures derived 
from VM and WGE confirmed a significant difference between these slopes (R2 = 0.84 vs. 0.27; 
F(1, 8) = 19.64, p < 0.01; Figure 5.9 B). These results suggest a significant difference in the rate 
of increase of Iba1+ microglia between cultures derived from E14 VM and WGE, although the 
use of more timepoints would be useful to confirm this.  
When assessing the effect of nicotinamide on WGE derived cultures, no significant 
difference was observed (two-way ANOVA n.s.; Figure 5.10). This shows that nicotinamide did 
not exert significant effects on the number of Iba1+ microglia present in WGE cultures, and 
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neither did time (7 vs 14 DIV), although Iba1+ numbers were low in both control and treatment 
conditions at both timepoints. 
 
Figure 5.9 VM cultures contained more Iba1+ microglia than WGE cultures at 7 DIV.  
A) Graph showing the average number of Iba1+ microglia per 10X micrograph (FOI = 1.16 mm2) in 
cultures derived from E14 rat VM (blue circle) and WGE (purple square), after 7 DIV. VM cultures 
contain significantly more Iba1+ cells than WGE cultures (** p < 0.01).  
B) Graph showing simple linear regression representing growth between 7 and 14 DIV in VM (blue 
circle) and WGE (purple square) derived cultures. A significant difference was observed between the 
slopes (p < 0.01).  
C) Representative 10X fluorescence micrograph showing DAPI and Iba1 immunocytochemistry for VM 
cultures at 7 DIV. D) Representative 10X fluorescence micrograph showing DAPI and Iba1 
immunocytochemistry for WGE cultures at 7 DIV. Scale bars hold across all images. DIV: days in vitro; 




Figure 5.10 Nicotinamide did not significantly affect numbers of Iba1+ cells in WGE cultures. Graph 
showing the average number of Iba1+ cells per 10X micrograph (FOI = 1.16 mm2) in control (blue circle) 
and nicotinamide treated (red square) WGE cultures at 7 and 14 days in vitro (DIV). No significant effect 
was observed using two-way ANOVA.  
 
5.3.7 Varied microglia morphology was present within VM 
cultures 
Iba1+ microglia within VM cultures displayed a range of morphologies including 
amoeboid, primary branching and secondary branching (Figure 5.11 A, B, C respectively). The 
morphology of microglia in both control and nicotinamide treated VM cultures changed over 
time (Figure 5.11 control: D-G; nicotinamide: H-K ). At 1 DIV, nearly all microglia were 
amoeboid shape or close to an amoeboid shape with short branching. At 4 DIV, different 
shapes were becoming apparent with some microglia developing primary branches. By 7 DIV 
more complex primary and secondary branching was observed alongside some amoeboid 
morphology. This variety of shapes continued to be displayed at 14 DIV. Treatment of VM 
cultures with 10 mM nicotinamide did not appear to affect the morphology of Iba1+ microglia 




Figure 5.11 Iba1+ microglia displayed various morphologies in VM cultures. A) Fluorescence micrograph 
showing amoeboid morphology. B) Fluorescence micrograph showing an example of primary 
branching with simple projections extending from the soma. C) Fluorescence micrograph showing an 
example of secondary branching with more complex processes containing further branching extending 
from the soma. Scale bar holds across A-C. D) Fluorescence micrographs showing DAPI and Iba1 
immunocytochemistry for control VM cultures at 1 DIV. E) Immunocytochemistry for control VM 
cultures at 4 DIV. F) Immunocytochemistry for control VM cultures at 7 DIV. G) Immunocytochemistry 
for control VM cultures at 14 DIV. H) Immunocytochemistry DAPI and Iba1 for nicotinamide treated 
VM cultures at 1 DIV. I) Immunocytochemistry for nicotinamide treated VM cultures at 4 DIV. J) 
Immunocytochemistry for nicotinamide treated VM cultures at 7 DIV. K) Immunocytochemistry for 
nicotinamide treated VM cultures at 14 DIV. * represents examples of amoeboid morphology; > 
represents examples of primary branching; # represents examples of secondary branching. Scale bar 
hold across D-K. DIV: Days in vitro; VM: ventral mesencephalon. 
221 
 
5.3.8 Nicotinamide reduced numbers of Iba1+ cells in microglia 
cultures derived from primary mixed glia 
The effect of nicotinamide was also tested on primary microglia cultures derived from 
mixed glial cultures. These isolated microglia cultures were seeded and grown for 5 days in 
control conditions or with 1, 5 or 10 mM nicotinamide. Numbers of Iba1+ microglia were 
quantified across 4 micrographs taken at 10X magnification for each of 3 technical replicates 
and 3 experimental repeats. Numbers of Iba1+ microglia were then normalised as described 
in Chapter 2.11. Microglia grown in control conditions displayed different morphology to 
microglia within E14 VM cultures. This morphology, shown in Figure 5.12 is characteristic of 
pure 2D microglial cultures with mostly amoeboid or large, flattened ‘fried egg’ morphology, 
some primary branching, rod-like or unipolar/bipolar morphologies (1 or 2 long, extending 
processes), and very limited secondary branching morphologies.  
Numbers of Iba1+ microglia were significantly affected by concentration of 
nicotinamide (one-way ANOVA F(3,32) = 0.62, p < 0.01). Post-hoc analysis revealed numbers 
were significantly reduced with application of 10 mM nicotinamide compared to control 
(Dunnett’s: p < 0.001; Figure 5.13). The morphology of Iba1+ microglia in nicotinamide treated 
cultures also appeared to be affected, with smaller cell bodies observed with increasing 
concentrations (Figure 5.13). At 10 mM, microglial cell bodies were barely larger than their 
nuclei, possibly indicating apoptotic or pyknotic cells, suggestive of toxicity. This shows that 
application of 10 mM nicotinamide to primary microglial cultures for 5 days reduced the 






Figure 5.12 Morphology of microglia isolated from mixed glial cultures. Representative fluorescence 
micrographs of microglia isolated from mixed glial cultures grown for 5 days in control conditions with 
immunocytochemistry for DAPI (blue) and Iba1 (red). A) Iba1+ microglia displaying large, flattened 
‘fried egg’ morphology (*) and some showing primary branching (#). B) Iba1+ microglia displaying 
unipolar (>) and bipolar (→) morphologies, the processes typically end with large flattened ‘bulbs’. 





Figure 5.13 The number of Iba1+ cells was reduced in isolated microglial cultures treated with 10 mM 
nicotinamide. A) Graph showing the number of Iba1+ microglia normalised to control in isolated 
microglial cultures in control (0; blue circle), and with 1 mM (red square), 5 mM (green triangle), and 
10 mM (purple diamond) nicotinamide treatment. 10 mM nicotinamide significantly reduced numbers 
of Iba1+ microglia in these cultures (** p < 0.01). B-E) Representative 40X fluorescence micrographs 
showing DAPI and Iba1 immunoreactivity control (B), 1 mM nicotinamide (C), 5 mM nicotinamide (D), 
and 10 mM nicotinamide (E). The morphology of Iba1 expression appears to change with nicotinamide 
treatment with cell size appearing to decrease with increasing nicotinamide concentrations (B-E). 10 




5.3.9 In isolated microglial cultures, GM-CSF increased numbers 
of Iba1+ microglia and counteracted nicotinamide 
Numbers of Iba1+ microglia were quantified and normalised as described in Chapter 
2.11. The addition of GM-CSF for 5 days to primary microglial cultures significantly increased 
numbers of Iba1+ cells by about 45% compared to control (t = 2.59; p < 0.05; Figure 5.14).  
 
Figure 5.14 GM-CSF increased the number of Iba1+ cells in isolated microglial cultures. Graph showing 
the number of Iba1+ cells normalised to control in control and GM-CSF treated isolated microglial 
cultures. Numbers of Iba1+ microglia were significantly higher with application of GM-CSF (20 ng/mL; 
pink square) compared to control (blue circle) after 5 days in culture (* p < 0.05). 
 
The addition of GM-CSF alongside nicotinamide resulted in no significant difference in 
Iba1+ cell numbers across all concentrations of nicotinamide, versus GM-CSF alone (1 mM, 5 
mM, 10 mM; one-way ANOVA: n.s.; Figure 5.15). This shows that GM-CSF counteracted the 





Figure 5.15 Nicotinamide treatment alongside GM-CSF did not affect the number of Iba1+ cells in 
isolated microglial cultures. Graph showing the average number of Iba1+ cells normalised to the control 
(Figure 5.14 blue circle) in isolated microglial cultures treated with GMCSF alone (pink circle) and 
alongside nicotinamide at concentrations of 1 mM (red square), 5 mM (green triangle), and 10 mM 
(purple diamond). No significant difference was observed across these conditions using one-way 
ANOVA. 
 
5.3.10 Numbers, morphology, and expression of Iba1+ microglia 
were differentially affected by GM-CSF and nicotinamide 
The morphology of Iba1+ cells showed stark differences between control and GM-CSF treated 
cultures (Figure 5.16 A, B). Cultures treated with GM-CSF appeared to have larger cell areas 
(as judged by membrane covering the substrate; cell volume could not be determined) with 
stronger intensity of Iba1 expression. Optical density (OD) measurements (described in 
Chapter 2.10) provided a rapid, facile, and high throughput assessment of these cultures. The 
OD of whole micrographs can be influenced by cell numbers, morphology and/or levels of Iba1 
expression. Results were normalised as described in Chapter 2.11. Results showed a significant 
effect of nicotinamide on the OD of these isolated microglial cultures (two-way ANOVA, 
nicotinamide as factor, F(3,64) = 3.84, p < 0.05). GM-CSF also had a significant impact on the OD 
of these cultures (two-way ANOVA, GM-CSF as factor, F(1,64) = 16.4, p < 0.001). Post-hoc 
analysis revealed a significant increase in OD in GM-CSF treated microglial cultures compared 
to control (Sidak’s: p < 0.001; Figure 5.16, A-C). This suggests an increase in the area covered 
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by cell membrane and/or the intensity of Iba1 staining when GM-CSF is applied to microglia 
cultures. This increase could be due to factors including numbers of Iba1+ cells, morphology 
of Iba1+ cells, and expression intensity of Iba1. 
Cultures treated with 1 mM, 5 mM or 10 mM nicotinamide alongside GM-CSF did not 
show a significant difference in OD compared to cultures receiving nicotinamide alone 
(Tukey’s: n.s.; Figure 5.16, C-G). However, OD was significantly decreased when comparing 
cultures treated with GM-CSF plus nicotinamide (1, 5 and 10 mM) versus GM-CSF alone 
(Tukey’s: p < 0.01; p < 0.05; p < 0.01 respectively; Figure 5.16 C-G). This suggests that 







Figure 5.16 Application of GM-CSF to isolated microglia cultures increased Iba1 expression measured 
by optical density (OD), an effect that was counteracted by nicotinamide treatment.  
A-B) Representative 40X micrographs (FOI = 0.073mm2) showing DAPI and Iba1 immunoreactivity in 
control (A) and GM-CSF treated (B) isolated microglial cultures. Iba1 expression appears more intense 
in GM-CSF treated cultures (B), with potentially larger cell bodies and more identifiable processes 
compared to control (A). Scale bar holds across A and B.  
C) Graph showing the OD, normalised to control, for Iba1 immunofluorescence in micrographs taken 
at 40X magnification, control (0, blue circle) and nicotinamide alone at concentrations of 1, 5 and 10 
mM (blue circles), and GM-CSF alone (0, red square) and GM-CSF with nicotinamide at concentrations 
of 1, 5, and 10 mM (red squares). * Significantly higher Iba1 OD was observed in GM-CSF alone treated 
cultures compared to control. # Significantly lower Iba1 OD was observed in cultures treated with 
nicotinamide alongside GM-CSF compared to GM-CSF alone. *** p < 0.001; # p < 0.05; ## p < 0.01.  
D-G) Representative 40X fluorescence micrographs showing immunoreactivity for DAPI and Iba1 in 
isolated microglial cultures grown for 5 days. D) GM-CSF alone, E) GM-CSF with 1 mM nicotinamide, F) 
GM-CSF with 5 mM nicotinamide, G) GM-CSF with 10 mM nicotinamide. It is apparent that cell 
morphology changes with increased nicotinamide treatment, with 10 mM nicotinamide and GM-CSF 
treated cells showing smaller, rounded cell bodies and some potentially pyknotic cells. Scale bar holds 







5.4.1 Identification of cell types within VM cultures 
As shown Figure 4.6, overall cell numbers in VM cultures were significantly reduced 
with nicotinamide application. This reduction in cell numbers was not due to a reduction in β-
III-tubulin+ neurons. This led to more detailed characterisation of the cell types present within 
these VM cultures. Control cultures predominantly stained for Nestin+ cells (46%), followed 
by β-III-tubulin+ cells (13%), then GFAP+ cells (2%) and Iba1+ cells (0.85%).  
Despite using multiple neural cell type-specific markers, it was not possible to identify 
~40% of cells. On morphological/microscopic examination at least some of these cells were 
consistent with oligodendroglial morphologies, or astrocyte morphologies, although the latter 
were not immune-positive for the DAKO GFAP antibody (discussed later in Chapter 5.4.2).  
One explanation for these cells being negative for the markers tested, is the possibility 
that they are non-neural cells, for example fibroblasts, which could have contaminated the 
culture from incomplete removal of meningeal tissue (Pruszak et al., 2009). Fibroblasts are 
difficult to positively identify, with few reliable antibodies available (Goodpaster et al., 2008). 
Vimentin can be used to identify fibroblasts, however this intermediate filament protein is 
also expressed in astrocytes (Kamphuis et al., 2012). Although it is difficult to confirm the 
presence or absence of fibroblasts in these VM cultures, steps were taken during dissection 
to reduce the risk of fibroblast contamination. For example, VM tissue was moved to fresh 
dissection media after removal of meningeal tissue for further trimming before collection, and 
tissue sections were washed 3 times with fresh dissection medium before dissociation. 
The cell populations of VM cultures described in the literature are displayed in Table 
5.1, although many papers using E14 rat VM cultures do not report on the presence or absence 
of non-neuronal populations. The proportions of astrocytes is often reported, based on GFAP 
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staining, including use of the DAKO GFAP antibody discussed in Chapter 5.3.2. Microglial 
populations are reported in less than half of the studies identified here, and in one case, the 
marker used for identification was not reported. None of the papers shown in Table 5.1 report 
on Nestin+ neural cell populations, or the presence of neural stem cells, based on any markers. 
The percentage of cells remaining uncharacterised in these papers was up to 29%, at 7 DIV 
(Callizot et al., 2019). None of these studies maintained cultures for 14 DIV.  
Differences in cell populations can arise from differences in dissection methods (which 
cell types are initially present) and media composition (which can influence survival, 
proliferation, and differentiation). These VM cultures contained a lower percentage of 
neurons than reported by others in the literature. The literature reports neuronal populations 
within VM cultures as being 40-97% of cells at 7 DIV. However, Cheung, Hickling, & Beart 
(1997) reported 97% (± 14 SEM) MAP2+ (microtubule-associated protein 2) neurons alongside 
13% (± 1 SEM) GFAP+ cells at 7 DIV. There is some difficulty reconciling these numbers 
suggesting inaccuracies in staining and/or counting methods. MAP2 has since been shown to 
be present in immature glial cells (Blümcke et al., 2001) suggesting that non-neuronal cells 
may have been incorrectly identified as neurons. These numbers are also reported as the 
percentage of stained cells without suggestion of a population that was not immune-positive 
for any of TH, MAP2, or GFAP.  
The lower percentage neuronal population reported here could arise from tougher 
manual dissociation, or from the staining/imaging techniques used as discussed in Chapter 
4.4.2.  
Nicotinamide treated cultures showed a change in the proportions of cell types 
present within the VM cultures. The reduction in Nestin+ cells is discussed later in Chapter 





Table 5.1 Table showing examples of VM culture populations from the literature. * indicates that no antibody was specified. Article number references: 1: Cheung, 
Hickling and Beart (1997); 2: Zhang et al. (2014); 3: Callizot et al. (2019); 4: Liu and J. Hong (2003); 5: Gaven, Marin and Claeysen (2014). 
Dopamine 
neurons 
Neurons Astrocytes Microglia Neural 
stem cells  
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well 
1 DIV 
Neurobasal, B27, L-glutamine (500 mM) and penicillin 






























: 97% GFAP+: 13% Not stated Not stated 7 DIV 
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+
: 2-3% of 
neurons 
Neu-N: 40% Astroglia*: 48% 
OX-42: 11% 




 per 24 well  
7 DIV 
Minimum essential medium, 10% heat-inactivated 
foetal bovine serum, 10% heat-inactivated horse serum, 
1 g/L glucose, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 100 μM non-essential amino acids, 50 U/mL 









As above, 1.5 mM Leu-Leu methyl ester hydrobromedia 
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 per 24 
well 
6 DIV 
Neurobasal, 2% B27, 2 mM L-glutamine, 2% PS solution, 
10 ng/mL brain-derived neurotrophic factor, 1 ng/mL 



















 per 24 well 
7 DIV 
Minimum essential medium, 10% heat-inactivated 
foetal bovine serum, 10% heat-inactivated horse serum, 
nonessential amino acids (1X), 1 mM sodium pyruvate, 2 
mM L-glutamine, penicillin–streptomycin (50 U/mL, 50 
























 per 24 well 
Up to 13 DIV 
TH
+
 peak at 6 DIV 
In sterile water, mix successively 40 ml of 5x Dulbecco's 
Modified Eagle/F12-Ham, 1 mL 1 M HEPES, 2 mL 200 
mM L-Glutamine, 2 mL penicillin-streptomycin, 4 mL 







5.4.2 Nicotinamide does not appear to affect GFAP+ astrocytes 
Astrocytes typically make up 13-50% of E14 rat VM cultures at 7 DIV in the literature 
(Table 5.1). VM cultures described here contained approximately 2% GFAP+ astrocytes of the 
total cell population. This low GFAP+ population alongside a large unstained population could 
mean that the majority of astrocytes present in these VM cultures did not express GFAP or 
the antibody used did not detect the GFAP isoform that was expressed.  
GFAP is a type III intermediate filament protein and is considered to be a marker of 
fully differentiated astrocytes that is upregulated in instances of injury and damage (Hol and 
Capetanaki, 2017). Although GFAP is widely used as an astrocyte marker indicative of reactive 
astrocytes, astrocyte expression patterns are not as simple as being either GFAP+ or GFAP- 
(Liddelow and Barres, 2017). Other markers, including Nestin, are also expressed in astrocytes 
in response to damaging stimuli (Cho et al., 2006; Luna et al., 2010). GFAP expression can vary 
dependent on culture preparation, with astrocytes in directly seeded primary culture of 
mouse cortex showing the weakest GFAP expression compared to subcultured astrocytes, 
after being placed on a rotary shaker (Du et al., 2010). Medium composition such as the 
presence of serum (Codeluppi et al., 2011), growth factors, and metabolites from other cell 
types can also affect expression patterns in cultured astrocytes (Lange et al., 2017). The 
culturing process used here, with only 7 DIV, and the presence of other neural cell types may 
have subdued GFAP expression in these VM cultures. Cultures grown from E14 WGE showed 
no GFAP+ cells in micrographs (taken at 40X magnification; although a few clusters were visible 
across the entire coverslip) at 7 DIV, however, micrographs (also taken at 40X magnification) 
from cultures at 14 DIV showed approximately 11% GFAP+ of total cells in control cultures 
(data not shown). This suggests that GFAP expression increases with time. 
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However, other studies have reported a decrease in GFAP+ astrocytes, and an increase 
in calbindin D28k immunoreactive astrocytes, from day 1-9 in astrocytes derived from 
postnatal mice, suggesting that GFAP may not be consistently expressed in astrocytes (Xu, 
2018). Zengli Zhang et al. (2019) also found different expression patterns for the astrocyte 
markers GFAP, S100-β, and NDRG2 (N-Myc downstream-regulated gene 2) in tissue slices 
obtained from different mouse brain regions, suggesting that the choice of astrocyte markers 
should be tailored to different brain regions.  
Another possibility for the lower than expected GFAP+ population is the differences in 
antibody specificity for GFAP isoforms. Nine variants of GFAP are described across human, 
mouse, and rat, with different expression patterns across brain regions (Kamphuis et al., 
2012). The DAKO anti-GFAP antibody was used for astrocyte identification in VM cultures in 
the majority of this PhD thesis, however, it detected low numbers of GFAP+ astrocytes. Figure 
5.5 shows the differences in GFAP staining between GFAP antibodies supplied by DAKO and 
Biolegend. This shows that the DAKO GFAP antibody did not identify all GFAP+ astrocytes in 
these VM cultures, resulting in the lower than expected numbers observed. The differences 
between these antibodies may arise from the generation of the antibody, although both the 
DAKO and Biolegend immunogens are derived using bovine spinal cord. However, DAKO is 
polyclonal, and Biolegend monoclonal; from this it would be expected that the DAKO antibody 
would recognise more epitopes than the Biolegend antibody, which is why it was initially 
chosen. The differences observed also could be because different antibodies may be selective 
for a particular isoform, or isoforms, of GFAP, with different specificities also found between 
human and mouse GFAP (Lin, Messing and Perng, 2017).  
From the results presented here, 10 mM nicotinamide did not have an effect on GFAP+ 
astrocytes in these VM cultures. However, further analysis using other astrocyte markers or 
cultures containing pure astrocyte populations should be used to test this conclusion, given 
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the uncertainty as to whether all astrocytes were reliably identified within these cultures. The 
data reported here does however correspond with data showing that nicotinamide did not 
affect the differentiation of glial (GFAP+ and neural/glial antigen-2 [NG2]+) cells from mESCs 
(Griffin et al., 2017). However, nicotinamide is an inhibitor of PARP-1, and PARP-1 knockout 
mice have shown increased differentiation of GFAP+ astrocytes and oligodendrocytes (Hong 
et al., 2019), suggesting that nicotinamide could have an effect on glial populations.  
 
5.4.3 Nicotinamide reduced numbers of Nestin+ cells in VM 
cultures 
Nestin+ cells made up the highest percentage of identified cells in both control and 
nicotinamide treated VM cultures at 7 DIV. Nestin is a class 6 intermediate filament protein 
and although it is commonly regarded as a NSC marker, it is also expressed in a number of 
nervous tissue tumours, and in non-neural cells, including, retina, muscle, skin, teeth and liver 
(review: Gilyarov, 2008). Due to the origin of the VM cultures used here, it is likely that the 
Nestin+ population is of neural lineage. Nestin+ cells have been shown to differentiate into 
both neurons and astrocytes (Andressen et al., 2001) and Nestin expression has been 
identified in neuronal and astrocyte populations after damage (Gilyarov, 2008; Luna et al., 
2010; Cho et al., 2013). Proliferating microglia have also been shown to transiently express 
Nestin after their depletion in vivo (Elmore et al., 2014; Huang et al., 2018).  
Nicotinamide treatment over 7 DIV reduced the number of Nestin+ cells in these VM 
cultures. Here, these cells are thought to represent the NSC population, although, as shown 
above, Nestin expression has been reported in neurons, astrocytes, and microglia. In these 
VM cultures, co-expression of Nestin and GFAP was observed, although incidence was very 
low with few presentations across cultures (<15 across experimental repeats; data not 
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included). NSCs are a proliferative population, and so nicotinamide may be expected to limit 
their proliferation. 
As discussed in Chapter 3, nicotinamide has been shown to reduce the proliferation 
capacity of a number of cell types. Treatment of the mouse NSC line C17.2 with nicotinamide 
dose dependently reduced proliferation, with a significant decrease seen from concentrations 
of 20 mM and above (Wang et al., 2012). Although this was a mouse cell line, it correlates with 
the effects seen by nicotinamide in these primary rat NSCs. Nicotinamide has also been found 
to decrease the number of Oct4 (an ESC marker) expressing cells in mESCs (Griffin et al., 2017). 
These results show that nicotinamide limited proliferation of Nestin+ cells in these VM 
cultures, correlating with results discussed in Chapter 3, with nicotinamide also reducing 
proliferation in the mESCs used in this PhD project. 
 
5.4.4 Nicotinamide limits the proliferation of Iba1+ microglia in 
VM cultures 
As shown in Chapter 5.3.4, the number of Iba1+ microglia in VM cultures was 
significantly lower with nicotinamide treatment. This effect also observed in an in vivo 
traumatic brain injury rat model, with significantly lower numbers of Iba1+ microglia present 
in nicotinamide treated rats compared to saline-treated (Smith et al., 2019). These results 
suggest that nicotinamide lowers microglia in vivo, with this effect being replicated in the in 
vitro cultures employed here.  
By observing the number of microglia present in these VM cultures across 1, 4, 7 and 
14 DIV it was possible to show that nicotinamide limited the proliferation of Iba1+ microglia. 
Furthermore, by addition or removal of nicotinamide treatment after 7 DIV, it was shown that 
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proliferation of microglia is only limited during application of nicotinamide, with the effect 
being reversible upon removal of nicotinamide.  
As previously discussed, microglia can transiently express Nestin, raising the possibility 
that these effects could be due to a decrease in the differentiation of microglia from Nestin+ 
progenitors, as distinct from microglia being generated by proliferation of microglial cells 
themselves. Elmore et al. (2014) suggest that microglia repopulation in vivo occurs through 
proliferation and differentiation of Nestin+ cells. However, a fate-mapping study failed to find 
microglia derived from Nestin+ cells (Huang et al., 2018) and Askew et al. (2017) found no 
evidence of Nestin expression in proliferating microglia involved in homeostatic maintenance. 
Much of the literature also coincides with the idea that microglia are highly proliferative, with 
general consensus suggesting proliferation rather than differentiation is responsible for 
establishing and maintaining the brain microglial population (Navascués et al., 2000; Ginhoux 
and Prinz, 2015; Askew et al., 2017; Huang et al., 2018). The use of a marker such as Ki67 or 
BrdU, combined with Nestin or Iba1, would help to definitively determine whether the 
increase in microglia observed in these VM cultures is due to proliferation rather than 
differentiation. 
This effect of nicotinamide limiting microglial proliferation was seen in VM cultures, 
which contain a number of other neural cell types, hindering the ability to determine whether 
nicotinamide acts directly on microglia. To further explore the effects of nicotinamide on 
microglia alone, high purity microglia cultures derived from mixed glia cultures were treated 




5.4.5 Nicotinamide reduced numbers of microglia in cultures 
derived from mixed glia 
Nicotinamide treatment of microglia derived from mixed glial cultures showed 
reduced numbers of Iba1+ microglia after 5 days with 10 mM nicotinamide treatment, but not 
with lower concentrations. It is not clear whether this is due to a restriction in proliferation, 
or promotion of cell death. The change in morphology exhibited by these microglia suggests 
that this could be due to toxicity. Microglia treated with 10 mM nicotinamide were typically 
much smaller than those in control cultures, with the Iba1+ cell body being barely larger than 
the nucleus, resembling the early effects of pyknosis (Figure 5.13). However, these 
observations do not represent definitive evidence of a toxic effect. 
To assess the toxicity of nicotinamide, further analyses could be performed. 
Possibilities include staining with TUNEL (Terminal deoxynucleotidyl transferase dUTP nick 
end labelling) or PI, or measures of metabolic activity such as an MTT assay. These assays could 
confirm if 10 mM nicotinamide is toxic to isolated microglial cultures derived from mixed glia. 
To further explore the nicotinamide-induced decrease in microglial numbers observed 
in microglial cultures, and the limitation of microglia proliferation observed in VM cultures. 
The effect of nicotinamide alongside GM-CSF, a cytokine known to promote microglial 
proliferation, was tested. 
 
5.4.6 GM-CSF counteracted the nicotinamide-induced decrease 
in numbers of microglia, but not Iba1 expression 
To assess potential mechanisms of nicotinamide-induced reduction in proliferation in 
VM cultures, and reduced numbers of microglia in cultures derived from mixed glia, GM-CSF 
was used to induce proliferation within microglia cultures. GM-CSF is released by astrocytes 
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after inflammatory activation (Aloisi et al., 1992; Lee et al., 1994), suggesting that GM-CSF 
could be a source of the microglial proliferation observed in these VM cultures. In cultures 
derived from mixed glia, application of GM-CSF for 5 days significantly increased both numbers 
of Iba1+ microglia and expression of Iba1 measured by OD. Application of nicotinamide 
alongside GM-CSF reduced levels of Iba1 expression measured by OD, but did not reduce 
numbers of microglia, an effect that was observed with application of 10 mM nicotinamide 
alone. This suggests that nicotinamide did not counteract the increased proliferation induced 
by GM-CSF (Figure 5.14), but did counteract the increase in Iba1 expression measured by OD 
(Figure 5.16). This may suggest that GM-CSF and nicotinamide affect microglial proliferation 
and Iba1 expression through separate mechanisms. 
The combination of nicotinamide and GM-CSF treatment of microglial cultures did not 
prevent GM-CSF-induced microglial proliferation. This suggests that the proliferation 
observed in VM cultures may not be associated with stimulation from endogenous GM-CSF, 
which is released by astrocytes after inflammatory activation, because if this was the case, 
then nicotinamide would not be expected to inhibit proliferation. The low numbers of GFAP+ 
cells within VM cultures at 7 DIV suggests that either numbers of astrocytes were low or that 
astrocytes were not mature or not activated in a way that promotes GFAP expression. This 
supports the idea that GM-CSF released by astrocytes may not be the cause of microglial 
proliferation in VM cultures. To investigate this, levels of GM-CSF in VM cultures could be 
tested. 
GM-CSF induces increased proliferation of microglia through phosphorylation of ERK1, 
ERK2, STAT5A, and STAT5B (Liva et al., 1999). The literature does not suggest that 
nicotinamide is associated with these pathways, although, recently published data has shown 
that nicotinamide treatment of retinas abolished a toxin-induced increase in ERK 
phosphorylation. The authors suggest that ERK phosphorylation is part of a self-protective 
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response of cells (Sugano et al., 2019). Therefore, preventing the activation of ERK may not be 
a direct effect of nicotinamide, but may be attributed to the overall protective role that 
nicotinamide showed in this disease model. The results found in this PhD thesis suggest that 
nicotinamide and GM-CSF involve separate pathways in control of proliferation, with no 
evidence in the literature suggesting an overlap of mechanisms. 
 
5.4.7 Nicotinamide (10 mM) induced different microglial 
responses between VM cultures and microglia cultures 
Studying microglia within VM cultures has advantages over 2D monocultures as the 
former more closely resembles the intact brain environment, however, the mechanisms 
behind effects of treatment are harder to elucidate as there are other cell types present within 
the cultures. Studying microglia as a monoculture can help to uncover how these cells respond 
to treatment, as confounding elements are omitted, and direct effects can be determined. In 
this PhD project, microglia in VM cultures and isolated microglia in cultures derived from 
mixed glia seemed to respond differently to treatment with 10 mM nicotinamide. However, 
even without nicotinamide treatment, microglia cultured within these two systems still 
showed differences in morphology (Figure 5.11 and Figure 5.12). 
Microglia are very sensitive to changes in their environment (Kettenmann et al., 2011) 
making it difficult to know whether in vitro observations are predictive of in vivo behaviours. 
Microglia derived from mixed glia cultures displayed morphologies typical of isolated 
microglia grown in a 2D culture system (Tamashiro, Dalgard and Byrnes, 2012) with mostly 
large and flattened, or rod-like appearance. However, VM cultures displayed microglia with 
morphology closer to microglia grown in 3D in vitro cultures (Figure 5.17), which are 
frequently highly ramified, with the small cell soma which earned microglia their name, and 
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more closely resembling morphologies displayed in vivo (Miller et al., 2019). This increase in 
ramification is observed when microglia are cultured with a bedlayer of cells, including 
epithelial cells and astrocytes (Rosenstiel et al., 2001; Rezaie et al., 2002). Microglia are 
influenced by signalling from other neural cell types, consequently, removal of neural cell 
interactions can affect microglia phenotypes (review: Timmerman, Burm, & Bajramovic, 
2018). The morphological differences observed between these cultures have been frequently 
reported in the literature. Morphological differences are even found in vivo between the pars 
reticula and pars compacta of the SN (De Biase et al., 2017). This adaptive nature of microglia 
make them difficult to study and to extrapolate observations from in vitro models (Mosser et 
al., 2017).  
 
Figure 5.17 Phase contract micrograph showing primary rat microglia grown in a collagen hydrogel 
providing a 3-dimensional substrate. *Microglia display more complex morphology with small cell 
soma, multiple branches, and secondary branching systems, more closely resembling morphology 
displayed by microglia in vivo. Cells were highly motile, with small somas typical of microglia in 
histological sections. Image courtesy of Dr Stuart Jenkins (Keele University). 
 
Nicotinamide treatment reduced numbers of Iba1+ microglia in VM cultures by limiting 
proliferation. The microglia in these cultures still displayed the morphologies that were 
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present, and progressed over time, in control cultures despite 14 days of 10 mM nicotinamide 
treatment. However, after 5 days of 10 mM nicotinamide treatment, Iba1+ microglia in 
cultures derived from mixed glia cultures had differing morphologies compared to control 
cultures. Microglia treated with 10 mM nicotinamide tended to have very small, rounded cell 
bodies with Iba1 expression being barely larger than the nucleus, indicative of toxicity. 
One potential explanation for the apparent toxicity of 10 mM nicotinamide in isolated 
microglia cultures, but not VM cultures, is the difference in cell numbers. Microglia derived 
from mixed glia cultures were plated at 20,000 cells per well, evenly dispersed, compared to 
50,000 cells in a 50 µL micro-drop used for VM cultures. These cell densities were used based 
on protocols established within the laboratory for each culture system. This reduction in total 
cell numbers for isolated microglial cultures may mean that individual cells are exposed to 
higher amounts of nicotinamide; for the same nicotinamide concentration in each cultures 
system, there is more nicotinamide per cell in the lower density microglial cultures.  
Each culture system was also grown in a different medium, specified from previous 
laboratory protocols unique to each cell model. As discussed in Chapter 5.4.2 with astrocytes, 
different culture medium can also produce different phenotypes in microglial cultures (Bohlen 
et al., 2017). The addition of serum can also affect microglia within cultures, inhibiting the 
development of ramified morphology (Navascués et al., 2000). Codeluppi et al. (2011) found 
that astrocyte cultures (derived from adult rat spinal cord) grown with lower levels of serum 
resulted in lower microglial populations. Similarly, microglial cultures exposed to serum 
showed increased proliferation compared to defined media (Bohlen et al., 2017). Microglia 
morphology in 2D cultures is also affected by serum. Microglial cultures isolated from mixed 
glial cultures (P0-2 rats), grown with 10% FBS showed larger, flatter morphologies with 
increased area of Iba1 expression, and fewer processes per cell, compared to microglia grown 
in defined medium without FBS (Montilla et al., 2020).  
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Ideally, a single medium that could be used by both culture systems would assist in 
isolating the specific effects of nicotinamide. To simplify issues arising from differences in 
culture systems, only Iba1 expression and cell numbers were analysed. Other factors such as 
expression of, what are considered, M1 and M2 specific markers would be more difficult to 
compare across such different cultures. 
Another potential explanation for the differences observed in microglia between 
different culture settings is the potential for secondary effects of nicotinamide through other 
cell types found in the VM cultures. Microglia react to many environmental cues including 
factors released by other neural cell types (Jeffrey J.Bajramovic, 2011; Tan, Yuan and Tian, 
2020). Microglia within VM cultures may be directly influenced by nicotinamide, or the 
reduced proliferation may be in response to cues released by other neural cell types 
influenced by nicotinamide treatment; although this possibility requires further exploration. 
The potential effects of other cell types on microglia may also have been observed in the 
differences seen between VM and WGE cultures. The significantly lower numbers of Iba1+ 
microglia observed in nicotinamide treated VM cultures at 14 DIV was not observed in WGE, 
however, numbers of Iba1+ microglia were very low in WGE cultures, making it more difficult 
to observe a genuine effect. The difference between VM and WGE microglia is further 
discussed in Chapter 5.4.9. 
Microglia also show heterogeneity in terms of density, morphology and gene 
expression across CNS regions (Tan, Yuan and Tian, 2020) and differences in gene expression 
have been shown between postnatal (P3-9) and 2 month old mice (Matcovitch-Natan et al., 
2016). Therefore, the regional and age differences in the collection of microglia between VM 
cultures (E14) and microglia derived from mixed glia (P0-3) could also play a role in the 
differences observed across culture systems in this PhD thesis. However, there is limited 
evidence that intrinsic factors are responsible for differences observed between microglia 
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(Tan, Yuan and Tian, 2020), suggesting the differences observed across the culture systems 
used here are due to the different environments that the cells are exposed to. Even spleen 
macrophages and blood monocytes adapt their membrane characteristics to those displayed 
by microglia when cultured with astrocytes (Schmidtmayer et al., 1994). 
PARP-1 inhibition in in vitro BV2 microglia and primary microglial cultures attenuated 
the release of pro-inflammatory factors after inflammatory stimulation, but did not decrease 
basal levels of iNOS expression or NF-ᴋB activity (i.e. levels of iNOS and NF- ᴋB prior to 
application of inflammatory stimulation; Stoica et al., 2014). Nicotinamide may not affect 
microglia under physiological conditions, but may instead prevent action in response to 
certain inflammatory stimuli. Fukushima, et al. (2015) found that inhibiting VEGF signalling 
attenuated LPS-induced microglial proliferation, however application of this inhibitor alone 
did not change basal proliferation levels. To explore this, the effect of nicotinamide on isolated 
microglia cultures could be assessed alongside application of pro-inflammatory factors such 
as LPS. 
 
5.4.8 Mechanisms of nicotinamide-restricted proliferation of 
microglia may be direct or in-direct 
Possibilities in the different response to nicotinamide seen here between Iba1+ 
microglia in VM cultures and Iba1+ microglia in cultures derived from mixed glia cultures could 
be due to the presence of other cell types within VM cultures. This raises problems in 
distinguishing between direct or indirect effects of nicotinamide on microglia. Nicotinamide 
may act indirectly on microglia present in VM cultures, potentially through nicotinamide-
induced release of factors from neurons, astrocytes or NSCs which are present in VM cultures 
but excluded from microglial cultures derived from mixed glia. However, nicotinamide-
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induced limitation of microglia proliferation could be a direct effect, while the proliferation of 
microglia within control VM cultures could be in response to factors from other cell types 
present in VM cultures.  
A direct mechanism for nicotinamide-induced reduction in proliferation observed in 
VM cultures could be through inhibition of PARP-1. Microglia cultures derived from PARP-1-/- 
mice were resistant to TNF-α induced proliferation (Kauppinen and Swanson, 2005) and, as 
previously discussed, nicotinamide is an inhibitor of PARP-1 activity. PARP-1 inhibition also 
protected against neuronal degeneration in an in vivo traumatic brain injury mouse model, 
with reductions in the release of inflammatory associated factors in microglia cultures derived 
from primary cortex and BV2 cells (Stoica et al., 2014). To further explore these possibilities, 
microglial PARP-1 expression in VM cultures could be explored. The nature of nicotinamide-
induced limitation of microglial proliferation found in VM cultures suggests that this could be 
in response to PARP-1 inhibition.  
Factors that induce microglial proliferation could be present within VM cultures. The 
possibility of GM-CSF released by astrocytes does not appear to be the cause of this 
proliferation as nicotinamide was unable to prevent GM-CSF induced proliferation. However, 
astrocytes and neurons secrete a number of other factors that can affect microglia (Goshi et 
al., 2020) with CSF-1, TGF-β2, and cholesterol suggested as essential to microglia survival 
(Bohlen et al., 2017). Further analysis of VM and isolated microglial culture conditioned 
medium could help to elucidate factors that may be influencing microglial proliferation.  
The response of microglia to other cells present in culture may be a factor in the lower 
numbers and slower proliferation rate of microglia observed in cultures derived from WGE 





5.4.9 The developing VM contains more microglia than the 
developing WGE 
The presence of microglia in VM cultures and their implications in disease models are 
not often commented on. In this PhD thesis, the microglial populations of cultures derived 
from two brain regions associated with PD were assessed. VM development produces the SN, 
and the WGE eventually forms the striatum. This allowed for assessment of two individual but 
related brain regions. Studies have shown that the adult mouse SN, and basal ganglia in 
general, have one of the highest adult microglial populations (De Biase et al., 2017; Lawson et 
al., 1990).  
Numbers of Iba1+ microglia in WGE were significantly lower than VM at 7 and 14 DIV. 
This difference correlates with studies showing different regional distributions of microglia 
(Tan, Yuan and Tian, 2020). Linear regression (Figure 5.9 B) showed differences in the 
proliferation rate of microglia in VM and WGE cultures. This could be due to differences in the 
initial proportions of microglia at seeding (if each developing brain region contains different 
densities of microglia at E14), region specific cues from other cell types derived from these 
tissues, or differences in microglial specialisation which have occurred due to their 
development within each region. Differences in the number of microglia between VM and 
WGE may arise from the process of microglia infiltration and migration within the developing 
brain. Migration of microglial cells is still underway in the postnatal brain (Mosser et al., 2017) 
suggesting that microglia have not fully populated all regions of the brain at E14, when these 
cultures were established.  
Microglia are present in the developing rat brain from E10 (Ghosh and Ghosh, 2016). 
Amoeboid microglia are suggested to enter the developing brain from the meninges, choroid 
plexus and ventricles (Verney et al., 2010), with observations of microglia arising earlier in the 
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mesencephalon, from which VM cultures are derived, than frontal lobes, which contain the 
developing WGE (Wierzba-Bobrowicz et al., 1998). This could account for the higher numbers 
of microglia observed in VM cultures at 7 DIV and could be confirmed by analysis of WGE 
cultures from 1 DIV. However, it does not explain the slower proliferation rate observed in 
WGE between 7 and 14 DIV compared with VM.  
Data was not collected from 1 and 4 DIV in WGE cultures, however, this would be an 
interesting point to investigate and would help to clarify differences for microglial 
proliferation in different brain regions. The difference in proliferation rate observed between 
7 and 14 DIV across VM and WGE cultures suggests that these differences are from region 
specific stimuli, but do not clarify extrinsic or intrinsic factors.  
After microglial ablation in the adult mouse, cortex, cerebellum and spinal cord 
showed different repopulation rates (Bruttger et al., 2015). An increase in microglial numbers 
compared to control was observed 7 days after ablation, with numbers stabilising to control 
levels after 14 days (Elmore et al., 2014). Repopulation exhibits the same heterogeneity across 
basal ganglia regions. The sparse distribution of ablation surviving microglia and the 
homogeneity observed during repopulation suggest that environmental cues, rather than 
intrinsic programming, are required for microglial region specificity (De Biase et al., 2017). De 
Biase et al. (2017) suggest that microglial regional specificity is in place in the basal ganglia 
from the second postnatal week, arising from external factors. The results from this PhD 
project showed regional differences in population densities in tissue derived from E14 brain 
regions (after 7 DIV; rat gestation is typically 21 days). 
Marshall, Demir, Steindler, & Laywell (2008) found that astrocyte monolayers cultured 
from the postnatal (P2-3), but not adult (4 month old), subventricular zone were able to 
repeatedly produce large numbers of microglia through addition of “microglial proliferation 
media” (media supplemented with 10% FBS and 20 ng/mL GM-CSF) to these monolayers. 
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Monolayers derived from the postnatal subventricular zone also showed higher repeated 
microglial yield than those derived from cortex or cerebellum. This study suggests extrinsic 
factors in microglia proliferation but do not clarify the potential of intrinsic factors involved in 
these results. However, later research using mixed cultures derived from P2-3 mouse 
subependymal zone or cortex suggested intrinsic proliferation characteristics of microglia 
derived from each area (Marshall et al., 2014). 
Region specific analysis of postnatal mouse basal ganglia tissues showed homogeneity 
of microglial distributions at P6, with regional differences observed at P12. Ki67 staining (a 
marker of proliferation) suggested that these changes are from proliferation, rather than 
differentiation, of microglia in each region (De Biase et al., 2017). Using markers of 
proliferation could be another route to examining the microglial differences observed in these 
VM and WGE cultures. 
Microglia expression profiles also vary across the CNS (Tan, Yuan and Tian, 2020). 
Expression profiles and morphological analysis were not carried out in this PhD thesis. 
Immunocytochemical stains, analysis of expression levels, and morphology can be difficult to 
accurately measure with microglia. These results are sometimes ambiguous, especially in 
vitro, due to the complexity and variation of features that are innate to microglia. Flow 
cytometry could be utilised to further explore potential differences in microglia expanded 
from VM and WGE cultures, however, it may be difficult to produce large enough sample sizes.  
Despite decades of research it is not clear whether differences in microglia observed 
across CNS regions are due to intrinsic or extrinsic factors with research highlighting evidence 
for both. These results show evidence for differences in microglia proliferation within cultures 
derived from different embryonic brain regions, however, further analysis is required to 




5.4.10 Conclusions and future study 
The results of this chapter suggest that nicotinamide is able to limit the proliferation 
of both NSCs and microglia but does not appear to influence GFAP+ astrocytes. Further 
research could use other astrocyte markers or purified astrocyte cultures to fully assess the 
potential effects of nicotinamide on astrocytes. Further analysis of NSC and microglial 
populations could involve the use of proliferation markers such as Ki67 or BrdU to confirm this 
reduction in proliferation for either or both cell types. This would be especially useful in 
isolated microglial populations alongside the use of TUNEL, PI or MTT to explore the possibility 
of a toxic effect of 10 mM nicotinamide in these cultures. Further analysis could also include 
the use of markers showing M1 or M2 polarisation, although the use of these in vitro may not 
be easy to extrapolate to in vivo characterisation of microglia, due to controversy around 
whether in vitro marker expression is representative of in vivo phenotypes/expression 
profiles.  
Further assessment of microglial populations could also explore the mechanisms for 
the exponential growth observed in VM but not WGE cultures. Potential avenues could look 
for measurement of factors that promote microglial proliferation. This would help to 
distinguish between external or intrinsic stimuli that may be responsible for these differences. 
It is not clear whether nicotinamide is limiting basal microglial proliferation rates or if it is 
limiting proliferation in response to other stimuli. Application of nicotinamide alongside 
factors that are known to promote proliferation may also be useful to determine the 
mechanisms behind the response observed in this PhD thesis.  
Results from these further experiments could also provide information on whether 
nicotinamide has a direct or indirect effect on microglia and how this could be utilised in 
therapies for neurodegeneration. For instance, the use of nicotinamide may be applicable to 
PD either through control of the inflammatory response observed in the SN of PD brains and 
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thought to contribute to or exacerbate SN degeneration (Chapter 1.4.4); or through the 
potential to limit the immune response that is observed in CRT to ensure integration and 
protection of grafted dopaminergic neurons (Tomov, 2020). 
Further experiments to build on the results discussed here would include: 
I. Further assessment of microglial proliferation in VM and WGE cultures through 
the use of BrdU. 
II. Assessment of VM microglia using immunocytochemistry for pro- and anti-
inflammatory markers including iNOS and Arg1. 
III. Assessment of isolated microglia cultures using TUNEL assay to assess 
apoptosis with nicotinamide treatment. 
IV. Assessment of NAD+/NADH levels using luminescence assays in isolated 
microglial cultures. 
V. Assessment of PARP-1 expression in microglia in both VM and isolated 





6 General conclusions and discussion 
6.1 Overview of thesis 
Despite decades of research, the exact pathology, cause, and an effective treatment 
for, PD are still being elucidated. The overarching aim of this thesis was to explore the 
implications that nicotinamide may have on neural cells regarding differentiation, 
neuroprotection, and neuroimmunomodulation, which may be beneficial to uncovering the 
pathology of, or potential novel treatments for, PD.  
Chapter 3 discussed the use of nicotinamide in the neural and neuronal differentiation 
of stem cells. The application of 5 mM and 10 mM nicotinamide to mESC cultures resulted in 
lower numbers of cells compared to controls in differentiating cultures. This suggests that 
nicotinamide is able to limit the proliferation of these cells, and this same effect of 10 mM 
nicotinamide has been observed in hESCs (Meng et al., 2018). Alongside reduced proliferation, 
the application of nicotinamide may also promote accelerated neural maturation (Griffin et 
al., 2013, 2017), observed in this PhD thesis by an earlier peak in Sox1-GFP expression with 
nicotinamide treatment during differentiation. Furthermore, cultures treated with 
nicotinamide did not show significantly lower numbers of β-III-tubulin+ neurons despite having 
significantly fewer cell numbers, suggesting that nicotinamide may be selective for the 
promotion of a neuronal fate; with a greater percentage of neurons within these cultures.  
Chapter 4 explored the potential of nicotinamide as a neuroprotectant through an in 
vitro PD model using VM-derived cultures and 6-OHDA. Despite suggestions that nicotinamide 
may be neuroprotective for PD (Seidl et al., 2014; Agim and Cannon, 2015), 10 mM 
nicotinamide failed to show neuroprotection against 6-OHDA-induced toxicity in 
dopaminergic neurons. However, the results from this model do not mean that nicotinamide 
cannot provide neuroprotection in PD, and further research could provide insight into the role 
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of nicotinamide, whether beneficial or detrimental, to PD (Williams and Ramsden, 2005a). 
Significantly higher numbers of TH+ neurons were observed in 10 mM nicotinamide treated 
cultures at 1, 4, and 7 DIV. Further exploration of this effect using markers of proliferation may 
help to uncover whether this effect is through neuroprotection of TH+ neurons that are 
present in the cultures from day 0, or whether it promotes the differentiation of dopaminergic 
neurons from precursors. If increased markers of proliferation are not found within TH+ 
neurons in nicotinamide treated cultures, this may suggest that nicotinamide is able to offer 
some form of neuroprotection. Although a neuroprotective effect was not found from 6-
OHDA toxicity, nicotinamide may provide neuroprotection from other forms of cytotoxicity 
which may also occur in PD degeneration. Further exploration of this field may assist in the 
development of novel treatments for PD (further discussed in Chapters 6.1.2 and 6.1.3). 
Chapter 5 explored the effects of nicotinamide on other cells of the CNS including 
GFAP+ astrocytes, Nestin+ neural stem cells, and microglia. Results showed no significant 
difference in the number of GFAP+ astrocytes in 10 mM nicotinamide treated cultures, 
however, overall numbers were low and, due to fluctuating expression, there is uncertainty 
about the suitability of GFAP as a marker for astrocyte populations (Lin, Messing and Perng, 
2017). Astrocytes represent a complex cell population, and to be able to effectively assess 
whether nicotinamide exerts and effect on these cells, further analysis would be needed. A 
variety of markers including vimentin (Bramanti et al., 2010), Aldh1l1, and glutamate 
transporter, their expression levels, and morphological differences between protoplasmic 
(type 1; large cell bodies with small processes) and fibrous (type 2; small soma with numerous, 
long processes) astrocytes could be assessed using immunocytochemistry. Transcriptome and 
proteomic analyses would also be able to further explore any potential changes in astrocytes 
with nicotinamide application (Khakh and Deneen, 2019).  
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Significantly lower numbers of Nestin+ cells were observed in 10 mM nicotinamide 
treated VM cultures after 7 DIV. This supports data from Chapter 3 that nicotinamide can limit 
the proliferation of stem cells without reducing numbers of neurons; a characteristic that may 
assist in the delivery of CRT for PD. To my knowledge, the presence of Nestin+ stem cells in 
VM cultures is not commonly commented on in the literature. This may represent a novel 
finding in the characterisation of cell types within these cultures and the potential for 
nicotinamide to limit the proliferation of cell types (that may not be desired) in these cultures 
without affecting the β-III-tubulin+ neuronal population.  
Nicotinamide also had a significant impact on the proliferation of Iba1+ microglia within 
VM cultures. Numbers of Iba1+ microglia showed an exponential increase over 14 DIV in 
control cultures, which was significantly limited with 10 mM nicotinamide treatment. Further 
exploration of this effect by addition or removal of nicotinamide (half-way through the 14 day 
culture period) confirmed that nicotinamide treatment did not induce microglial cell death in 
these cultures, but halted proliferation, an effect that was released upon removal of 
nicotinamide treatment. To my knowledge this represents a novel and potentially 
therapeutically useful finding surrounding how the microglial population within normal VM 
cultures behave, and the effect that nicotinamide has on these cells. 
To further explore the effects of nicotinamide on microglia, isolated microglial cultures 
were treated with nicotinamide concentrations of 1, 5, and 10 mM. Nicotinamide showed a 
dose-dependent decrease in the number of Iba1+ microglia in isolated cultures, with 
significantly lower numbers observed with 10 mM treatment for 5 days. The morphology of 
isolated microglia treated with 10 mM nicotinamide suggested a toxic effect although further 
analysis, and perhaps longer-term culture, would be needed to confirm this.  
To address the potential mechanism by which nicotinamide limited proliferation of 
Iba1+ microglia in VM cultures, isolated microglia were treated with nicotinamide alongside 
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GM-CSF, a stimulator of microglial proliferation associated with M2a activation (Figure 1.6). 
Nicotinamide did not prevent the GM-CSF-induced increase in numbers of Iba1+ microglia in 
cultures, suggesting that nicotinamide may limit proliferation through a different mechanism 
than that by which GM-CSF promotes proliferation. However, another possible explanation is 
that the concentration of GM-CSF overrode the influence of nicotinamide. Further analysis 
using different concentrations of GM-CSF may help to ascertain whether nicotinamide has a 
direct inhibitory effect on GM-CSF-induced proliferation. To my knowledge, the literature 
does not suggest that the mechanistic action of GM-CSF overlaps with the factors that 
nicotinamide is known to influence. Therefore other mechanisms should be explored for 
nicotinamide, including sirtuin or PARP inhibition. 
Additional exploration of the mechanisms for nicotinamide-induced limitation of 
microglial proliferation could utilise pro-inflammatory factors such as LPS, which stimulates 
an M1 activation state (Figure 1.6). Markers of microglial activation states could also assist to 
determine more specific effects of nicotinamide on microglia; although these can be difficult 
to accurately study in in vitro cultures, they could help to understand the mechanisms by 
which nicotinamide limits proliferation. The limitation of microglial proliferation may be a 
useful tool in the treatment of diseases involving pro-inflammatory activation which is 
typically associated with an increase in proliferation and can result in exacerbated damage 
(Mathys et al., 2017). Further research into the novel effects of nicotinamide-limited 
microglial proliferation found in this PhD thesis may assist in the development of 
immunomodulatory therapies that could help to treat PD; or be used alongside future 
therapies such as CRT to assist with graft integration by modifying/limiting microglial 
proliferation/activation and thus a negative host response to the transplant. 
Results from Chapter 5 also showed lower numbers of microglia in cultures derived 
from the E14 WGE (from which the striatum develops) compared to those derived from E14 
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VM (from which the SN develops), both of which are areas of interest in PD. Microglia show 
regional heterogeneity across the brain and this also varies with age (Tan, Yuan and Tian, 
2020). Microglia within WGE cultures also appeared to proliferate at a slower rate than those 
within VM cultures. Further analysis of WGE cultures at 1 and 4 DIV could confirm the 
differences observed here and further analysis of cells types and secreted factors may shed 
light on the environmental influences that drive microglial proliferation, how this could be 
affected by nicotinamide treatment, and whether this may be utilised in PD research. 
Nicotinamide, associated compounds, and their interactions could play a role in 
neurodevelopment, neuroprotection, and neurodegeneration. However, the mechanisms and 
interactions are complex. Determining the most effective way to utilise the beneficial effects 
of nicotinamide and its derivatives still requires more work. Novel results from this thesis may 
be able to contribute to our understanding of the mechanisms behind PD and the 




6.2 The mechanistic actions of nicotinamide are yet to be 
elucidated 
A clear effect of nicotinamide was observed in all culture systems (mESCs, primary VM, 
and primary microglia) used in this PhD project. The mechanistic action of nicotinamide has 
been attributed to inhibition of PARPs, sirtuins, kinase activity, and increased levels of pyridine 
nucleotides (Li, Chong and Maiese, 2006; Meng et al., 2018). Understanding the functions and 
mechanisms of nicotinamide may provide a valuable tool for future therapies.  
The novel observation that nicotinamide-restricted proliferation of microglia in VM 
cultures, could be explained through direct inhibition of PARPs or sirtuins by nicotinamide, or 
potentially through increased levels of NAD+. For instance, the proliferation of rat T cells, 
cultured in vitro, was found to be inhibited by NAD+, but not nicotinamide (Bortell et al., 2001), 
highlighting a potential pathway by which nicotinamide exerts this effect. To explore the 
possibility that nicotinamide exerts the observed effects through increases in NAD+ levels, an 
experiment was designed during this PhD project to measure the intracellular levels of 
NAD+/NADH, using a luminescence assay, in both VM and isolated microglial cultures. Due to 
the COVID-19 pandemic and laboratory closure, these experiments were not able to be 
completed, however, some preliminary data was obtained suggesting that nicotinamide 
treatment may dose-dependently increase intracellular levels of NAD+/NADH in both VM and 
microglial cultures. This warrants investigation. Further optimisation of the protocol, and 
more experimental repeats, could clarify whether nicotinamide is definitively able to increase 
intracellular levels of NAD+/NADH, and whether this effect is observed in both VM and high 
purity microglial cultures. Analysing these cultures separately may also assist in discerning 
between the effects observed in the multi-cellular VM cultures, and the effects observed in 
high purity microglial cultures. 
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The exponential increase in the number of microglia over time in standard VM cultures 
may have been due to factors released by other cell types within these cultures. For instance, 
factors released by astrocytes have been shown to induce microglial proliferation (Goshi et 
al., 2020). This idea was supported by the difference in growth rate observed between 7 and 
14 DIV in VM compared to WGE cultures. To explore external factors released by astrocytes 
that may influence the difference in growth rate observed between cultures, and the 
mechanism by which nicotinamide may limit proliferation, isolated microglial cultures were 
treated with nicotinamide alongside GM-CSF, a molecule released by astrocytes and known 
to promote microglial proliferation. As expected, GM-CSF was able to induce proliferation in 
isolated microglial cultures and may be a factor that is released in VM cultures to stimulate 
microglial proliferation. However, nicotinamide did not limit GM-CSF-induced proliferation, 
despite resulting in the microglial cells’ morphology resembling pyknotic cells. Although 
further evidence would be required before reaching a firm conclusion, the results suggested 
that GM-CSF promotes proliferation through a mechanism separate to which nicotinamide 
inhibits proliferation. An experimental procedure utilising conditioned medium from VM and 
WGE cultures may reveal whether factors released from different cell types present in these 
cultures can contribute to differences in proliferation rates. Further analysis of the culture 
medium from VM and WGE cultures may be able to reveal specific factors released by cells 
that could contribute to the proliferation of microglia observed in standard primary cell 
cultures; from this it may be possible to deduce potential mechanisms/pathways by which 
nicotinamide limits proliferation. 
Nicotinamide and its derivatives have broad, wide-ranging actions and the potential to 
influence many cellular mechanisms (Li, Chong and Maiese, 2006). A broad and inclusive 
method to study the potential mechanisms of nicotinamide in these cultures could be through 
the use of transcriptome and proteome analysis. This may assist to highlight changes in the 
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expression profiles of cells exposed to nicotinamide, the pathways that nicotinamide may 
influence, and behaviours that are associated with these pathways. This type of analysis may 
also help to explain the observed effects of nicotinamide on proliferation and differentiation 




6.3 Nicotinamide may aid in the development of CRT for 
PD 
The results discussed in this PhD thesis may be relevant in the development of CRT as 
a treatment for PD. Nicotinamide treated mESCs showed reduced proliferation over the 
differentiation period observed here. Addition of nicotinamide to differentiating stem cell 
cultures may help to prevent the presence of proliferating cells within grafts, an aspect that is 
essential for developing CRT as a safe and effective treatment for PD, by reducing the chances 
of teratoma formation (Hagell and Brundin, 2001). Despite reducing total cell numbers 
through diminished proliferation, nicotinamide did not alter the number of β-III-tubulin+ 
neurons after 7 days of differentiation, resulting in a higher percentage neuronal population. 
Therefore, the addition of nicotinamide to dopaminergic differentiation protocols may help 
to increase the percentage neuron yield. Nicotinamide treated cultures also showed an earlier 
peak in Sox1-GFP expression measured with flow cytometry. This is in agreement with 
previously observed data using different analysis methods, suggesting enhanced maturation 
of neuronal populations from stem cells using nicotinamide (Griffin et al., 2017). This effect 
may also be beneficial in reducing the protocol length required to differentiate transplantable 
cells from stem cells. This would benefit the clinical translation of CRT by enabling a higher 
throughput system for the development of suitable grafts. It may also assist in developing the 
potential of iPSCs by reducing the time between cell retrieval and grafting.  
As well as reducing the proliferation of stem cells, nicotinamide also limited the 
proliferation of microglia, a behaviour that is associated with pro-inflammatory activation. In 
this regard, nicotinamide could provide immunosuppressive benefit when combined with the 
grafting procedure. Grafting cells is thought to illicit an immune response from both the graft 
itself, and the procedure of graft placement. Limiting this immune response is believed to be 
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beneficial to graft survival (Moriarty, Parish and Dowd, 2018), however immune suppression 
can have serious side effects and may not be suitable long-term (Kovarik, 2013). Nicotinamide 
could be administered with the graft or potentially incorporated into a bio-material to protect 
cells from a pro-inflammatory immune response and graft infiltration by host microglia. 
Nicotinamide treated VM cultures also showed higher numbers of TH+ neurons compared to 
control at 1 ,4 and 7 DIV. This effect may be through nicotinamide-induced promotion of 
dopaminergic differentiation, or protection of dopamine neurons present at cell seeding, 
potentially be reducing the numbers of reactive microglia in the cultures. Although this 
mechanism requires further exploration, it indicates another function of nicotinamide that 
could benefit CRT for PD.  
Furthermore, nicotinamide is well-described and food and drug administration 
approved meaning it can be included in GMP grade protocols for the generation of 
dopaminergic neurons, or in combination with bio-materials suitable for CRT for PD. 
Nicotinamide can also cross the BBB and high doses are generally well tolerated with plasma 
concentrations reaching the millimolar range after oral supplementation (Dragovic et al., 
1995). However, further investigation is needed to understand how orally administered 
nicotinamide may influence levels of nicotinamide in cerebrospinal fluid, or the striatum 





6.4 Nicotinamide may offer a neuroprotective therapy for 
PD 
If nicotinamide could influence microglia in vivo, it may be possible for nicotinamide 
to provide neuroprotection against dopaminergic neuron degeneration in PD patients. 
Although nicotinamide did not show neuroprotection against 6-OHDA in the in vitro model 
used here, PARP-1 inhibition (an effect of nicotinamide) has shown neuroprotection in an in 
vivo traumatic brain injury model (Stoica et al., 2014). However, PARP-1 inhibition did not 
show neuroprotection in 6-OHDA treated VM cultures (Callizot et al., 2019) which is consistent 
with the lack of neuroprotection observed here. Direct use of nicotinamide has shown 
protection of SNpc neurons and striatal dopamine levels in two MPTP mouse models of PD 
(Anderson, Bradbury and Schneider, 2008) and numerous other studies have also highlighted 
the potential of nicotinamide and/or its derivatives in neuroprotection (discussed in Chapters 
1.10 and 4.4.4). To my knowledge, nicotinamide has not been tested as a potential 
neuroprotectant in an in vitro VM 6-OHDA PD model, representing a novel finding here and 
one that correlates with a lack of nicotinamide-induced neuroprotection also observed in an 
in vivo lactacystin PD model (Harrison, Powell and Dexter, 2019). Further analysis of cell 
cultures treated with nicotinamide and 6-OHDA may elucidate why neuroprotection was not 
observed here.  
Although more information is needed, these results suggest that microglia may not be 
critically involved in the degeneration of TH+ neurons after 6-OHDA application in VM cultures, 
as reduced microglial numbers did not alter levels of neuronal survival in nicotinamide treated 
cultures. Assessment of the microglial population in these cultures after 6-OHDA treatment 
may reveal their reaction to 6-OHDA and 6-OHDA-induced neuron degeneration. 
Furthermore, by limiting their proliferation using nicotinamide treatment, it may be possible 
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to observe whether 6-OHDA and associated neuron degeneration influence microglial 
proliferation, and whether nicotinamide would be effective at reducing this reaction.  
Nicotinamide strongly limited microglia proliferation in VM cultures, a finding that I 
believe to be novel. Further exploration of this effect could involve the use of markers 
indicative of M1/M2 polarisation to assess whether nicotinamide can influence phenotype as 
well as proliferation. Although this can be difficult to study using in vitro cultures, methods 
including immunocytochemistry and PCR may be beneficial. Building on this, flow cytometry 
and immunohistochemistry could be used to explore in vivo effects of nicotinamide on 
microglial populations. Exploring the effects of nicotinamide in vivo, with and without 
different inflammatory stimuli could assess whether nicotinamide may be a suitable 
neuroprotective strategy for PD. Exposure to certain anti-inflammatory medication is 
associated with a decreased risk of PD, although the exact role/mechanism, and reasoning 
behind the specificity of certain medications is not clear (Rees et al., 2011; Racette et al., 
2018).  
If biomarkers for preclinical PD become available, it may be possible to utilise 
nicotinamide as a neuroprotective strategy before substantial loss of dopamine neurons from 
the SNpc occurs. This may help to prevent or limit progression of PD, reducing the need for 
more drastic therapies such as DBS or CRT.  
However, there is also the potential for nicotinamide to be involved in the 
degeneration aspects of PD, with increased meat consumption (and therefore increased 
nicotinamide intake) correlating with an increased risk of PD, at a population level (McCarty, 
2001; Hill and Williams, 2017). In these VM cultures, nicotinamide did not exert a neurotoxic 
effect at concentrations of 10 mM, a dose that greatly exceeds the estimated cerebrospinal 
fluid concentration of 15 µM (Spector, 1979), and plasma concentration of 1.4 mM after oral 
administration of 10 g (Dragovic et al., 1995). However, it does not rule out the possibility that 
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high levels of nicotinamide may be a contributing factor alongside other genetic or 
environmental influences. Also, in this PhD, additional nicotinamide was only applied for up 2 
weeks which would not account for the potential of accumulative negative impacts of 
increased nicotinamide throughout a lifetime potentially contributing to late-onset PD. 
 
The results shown in this PhD thesis discuss exciting and novel applications of 
nicotinamide, especially surrounding PD research. This opens possibilities of the use of 
nicotinamide in therapies for PD, providing groundwork for assessing the potential influences 
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